var images_info;if (!images_info) images_info =[]; images_info["100"]={"100004":{"type":"graphic_table","displayName":"Clinical presentations of CFLD","title":"Clinical presentations of cystic fibrosis-related liver disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentations of cystic fibrosis-related liver disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Approximate frequency in individuals with CF</td> <td class=\"subtitle1\">Typical characteristics</td> </tr> <tr> <td>Neonatal cholestasis</td> <td>&#60;10%</td> <td>Conjugated hyperbilirubinemia in a neonate, often with hepatomegaly. Usually regresses within months and is not a predictor of later CFLD, unless there is prolonged TPN exposure or surgery related to MI.</td> </tr> <tr> <td>Focal biliary cirrhosis</td> <td>20 to 40%</td> <td>May or may not be associated with persistently elevated aminotransferases and hepatomegaly, usually asymptomatic and developing within the first 12 years of life.</td> </tr> <tr> <td>Multilobular cirrhosis</td> <td>5 to 10%</td> <td>Advanced stage of focal biliary cirrhosis. May be complicated by portal hypertension (causing splenomegaly, ascites, and esophageal varices), gastrointestinal bleeding, and nutritional deficiencies. Hepatic synthetic dysfunction (coagulopathy and hypoalbuminemia) is a late and rare occurrence.</td> </tr> <tr> <td>Hepatic steatosis</td> <td>10 to 60%</td> <td> <p>Incidental finding on ultrasound or liver biopsy, with transient hepatomegaly. The relationship between hepatic steatosis and the development of focal biliary cirrhosis in CF is unclear. May be seen from infancy to adolescence, and may be associated with stunting or wasting.</p> Steatosis may be caused by iatrogenic or environmental factors such as malnutrition, medications, essential fatty acid deficiency, and ethanol ingestion.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CF: cystic fibrosis; CFLD: cystic fibrosis-related liver disease; TPN: total parenteral nutrition; MI: meconium ileus.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36:1374.</li>&#xD;&#xA;    <li>Lamireau T, Monnereau S, Martin S, et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004; 41:920.</li>&#xD;&#xA;    <li>Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011; 10 Suppl 2:S29.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 100004 Version 2.0</div></div></div>"},"100016":{"type":"graphic_picture","displayName":"Infantile digital fibroma","title":"Infantile digital fibroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile digital fibroma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100016_Infantile_digital_fibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A skin-colored nodule is visible on the lateral aspect of a toe in this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100016 Version 1.0</div></div></div>"},"100017":{"type":"graphic_picture","displayName":"Infantile digital fibroma multiple","title":"Infantile digital fibroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile digital fibroma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100017_Infntl_digital_fibrom_mltpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin-colored dermal nodules are visible on the lateral aspect of the toes of a young child.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100017 Version 1.0</div></div></div>"},"100019":{"type":"graphic_picture","displayName":"Tinea versicolor on neck","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100019_Tinea_versicolor_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented macules and patches on the neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100019 Version 1.0</div></div></div>"},"100020":{"type":"graphic_picture","displayName":"Tinea versicolor erythematous","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100020_Tinea_vrsclr_erythematous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mildly erythematous macules, patches, and thin plaques on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100020 Version 1.0</div></div></div>"},"100021":{"type":"graphic_picture","displayName":"Tinea versicolor hypopigmented","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100021_Tinea_vrsclr_hypopigmented.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hypopigmented macules on the neck, shoulder, and chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A spellcheck=true href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100021 Version 1.0</div></div></div>"},"100022":{"type":"graphic_picture","displayName":"Tinea versicolor hyperpigmented","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100022_Tineaversicolorhyperpgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented, coalescing macules and thin plaques on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100022 Version 3.0</div></div></div>"},"100024":{"type":"graphic_picture","displayName":"Tinea versicolor on face and neck","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100024_Tinea_versicolor_face_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented macules on the face and neck of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100024 Version 1.0</div></div></div>"},"100025":{"type":"graphic_picture","displayName":"Tinea versicolor on the face","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100025_Tinea_versicolor_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented macules on the face of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100025 Version 1.0</div></div></div>"},"100026":{"type":"graphic_picture","displayName":"Tinea versicolor on the upper trunk","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100026_Tineaversicoloruppertrnk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple mildly erythematous, thin plaques on the upper trunk and proximal upper extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100026 Version 3.0</div></div></div>"},"100051":{"type":"graphic_diagnosticimage","displayName":"Radiograph of anterior subluxation of C1 on C2 in RA","title":"Anterior subluxation of C1 on C2 in rheumatoid arthritis on radiography","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Anterior subluxation of C1 on C2 in&nbsp;rheumatoid arthritis&nbsp;on radiography</div><div class=\"cntnt\"><img style=\"width:725px; height:458px;\" src=\"images/RADIOL/100051_Rdgrph_antrr_sblxt_C1_C2_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral examination of the cervical spine (A) shows anterior subluxation of C1 on C2. The magnified view (B) shows a 12 mm separation between the posterior border of the arch of C1 (arrowhead) and the anterior border of the odontoid process of C2 (arrow).</div><div class=\"graphic_footnotes\">RA: rheumatoid arthritis.</div><div id=\"graphicVersion\">Graphic 100051 Version 2.0</div></div></div>"},"100052":{"type":"graphic_diagnosticimage","displayName":"CT anterior dislocation C1 on C2 in RA","title":"Anterior dislocation of C1 on C2 in rheumatoid arthritis on CT","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">Anterior dislocation of C1 on C2 in&nbsp;rheumatoid arthritis&nbsp;on CT</div><div class=\"cntnt\"><img style=\"width:660px; height:495px;\" src=\"images/RADIOL/100052_CT_ant_dslct_C1_C2_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal reconstruction of a CT scan (A) shows a 7.5 mm separation between the posterior part of the arch of C1 (arrowhead) and the anterior aspect of the dens (arrow). Image B is a coronal reconstruction of a CT scan and shows a large erosion on the lateral aspect of the dens (arrowhead). Image C is an axial image and shows a large erosion (arrowhead) on the eccentrically positioned dens. Image D is an axial image using soft tissue windows through the same region as C, and shows extensive pannus formation around the dens (asterisks), which impinges on the CSF space (arrow) surrounding the spinal cord (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100052 Version 2.0</div></div></div>"},"100053":{"type":"graphic_diagnosticimage","displayName":"MRI anterior subluxation of C1 on C2 in RA with cord indentation","title":"Anterior subluxation of C1 on C2 in rheumatoid arthritis with cord indentation on MRI","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Anterior subluxation of C1 on C2 in&nbsp;rheumatoid arthritis&nbsp;with cord indentation on MRI</div><div class=\"cntnt\"><img style=\"width:708px; height:426px;\" src=\"images/RADIOL/100053_MRI_ant_sbx_C1_C2_RA_crd_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T2-weighted image of the cervical spine in the sagittal plain (A) shows a 5 mm separation (arrows) between the posterior border of C1 arch (anterior arrow) and the anterior border of the dens (posterior arrow). Multilevel spondylosis is also present between C3 and C7. Image B is a magnified view of image A, and shows the C1-C2 separation (arrows), pannus formation posterior to the dens (asterisk), with impingement on the cord and the anterior CSF space (dashed arrow), and the cord (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 100053 Version 2.0</div></div></div>"},"100055":{"type":"graphic_diagnosticimage","displayName":"CT of Bosniak II cyst fine calcifications","title":"Bosniak II cyst with fine calcifications on CT","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Bosniak II cyst with fine calcifications on CT</div><div class=\"cntnt\"><img style=\"width:728px; height:520px;\" src=\"images/RADIOL/100055_CTBsnkIIcystfnclcfctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An axial CT scan shows a nonenhancing cyst (asterisk) in the left kidney with fine calcifications (arrowheads). <br />(B)&nbsp;A CT scan reformatted in the coronal plain and shows the cyst (asterisk) in the left upper pole with fine calcification in the wall (arrowhead). <br />(C)&nbsp;A magnified view of (A) and shows short, fine, segment calcifications (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100055 Version 2.0</div></div></div>"},"100056":{"type":"graphic_diagnosticimage","displayName":"Carotid pseudoaneurysm on neck CT","title":"Carotid pseudoaneurysm on neck CT","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Carotid pseudoaneurysm on neck CT</div><div class=\"cntnt\"><img style=\"width:594px; height:467px;\" src=\"images/SURG/100056_Nck_CT_rght_crtd_psdnrysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal view of a neck CT scan shows a large pseudoaneurysm (arrow) of the right carotid artery.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100056 Version 4.0</div></div></div>"},"100058":{"type":"graphic_picture","displayName":"Stucco keratosis","title":"Stucco keratosis","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Stucco keratosis</div><div class=\"cntnt\"><img style=\"width:505px; height:782px;\" src=\"images/DERM/100058_Stucco_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous papular warty lesions are present on the ankle and dorsum of the foot in this 79-year-old patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100058 Version 1.0</div></div></div>"},"100059":{"type":"graphic_picture","displayName":"Seb keratosis","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/100059_Seb_keratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratoses typically present as waxy, stuck-on appearing lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100059 Version 1.0</div></div></div>"},"100061":{"type":"graphic_picture","displayName":"Large-cell acanthoma","title":"Large-cell acanthoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Large-cell acanthoma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/100061_Large_cell_acanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flat, slightly scaly pigmented macule is present on the sun-damaged skin of the arm of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100061 Version 1.0</div></div></div>"},"100062":{"type":"graphic_picture","displayName":"Seb keratosis keratin plugs","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100062_Seb_keratosis_keratin_plug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dark keratotic plugs are visible on the surface of this seborrheic keratosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100062 Version 1.0</div></div></div>"},"100065":{"type":"graphic_picture","displayName":"Seborrheic keratoses back","title":"Multiple seborrheic keratoses","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Multiple seborrheic keratoses</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/100065_Seborrheic_keratoses_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seborrheic keratosis in a \"Christmas tree\" distribution on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100065 Version 1.0</div></div></div>"},"100078":{"type":"graphic_figure","displayName":"Thromboelastography (TEG) tracing parameters","title":"Thromboelastography (TEG) tracing parameters","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Thromboelastography (TEG) tracing parameters</div><div class=\"cntnt\"><img style=\"width:488px; height:308px;\" src=\"images/HEME/100078_Thrmblstgrphy_trac_prmtr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"R\"&nbsp;is the reaction time (the time&nbsp;it takes the coagulation cascade&nbsp;to generate thrombin and fibrin). \"K\"&nbsp;is the clot firmness. \"α\"&nbsp;(alpha) is the angle (describes the kinetics of clot formation).&nbsp;MA is the maximum amplitude (describes the maximum clot strength). Ly30 is the percent clot lysis 30 minutes after the MA is reached. Refer to UpToDate topics on platelet function testing and trauma management for details of the use and interpretation of thromboelastography.</div><div class=\"graphic_reference\">TEG&reg; Hemostasis Analyzer Tracing Image reproduced with permission of Haemonetics Corporation. TEG&reg; and Thrombelastograph&reg; are registered trademarks of Haemonetics Corporation in the US, other countries or both.</div><div id=\"graphicVersion\">Graphic 100078 Version 1.0</div></div></div>"},"100099":{"type":"graphic_table","displayName":"Congenital CMV: initial antiviral therapy","title":"Choice of initial antiviral therapy in infants with virologically-confirmed congenital CMV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of initial antiviral therapy in infants with virologically-confirmed congenital CMV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Suggested initial antiviral agent</td> </tr> <tr> <td class=\"subtitle2\">Ganciclovir*</td> <td class=\"subtitle2\">Valganciclovir<sup>&#182;</sup></td> <td class=\"subtitle2\">Antiviral therapy <strong>not</strong> indicated</td> </tr> <tr> <td>CMV-specific symptoms</td> <td> <p><strong>Life-threatening&nbsp;symptoms</strong></p> <strong>Any</strong> of the following: <ul class=\"decimal_heading\"> <li>Viral sepsis-like syndrome </li> <li>Pneumonitis </li> <li>Myocarditis </li> <li>Severe hepatitis </li> <li>Enterocolitis </li> <li>Severe and refractory thrombocytopenia </li> <li>Sight-threatening retinitis </li> </ul> </td> <td> <p><strong>Non-life-threatening&nbsp;symptoms</strong></p> <p>Examples include:&nbsp;</p> <ul> <li>Microcephaly or intracranial calcifications without seizures or encephalopathy</li> <li>Jaundice or hepatosplenomegaly without severe hepatitis or refractory thrombocytopenia</li> <li>Isolated hearing loss<sup>&#916;</sup></li> </ul> <p><sup></sup>&nbsp;</p> <p><strong>Severe symptoms</strong></p> Infants with one or more of the conditions listed to the left may be candidates for oral valganciclovir if they meet all of the general medical condition criteria listed below</td> <td><strong>Asymptomatic</strong> (including passed newborn hearing screen)</td> </tr> <tr> <td>General medical condition</td> <td><strong>Any</strong> of the following: <ul class=\"decimal_heading\"> <li>Seriously or critically ill, requiring NICU care </li> <li>Requiring mechanical ventilation, CPAP, or&nbsp;supplemental oxygen </li> <li>NPO </li> <li>Unable to tolerate oral feeds </li> <li>Malabsorption </li> </ul> </td> <td><strong>All</strong> of the following: <ul class=\"decimal_heading\"> <li>Well appearing or mildly ill, being managed in newborn unit or at home </li> <li>On room air or low supplemental oxygen </li> <li>Able to tolerate oral feeds </li> <li>Stable and gaining weight </li> </ul> </td> <td>Stable and well appearing</td> </tr> <tr> <td>Immune status</td> <td>Primary immunodeficiency (eg, SCID)</td> <td>Immunocompetent</td> <td>Immunocompetent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; NICU: neonatal intensive care unit; CPAP: continuous positive airway pressure; NPO: nothing by mouth; SCID: severe combined immunodeficiency.<br />* Ganciclovir dosing is 6 mg/kg per dose administered intravenously (IV) every 12 hours. Treatment with IV ganciclovir should be for a maximum of 6 weeks. <FONT color=blue><SPAN style=\"COLOR: black\">Ganciclovir is dependent on renal function for clearance. Dose listed&nbsp;is for infant with normal renal function</SPAN></FONT><SPAN style=\"COLOR: black\">. Infants initially treated with IV ganciclovir may transition to oral valganciclovir when their condition improves and oral feedings are tolerated.<br />¶ Valganciclovir dosing is 16 mg/kg per dose of commercially available suspension administered orally every 12 hours. Treatment with oral valganciclovir should be continued for a total of 6 months for most newborns with symptomatic congenital CMV infection. Dose listed&nbsp;is for infant with normal renal function.</SPAN><br />Δ Evidence is lacking and expert opinion varies as to whether the benefits of antiviral therapy outweigh the risks in infants with isolated hearing loss.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Harrison GJ. Cytomegalovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1969.</LI>&#xD;&#xA;<LI>Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16.</LI>&#xD;&#xA;<LI>Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372:933.</LI></OL></div><div id=\"graphicVersion\">Graphic 100099 Version 2.0</div></div></div>"},"100103":{"type":"graphic_diagnosticimage","displayName":"MRI of liver showing possible residual disease after TACE","title":"Contrast-enhanced MRI of the liver, demonstrating rim enhancement six weeks after transarterial chemoembolization (TACE), suggestive of disease recurrence","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced MRI of the liver, demonstrating rim enhancement six weeks after transarterial chemoembolization (TACE), suggestive of disease recurrence</div><div class=\"cntnt\"><img style=\"width:476px; height:317px;\" src=\"images/ONC/100103_Recurrent_disease_aft_TACE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image of a gadolinium-enhanced MRI of the liver performed six weeks after TACE. The lesion in segment 4 of the liver has central necrosis that is compatible with treatment; the thick rind of enhancement (arrows) is suggestive of residual disease. This lesion would be difficult to classify using any of the response evaluation criteria. The patient was retreated with a second TACE procedure.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 100103 Version 2.0</div></div></div>"},"100105":{"type":"graphic_table","displayName":"Adult primary continuous-flow LVAD and BiVAD implants","title":"Adult primary continuous-flow LVAD and BiVAD implants: June 2006 to December 2013 (N = 9372)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult primary continuous-flow LVAD and BiVAD implants: June 2006 to December 2013 (N = 9372)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factors for death</td> <td class=\"subtitle1\" colspan=\"2\">Early hazard</td> <td class=\"subtitle1\" colspan=\"2\">Late hazard</td> </tr> <tr> <td class=\"subtitle2\">Hazard ratio</td> <td class=\"subtitle2\">p-value</td> <td class=\"subtitle2\">Hazard ratio</td> <td class=\"subtitle2\">p-value</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Demographics</td> </tr> <tr> <td class=\"indent2\">Age (older)</td> <td class=\"centered\">1.36</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Female</td> <td class=\"centered\">1.20</td> <td class=\"centered\">0.007</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">BMI (higher)</td> <td class=\"centered\">1.13</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Clinical status</td> </tr> <tr> <td class=\"indent2\">History of stroke</td> <td class=\"centered\">1.30</td> <td class=\"centered\">0.03</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">INTERMACS Level 1</td> <td class=\"centered\">1.69</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">INTERMACS Level 2</td> <td class=\"centered\">1.44</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Destination therapy</td> <td class=\"centered\">1.24</td> <td class=\"centered\">0.0005</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Non-cardiac systems</td> </tr> <tr> <td class=\"indent2\">Albumin (lower)</td> <td class=\"centered\">0.9</td> <td class=\"centered\">0.02</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Creatinine (higher)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.05</td> <td class=\"centered\">0.0003</td> </tr> <tr> <td class=\"indent2\">Dialysis</td> <td class=\"centered\">2.37</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">BUN (higher)</td> <td class=\"centered\">1.06</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">1.06</td> <td class=\"centered\">0.01</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Right heart dysfunction</td> </tr> <tr> <td class=\"indent2\">Right atrial pressure (higher)</td> <td class=\"centered\">1.11</td> <td class=\"centered\">0.02</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">RVAD in same operation</td> <td class=\"centered\">2.45</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Bilirubin (higher)</td> <td class=\"centered\">1.21</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ascites</td> <td class=\"centered\">1.27</td> <td class=\"centered\">0.01</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Surgical complexities</td> </tr> <tr> <td class=\"indent2\">History of cardiac surgery</td> <td class=\"centered\">1.43</td> <td class=\"centered\">&#60;0.0001</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Concomitant cardiac surgery</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.21</td> <td class=\"centered\">0.0008</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BiVAD: biventricular assist device; BMI: body mass index; BTT: bridge to transplant; BUN: blood urea nitrogen; DT: destination therapy; LVAD: left ventricular assist device; RVAD: right ventricular assist device.</div><div class=\"graphic_reference\">Reproduced from: Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual report: A 10,000-patient database. J Heart Lung Transplant 2014; 33:555. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100105 Version 1.0</div></div></div>"},"100109":{"type":"graphic_picture","displayName":"Skin manifestations of Henoch-Schönlein purpura (IgA vasculitis)","title":"Skin manifestations of Henoch-Schönlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Skin manifestations of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:708px; height:530px;\" src=\"images/ALLRG/100109_SknmnfHnchSchnlnprpIgA.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 100109 Version 2.0</div></div></div>"},"100110":{"type":"graphic_picture","displayName":"Skin lesions in Henoch-Schönlein purpura (IgA vasculitis)","title":"Skin lesions in Henoch-Schönlein purpura (IgA vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Skin lesions in Henoch-Sch&ouml;nlein purpura (IgA vasculitis)</div><div class=\"cntnt\"><img style=\"width:711px; height:542px;\" src=\"images/ALLRG/100110_SknlsnHnchSchnlnprpIgA.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 100110 Version 2.0</div></div></div>"},"100111":{"type":"graphic_picture","displayName":"Acute hemorrhagic edema - Infancy","title":"Acute hemorrhagic edema of infancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute hemorrhagic edema of infancy</div><div class=\"cntnt\"><img style=\"width:429px; height:710px;\" src=\"images/ALLRG/100111_Act_hmrrhgc_edm_infn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note purpura, ecchymosis, and inflammatory edema of the extremities.</div><div id=\"graphicVersion\">Graphic 100111 Version 2.0</div></div></div>"},"100112":{"type":"graphic_picture","displayName":"Localized subcutaneous edema in Henoch-Schönlein purpura","title":"Localized subcutaneous edema in Henoch-Schönlein purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Localized subcutaneous edema in Henoch-Sch&ouml;nlein purpura</div><div class=\"cntnt\"><img style=\"width:243px; height:353px;\" src=\"images/ALLRG/100112_Lclz_sbctn_edm_hnc_schn_prp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note swelling in the lower extremities, particularly the right leg/foot.</div><div id=\"graphicVersion\">Graphic 100112 Version 1.0</div></div></div>"},"100114":{"type":"graphic_diagnosticimage","displayName":"Catheter-based angiography of a renal artery in FMD","title":"Catheter-based angiography of a renal artery in fibromuscular dysplasia","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Catheter-based angiography of a renal artery in fibromuscular dysplasia</div><div class=\"cntnt\"><img style=\"width:782px; height:631px;\" src=\"images/NEPH/100114_Cthtr_anggrph_rnl_artry_FMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical appearance of multifocal fibromuscular dysplasia (multifocal FMD). Note the \"string of beads\" in the mid-distal right renal artery and its branches. The beading represents areas of constriction (by the fibrous webs) and dilatation.</div><div id=\"graphicVersion\">Graphic 100114 Version 1.0</div></div></div>"},"100115":{"type":"graphic_figure","displayName":"Classification of aortic dissection","title":"Classification of aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Classification of aortic dissection</div><div class=\"cntnt\"><img style=\"width:540px; height:514px;\" src=\"images/SURG/100115_Classification_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">In the DeBakey classification of aortic dissection: </SPAN>&#xD;&#xA;<UL>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type I involves the ascending aorta, arch, and descending thoracic aorta and may progress to involve the abdominal aorta.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type II is confined to the ascending aorta.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type IIIa involves the descending thoracic aorta distal to the left subclavian artery and proximal to the celiac artery.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type IIIb dissection involves the thoracic and abdominal aorta distal to the left subclavian artery.</SPAN></LI></UL><SPAN style=\"COLOR: black\">In the Stanford classification of aortic dissection: </SPAN>&#xD;&#xA;<UL>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type A involves the ascending aorta and may progress to involve the arch and thoracoabdominal aorta.</SPAN></LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Type B involves the descending thoracic or thoracoabdominal aorta distal to the left subclavian artery without involvement of ascending aorta.</SPAN></LI></UL></div><div id=\"graphicVersion\">Graphic 100115 Version 4.0</div></div></div>"},"100116":{"type":"graphic_diagnosticimage","displayName":"Catheter-based angiography showing focal FMD","title":"Catheter-based angiography showing focal fibromuscular dysplasia","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Catheter-based angiography showing focal fibromuscular dysplasia</div><div class=\"cntnt\"><img style=\"width:457px; height:308px;\" src=\"images/NEPH/100116_Cthtr_anggrphy_shw_fcl_FMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Catheter-based angiogram showing a focal area of severe stenosis in the mid portion of the right renal artery. This appearance is typical for focal fibromuscular dysplasia (focal FMD).</div><div id=\"graphicVersion\">Graphic 100116 Version 1.0</div></div></div>"},"100117":{"type":"graphic_table","displayName":"Working Alliance Inventory - Client","title":"Working Alliance Inventory - Client","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Working Alliance Inventory - Client</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"7\">Short form (C)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"7\">Instructions</td> </tr> <tr> <td colspan=\"7\"> <ul> <li>On the following pages there are sentences that describe some of the different ways a person might think or feel about his or her therapist (counselor). As you read the sentences mentally insert the name of your therapist (counselor) in place of _____________ in the text. </li> </ul> </td> </tr> <tr> <td colspan=\"7\"> <ul> <li>Below each statement inside there is a seven point scale: </li> </ul> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"> <ul> <li>If the statement describes the way you <strong>always</strong> feel (or think) circle the number 7; if it <strong>never</strong> applies to you circle the number 1. Use the numbers in between to describe the variations between these extremes. </li> </ul> </td> </tr> <tr> <td colspan=\"7\"> <ul> <li><strong>This questionnaire is CONFIDENTIAL; neither your therapist nor the agency will see your answers.</strong> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\"> <ul> <li>Work fast, your first impressions are the ones we would like to see. (PLEASE DON'T FORGET TO RESPOND TO <strong>EVERY</strong> ITEM.) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"7\"> <p>&nbsp;</p> Thank you for your cooperation. <p>&nbsp;</p> </td> </tr> <tr> <td colspan=\"7\"><br /> <ol> <li>_______________ and I agree about the things I will need to do in therapy to help improve my situation. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"2\"> <li>What I am doing in therapy gives me new ways of looking at my problem. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"3\"> <li>I believe _______________ likes me. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"4\"> <li>_______________ does not understand what I am trying to accomplish in therapy. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"5\"> <li>I am confident in _______________ 's ability to help me. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"6\"> <li>_______________ and I are working towards mutually agreed upon goals. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"7\"> <li>I feel that _______________ appreciates me. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"8\"> <li>We agree on what is important for me to work on. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"9\"> <li>_______________ and I trust one another. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"10\"> <li>_______________ and I have different ideas on what my problems are. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"11\"> <li>We have established a good understanding of the kind of changes that would be good for me. </li> </ol> </td> </tr> <tr class=\"centered\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr> <td colspan=\"7\"><br /> <ol start=\"12\"> <li>I believe the way we are working with my problem is correct. </li> </ol> </td> </tr> <tr class=\"centered divider_bottom\"> <td> <p>1</p> Never</td> <td> <p>2</p> Rarely</td> <td> <p>3</p> Occasionally</td> <td> <p>4</p> Sometimes</td> <td> <p>5</p> Often</td> <td> <p>6</p> Very often</td> <td> <p>7</p> Always</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1 highlight_gray_text\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Scoring key for the WAI Short form (C)</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Task scale items:</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">8</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Direction* of scoring:</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"sublist1\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Bond scale items:</td> <td class=\"centered\">3</td> <td class=\"centered\">5</td> <td class=\"centered\">7</td> <td class=\"centered\">9</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Direction* of scoring:</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"sublist1\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Goal scale items:</td> <td class=\"centered\">4</td> <td class=\"centered\">6</td> <td class=\"centered\">10</td> <td class=\"centered\">11</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Direction* of scoring:</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Items marked positive (+) -&gt; high values are better alliance; otherwise (&ndash;) reverse scoring.</div><div class=\"graphic_reference\">The Working Alliance Inventory is copyright (&copy; A. O. Horvath, 1981,1986) for copyright permission go to <a href=\"http://websurvey.sfu.ca/survey/33238145\" target=\"_blank\">http://websurvey.sfu.ca/survey/33238145</a>.</div><div id=\"graphicVersion\">Graphic 100117 Version 1.0</div></div></div>"},"100119":{"type":"graphic_waveform","displayName":"ECG changes with fever in Brugada syndrome","title":"Narrow QRS complex tachycardia with ST segment changes due to fever in an 11-month-old child with Brugada syndrome","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Narrow QRS complex tachycardia with ST segment changes due to fever in an 11-month-old child with Brugada syndrome</div><div class=\"cntnt\"><img style=\"width:594px; height:491px;\" src=\"images/PEDS/100119_ECG_chng_fvr_brgd_syndrm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Electrocardiography demonstrating narrow QRS complex tachycardia and ST segment changes&nbsp;triggered by fever in an 11-month-old child with Brugada syndrome.<br />(B) Electrocardiography reverts to normal with the resolution of fever in the same patient.</div><div id=\"graphicVersion\">Graphic 100119 Version 2.0</div></div></div>"},"100124":{"type":"graphic_figure","displayName":"Muscles of anterolateral abdominal wall","title":"Muscles of anterolateral abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Muscles of anterolateral abdominal wall</div><div class=\"cntnt\"><img style=\"width:633px; height:530px;\" src=\"images/EM/100124_Muscleantrltrlabdmnlwall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-C) Three layers of muscles of anterolateral abdominal wall.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100124 Version 3.0</div></div></div>"},"100126":{"type":"graphic_picture","displayName":"Seb keratosis multiple","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100126_Seb_keratosis_multiple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple seborrheic keratoses on the back with a characteristic \"Christmas tree\" distribution.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100126 Version 1.0</div></div></div>"},"100127":{"type":"graphic_picture","displayName":"Prone position on horseshoe headrest","title":"Prone position on horseshoe headrest","html":"<div class=\"graphic\"><div style=\"width: 721px\" class=\"figure\"><div class=\"ttl\">Prone position on horseshoe headrest</div><div class=\"cntnt\"><img style=\"width:701px; height:703px;\" src=\"images/ANEST/100127_Prn_pstn_hrssh_hdrst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient's eyes are very close to the device when&nbsp;positioned prone&nbsp;using the&nbsp;horseshoe headrest. A minor&nbsp;shift in the&nbsp;head position can result in pressure on the globe and potential injury.</div><div id=\"graphicVersion\">Graphic 100127 Version 2.0</div></div></div>"},"100130":{"type":"graphic_table","displayName":"ASA POVL practice advisory summary","title":"Practice advisory for perioperative visual loss associated with spine surgery: Advisory statements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Practice advisory for perioperative visual loss associated with spine surgery: Advisory statements</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">American Society of Anesthesiologists Task Force on Perioperative Visual Loss</td> </tr> <tr> <td class=\"subtitle2\">Practice advisory for perioperative visual loss associated with spine surgery (updated report, 2012)</td> </tr> <tr> <td>1. Preoperative preparation: Consider informing patients who will undergo prolonged spine surgery in the prone position with or without substantial blood loss of the risk of postoperative visual loss.</td> </tr> <tr> <td>2. Intraoperative management:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Monitor blood pressure continually. </li> <li>Administer colloids along with crystalloids to maintain euvolemia for patients who have substantial blood loss. </li> <li>Monitor hemoglobin or hematocrit periodically during cases with substantial blood loss. </li> <li>Position the head at the level of the heart or higher and in a neutral forward position, ie, without significant neck flexion, extension, lateral flexion, or rotation when possible. </li> <li>Avoid direct pressure on the globe to prevent central retinal artery occlusion. </li> <li>Consider staging spine procedures in high-risk patients. </li> </ul> </td> </tr> <tr> <td>3. Postoperative management:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Vision should be assessed when patient becomes alert after anesthesia. </li> <li>If there is potential visual loss: <ul> <li>Urgent ophthalmologic consultation should be obtained. </li> <li>Additional management may include optimizing hemoglobin or hematocrit, hemodynamic status, and arterial oxygenation. </li> <li>Consider magnetic resonance imaging to rule out intracranial causes of visual loss. </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: American Society of Anesthesiologists Task Force on Perioperative Visual Loss. Practice advisory for perioperative visual loss associated with spine surgery: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Visual Loss. Anesthesiology 2012; 116:274.</div><div id=\"graphicVersion\">Graphic 100130 Version 2.0</div></div></div>"},"100131":{"type":"graphic_picture","displayName":"Dermatosis papulosa nigra 3","title":"Dermatosis papulosa nigra","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dermatosis papulosa nigra</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100131_Dermatosis_papulos_nigra_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous hyperpigmented papules on the cheek and periocular region of this patient with dermatosis papulosa nigra.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100131 Version 1.0</div></div></div>"},"100139":{"type":"graphic_picture","displayName":"Epidermoid cyst punctum","title":"Epidermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Epidermoid cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/100139_Epidermoid_cyst_punctum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A central punctum corresponding to the follicular opening is visible on this epidermoid cyst.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100139 Version 1.0</div></div></div>"},"100140":{"type":"graphic_picture","displayName":"Epidermoid cyst close-up","title":"Epidermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Epidermoid cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100140_Epidermoid_cyst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermoid (sebaceous) cyst presenting as a skin-colored subcutaneous nodule. A few telangiectasias are visible on the surface.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100140 Version 1.0</div></div></div>"},"100141":{"type":"graphic_picture","displayName":"Epidermoid cyst inflamed","title":"Epidermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Epidermoid cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100141_Epidermoid_cyst_inflamed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed epidermoid cyst undergoing spontaneous rupture.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100141 Version 1.0</div></div></div>"},"100143":{"type":"graphic_picture","displayName":"Keratin granuloma","title":"Keratin granuloma","html":"<div class=\"graphic\"><div style=\"width: 891px\" class=\"figure\"><div class=\"ttl\">Keratin granuloma</div><div class=\"cntnt\"><img style=\"width:871px; height:331px;\" src=\"images/DERM/100143_Keratin_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A granulomatous inflammatory reaction surrounding eosinophilic keratinous material released into the dermis by a ruptured epidermoid cyst.<br />(B) At higher magnification, foreign body-type giant cells and keratin flakes are visible.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100143 Version 1.0</div></div></div>"},"100144":{"type":"graphic_figure","displayName":"Ileocecectomy","title":"Ileocecectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ileocecectomy</div><div class=\"cntnt\"><img style=\"width:428px; height:529px;\" src=\"images/SURG/100144_Ileocecectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ileocecectomy resects the cecum along with 12 to 15 cm of small bowel for benign pathologies.</div><div id=\"graphicVersion\">Graphic 100144 Version 2.0</div></div></div>"},"100145":{"type":"graphic_picture","displayName":"Ganglion cyst","title":"Ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ganglion cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100145_Ganglion_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ganglion cyst presenting as a firm nodular swelling on the dorsal aspect of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100145 Version 1.0</div></div></div>"},"100146":{"type":"graphic_picture","displayName":"Ganglion cyst multiple","title":"Ganglion cyst","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ganglion cyst</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100146_Ganglion_cyst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple ganglion cysts presenting as firm subcutaneous nodules attached to the underlying tissues.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100146 Version 1.0</div></div></div>"},"100147":{"type":"graphic_picture","displayName":"Lipoma neck","title":"Lipoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lipoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100147_Lipoma_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lipoma presenting as a large subcutaneous mass at the base of the neck of this patient. Several red-blue cherry angiomas are present on the surrounding skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100147 Version 1.0</div></div></div>"},"100149":{"type":"graphic_picture","displayName":"Vellus hair cysts","title":"Eruptive vellus hair cysts","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eruptive vellus hair cysts</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100149_Vellus_hair_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous monomorphous follicular, dome-shaped papules are present on the chest of this patient. Histologic examination revealed vellus hair cysts.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100149 Version 1.0</div></div></div>"},"100150":{"type":"graphic_table","displayName":"Clinical sequelae of pica","title":"Clinical sequelae of pica by item ingested","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical sequelae of pica by item ingested</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item of pica craving</td> <td class=\"subtitle1\">Potential clinical sequelae</td> </tr> <tr> <td>Earth, including soil or other earth-rich items such as adobe, clay preparations, pottery, or bean stones</td> <td> <ul> <li>Low gestational weight gain </li> <li>Constipation, intestinal obstruction </li> <li>Micronutrient and trace mineral deficiencies </li> <li>Hypokalemia </li> <li>Exposure to toxins (eg, lead, arsenic, mercury, cadmium, organic pollutants) </li> <li>Infection (microbial,&nbsp;parasites found in soil,&nbsp;including&nbsp;<em>Toxoplasma </em>and<em> Toxocara</em>) </li> <li>Reduced effectiveness of medications </li> </ul> </td> </tr> <tr> <td>Raw starches, including corn starch, laundry starch, raw rice, flour, raw wheat</td> <td> <ul> <li>Excessive weight gain </li> <li>Poor glucose control in women with diabetes </li> <li>Abdominal discomfort </li> <li>Jaw pain,&nbsp;dental damage </li> </ul> </td> </tr> <tr> <td>Baking powder, baking soda</td> <td> <ul> <li>Electrolyte abnormalities </li> <li>Metabolic alkalosis </li> <li>Hypertension, edema </li> </ul> </td> </tr> <tr> <td>Ice</td> <td> <ul> <li>Low gestational weight gain </li> <li>Jaw pain, dental damage </li> </ul> </td> </tr> <tr> <td>Foam, cloth</td> <td> <ul> <li>Bezoar </li> <li>Intestinal obstruction </li> </ul> </td> </tr> <tr> <td>Paper, cardboard</td> <td> <ul> <li>Gastrointestinal obstruction </li> <li>Exposure to toxins in ink </li> </ul> </td> </tr> <tr> <td>Toothpaste</td> <td> <ul> <li>Fluoride toxicity </li> <li>Fluorosis in offspring </li> <li>Hypertension, edema </li> </ul> </td> </tr> <tr> <td>Coffee grounds</td> <td> <ul> <li>Caffeine toxicity </li> </ul> </td> </tr> <tr> <td>Cigarette filters</td> <td> <ul> <li>Nicotine toxicity </li> </ul> </td> </tr> <tr> <td>Chemicals, paint</td> <td> <ul> <li>Nausea, vomiting </li> <li>Lead toxicity&nbsp;&nbsp; </li> </ul> </td> </tr> <tr> <td>Bleach&nbsp;</td> <td> <ul> <li>Nausea, vomiting </li> <li>Internal burns </li> </ul> </td> </tr> <tr> <td>Chalk&nbsp;</td> <td> <ul> <li>Lead toxicity </li> </ul> </td> </tr> <tr> <td>Burnt matches&nbsp;</td> <td> <ul> <li>Hyperkalemia </li> <li>Neonatal hemolysis </li> </ul> </td> </tr> <tr> <td>Mothballs (naphthalene&nbsp;or paradichlorobenzene)</td> <td> <ul> <li>Maternal and fetal hemolytic anemia </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 100150 Version 2.0</div></div></div>"},"100178":{"type":"graphic_picture","displayName":"Knee immobilization for quadriceps contusion","title":"Knee immobilization for quadriceps contusion","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Knee immobilization for quadriceps contusion</div><div class=\"cntnt\"><img style=\"width:532px; height:710px;\" src=\"images/EM/100178_120_degree_wrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A quadriceps muscle with a significant contusion should be immobilized as soon as possible with the knee in 120 degrees of flexion, as pictured above.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100178 Version 3.0</div></div></div>"},"100180":{"type":"graphic_picture","displayName":"Leg extension machine","title":"Leg extension machine","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Leg extension machine</div><div class=\"cntnt\"><img style=\"width:727px; height:276px;\" src=\"images/EM/100180_Eccentric_leg_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The knee or&nbsp;leg extension machine is used to strengthen the quadriceps muscles during rehabilitation. In the photographs above, the machine is used for eccentric quadriceps contraction: starting position (A) and finishing position (B). The concentric contraction needed to return to the starting position is performed with the unaffected limb. The machine may be used in standard fashion using one or both legs to perform both the concentric (raising) and eccentric (lowering) movements. </div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100180 Version 3.0</div></div></div>"},"100181":{"type":"graphic_picture","displayName":"Leg press machine","title":"Leg press machine","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Leg press machine</div><div class=\"cntnt\"><img style=\"width:713px; height:534px;\" src=\"images/EM/100181_Unloaded_eccentric_squat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The machine leg press&nbsp;can be performed in several ways.&nbsp;The \"unloaded\" (ie,&nbsp;no bodyweight)&nbsp;eccentric squat may be performed using a leg press or a Shuttle. The exercise may be performed unilaterally&nbsp;using the affected extremity, with the concentric portion (pushing from platform)&nbsp;performed using the unaffected extremity as well. The exercise may be done bilaterally if pain is too great during the unilateral version. Alternatively, a standard leg press may be performed using one or both legs.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100181 Version 2.0</div></div></div>"},"100182":{"type":"graphic_picture","displayName":"Leg raises in all planes (around the world)","title":"Leg raises in all planes (around the world)","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Leg raises in all planes (around the world)</div><div class=\"cntnt\"><img style=\"width:728px; height:550px;\" src=\"images/EM/100182_Around_world_leg_raises.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leg raises are an example of light resistance exercise and can be performed relatively early during rehabilitation, provided they do not cause pain: (A) hip flexion; (B) hip abduction; (C) hip adduction; (D) prone hip extension.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100182 Version 3.0</div></div></div>"},"100183":{"type":"graphic_picture","displayName":"Eccentric decline squat","title":"Eccentric decline squat","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Eccentric decline squat</div><div class=\"cntnt\"><img style=\"width:727px; height:486px;\" src=\"images/EM/100183_Eccentric_decline_squat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eccentric squat is performed on an inclined surface&nbsp;using only&nbsp;the affected leg during descent&nbsp;until the knee is flexed to approximately 60 degrees&nbsp;(A). It is important to sit back and not allow the knee to move forward. The unaffected limb can be used to bear most of the patient's weight (B)&nbsp;as&nbsp;she or he&nbsp;returns to the starting standing position.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100183 Version 1.0</div></div></div>"},"100185":{"type":"graphic_picture","displayName":"Drop squats","title":"Drop squats","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Drop squats</div><div class=\"cntnt\"><img style=\"width:718px; height:477px;\" src=\"images/EM/100185_Drop_squats.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A drop squat is performed by rapidly dropping from starting position (A) and&nbsp;into a&nbsp;squat position (B), and then maintaining the squat position. The exercise&nbsp;can be made more difficult by adding weight or by&nbsp;increasing the&nbsp;time&nbsp;the&nbsp;squat position is held—usually between 1 to 10 seconds.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100185 Version 1.0</div></div></div>"},"100186":{"type":"graphic_picture","displayName":"Eccentric step down quadriceps exercise","title":"Eccentric step down quadriceps exercise","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Eccentric step down quadriceps exercise</div><div class=\"cntnt\"><img style=\"width:727px; height:485px;\" src=\"images/EM/100186_Step_downs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The eccentric step down exercise is used for the rehabilitation of quadriceps injuries. The starting position (A) and finishing position (B) are shown above.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100186 Version 2.0</div></div></div>"},"100187":{"type":"graphic_picture","displayName":"Drop jump","title":"Drop jump","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Drop jump</div><div class=\"cntnt\"><img style=\"width:727px; height:484px;\" src=\"images/EM/100187_Drop_jumps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drop jumps are&nbsp;used diagnostically to evaluate landing mechanics and lower extremity stability, and as an exercise during rehabilitation. Starting position (A) and finishing position (B) are pictured.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100187 Version 2.0</div></div></div>"},"100188":{"type":"graphic_picture","displayName":"Knee extension with 30 degree arc","title":"Knee extension with 30 degree arc","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Knee extension with 30 degree arc</div><div class=\"cntnt\"><img style=\"width:729px; height:276px;\" src=\"images/EM/100188_30_degree_extension_arc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early rehabilitation for partial quadriceps tears includes knee extensions performed in a short arc &mdash; typically 30 degrees. A support is placed under the knee for comfort in the starting position (A) and the patient fully extends the knee (B).</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100188 Version 2.0</div></div></div>"},"100189":{"type":"graphic_picture","displayName":"Reverse Nordic lower","title":"Reverse Nordic lower","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Reverse Nordic lower</div><div class=\"cntnt\"><img style=\"width:715px; height:481px;\" src=\"images/EM/100189_Reverse_nordic_lower.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The reverse Nordic lower is an eccentric quadriceps exercise. The patient begins on a mat with knees at 90 degrees flexion (A) and lowers the upper body in a controlled manner with increasing knee flexion (B).</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100189 Version 1.0</div></div></div>"},"100190":{"type":"graphic_table","displayName":"Iron and zinc content of selected foods","title":"Iron and zinc content of selected foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iron and zinc content of selected foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\">All serving sizes are 3 oz (85 g) cooked portions unless otherwise noted. Foods are grouped by their iron content; ranges depend on the type of animal (in the case of organ meats) or the cut of the meat. Check your local food composition tables for additional options.</td> </tr> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Iron (mg)</td> <td class=\"subtitle1\">Zinc (mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Excellent sources of iron</td> </tr> <tr> <td class=\"indent1\">Bear</td> <td class=\"centered\">9.12</td> <td class=\"centered\">8.73</td> </tr> <tr> <td class=\"indent1\">Beaver</td> <td class=\"centered\">8.50</td> <td class=\"centered\">1.93</td> </tr> <tr> <td class=\"indent1\">Blood sausage</td> <td class=\"centered\">5.44</td> <td class=\"centered\">1.10</td> </tr> <tr> <td class=\"indent1\">Caribou</td> <td class=\"centered\">5.24</td> <td class=\"centered\">4.47</td> </tr> <tr> <td class=\"indent1\">Cuttlefish</td> <td class=\"centered\">9.21</td> <td class=\"centered\">2.94</td> </tr> <tr> <td class=\"indent1\">Emu</td> <td class=\"centered\">3.88 to 6.18</td> <td class=\"centered\">2.71 to 4.33</td> </tr> <tr> <td class=\"indent1\">Heart</td> <td class=\"centered\">3.67 to 7.68</td> <td class=\"centered\">1.90 to 6.21</td> </tr> <tr> <td class=\"indent1\">Horse</td> <td class=\"centered\">4.28</td> <td class=\"centered\">3.25</td> </tr> <tr> <td class=\"indent1\">Kidneys</td> <td class=\"centered\">2.58 to 10.54</td> <td class=\"centered\">2.41 to 3.61</td> </tr> <tr> <td class=\"indent1\">Liver</td> <td class=\"centered\">4.34 to 15.23</td> <td class=\"centered\">3.38 to 10.12</td> </tr> <tr> <td class=\"indent1\">Liver sausage<br /> (braunschweiger, liverwurst, pat&#233;)</td> <td class=\"centered\">4.67 to 9.52</td> <td class=\"centered\">0.78 to 2.89</td> </tr> <tr> <td class=\"indent1\">Lungs</td> <td class=\"centered\">3.07 to 13.95</td> <td class=\"centered\">1.02 to 2.08</td> </tr> <tr> <td class=\"indent1\">Moose</td> <td class=\"centered\">3.59</td> <td class=\"centered\">3.13</td> </tr> <tr> <td class=\"indent1\">Muskrat</td> <td class=\"centered\">6.04</td> <td class=\"centered\">1.93</td> </tr> <tr> <td class=\"indent1\">Mussels, blue</td> <td class=\"centered\">5.71</td> <td class=\"centered\">2.27</td> </tr> <tr> <td class=\"indent1\">Mutton</td> <td class=\"centered\">4.05</td> <td class=\"centered\">5.04</td> </tr> <tr> <td class=\"indent1\">Octopus</td> <td class=\"centered\">8.11</td> <td class=\"centered\">2.86</td> </tr> <tr> <td class=\"indent1\">Opossum</td> <td class=\"centered\">3.94</td> <td class=\"centered\">1.94</td> </tr> <tr> <td class=\"indent1\">Oysters</td> <td class=\"centered\">5.70 to 7.83</td> <td class=\"centered\">28.25 to 77.31</td> </tr> <tr> <td class=\"indent1\">Quail</td> <td class=\"centered\">3.77</td> <td class=\"centered\">2.63</td> </tr> <tr> <td class=\"indent1\">Raccoon</td> <td class=\"centered\">6.04</td> <td class=\"centered\">1.93</td> </tr> <tr> <td class=\"indent1\">Squirrel</td> <td class=\"centered\">5.79</td> <td class=\"centered\">1.51</td> </tr> <tr> <td class=\"indent1\">Spleen</td> <td class=\"centered\">6.26 to 33.46</td> <td class=\"centered\">1.62 to 3.35</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Whelk</td> <td class=\"centered\">8.55</td> <td class=\"centered\">2.77</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Good sources of iron</td> </tr> <tr> <td class=\"indent1\">Antelope</td> <td class=\"centered\">3.57</td> <td class=\"centered\">1.43</td> </tr> <tr> <td class=\"indent1\">Beef</td> <td class=\"centered\">1.44 to 3.20</td> <td class=\"centered\">3.43 to 10.16</td> </tr> <tr> <td class=\"indent1\">Bison/Buffalo</td> <td class=\"centered\">2.45 to 4.13</td> <td class=\"centered\">3.13 to 7.34</td> </tr> <tr> <td class=\"indent1\">Brains</td> <td class=\"centered\">0.91 to 1.95</td> <td class=\"centered\">0.93 to 1.70</td> </tr> <tr> <td class=\"indent1\">Clams</td> <td class=\"centered\">2.28 to 2.39</td> <td class=\"centered\">0.71 to 2.32</td> </tr> <tr> <td class=\"indent1\">Deer/Venison</td> <td class=\"centered\">2.85 to 4.26</td> <td class=\"centered\">2.34 to 7.34</td> </tr> <tr> <td class=\"indent1\">Duck</td> <td class=\"centered\">2.29 to 3.82</td> <td class=\"centered\">2.21</td> </tr> <tr> <td class=\"indent1\">Elk</td> <td class=\"centered\">2.28 to 7.70</td> <td class=\"centered\">2.69 to 6.62</td> </tr> <tr> <td class=\"indent1\">Gizzards</td> <td class=\"centered\">2.71 to 3.13</td> <td class=\"centered\">3.33 to 3.76</td> </tr> <tr> <td class=\"indent1\">Goat</td> <td class=\"centered\">3.17</td> <td class=\"centered\">4.48</td> </tr> <tr> <td class=\"indent1\">Lamb</td> <td class=\"centered\">1.50 to 1.93</td> <td class=\"centered\">2.90 to 7.36</td> </tr> <tr> <td class=\"indent1\">Ostrich</td> <td class=\"centered\">2.37 to 4.08</td> <td class=\"centered\">3.68 to 4.17</td> </tr> <tr> <td class=\"indent1\">Pancreas</td> <td class=\"centered\">1.80 to 2.29</td> <td class=\"centered\">2.28 to 4.42</td> </tr> <tr> <td class=\"indent1\">Rabbit</td> <td class=\"centered\">1.93 to 4.12</td> <td class=\"centered\">1.93 to 2.02</td> </tr> <tr> <td class=\"indent1\">Sardines</td> <td class=\"centered\">1.95 to 2.48</td> <td class=\"centered\">1.11 to 1.19</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tongue</td> <td class=\"centered\">1.78 to 4.24</td> <td class=\"centered\">2.54 to 3.85</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Fair sources of iron</td> </tr> <tr> <td class=\"indent1\">Boar, wild</td> <td class=\"centered\">0.95</td> <td class=\"centered\">2.56</td> </tr> <tr> <td class=\"indent1\">Chicken breast</td> <td class=\"centered\">0.88</td> <td class=\"centered\">0.85</td> </tr> <tr> <td class=\"indent1\">Chicken leg/thigh</td> <td class=\"centered\">0.92 to 1.21</td> <td class=\"centered\">1.63 to 2.36</td> </tr> <tr> <td class=\"indent1\">Cod</td> <td class=\"centered\">0.14 to 0.42</td> <td class=\"centered\">0.33 to 0.49</td> </tr> <tr> <td class=\"indent1\">Intestines</td> <td class=\"centered\">1.25</td> <td class=\"centered\">1.57</td> </tr> <tr> <td class=\"indent1\">Pork</td> <td class=\"centered\">0.54 to 1.57</td> <td class=\"centered\">1.78 to 4.42</td> </tr> <tr> <td class=\"indent1\">Salmon</td> <td class=\"centered\">0.29 to 0.88</td> <td class=\"centered\">0.37 to 0.82</td> </tr> <tr> <td class=\"indent1\">Shrimp</td> <td class=\"centered\">0.27 to 1.81</td> <td class=\"centered\">1.39 to 1.67</td> </tr> <tr> <td class=\"indent1\">Stomach/Tripe</td> <td class=\"centered\">0.56 to 1.05</td> <td class=\"centered\">1.45 to 2.48</td> </tr> <tr> <td class=\"indent1\">Tilapia</td> <td class=\"centered\">0.59</td> <td class=\"centered\">0.35</td> </tr> <tr> <td class=\"indent1\">Trout</td> <td class=\"centered\">0.31 to 1.63</td> <td class=\"centered\">0.43 to 0.72</td> </tr> <tr> <td class=\"indent1\">Tuna</td> <td class=\"centered\">0.55 to 1.39</td> <td class=\"centered\">0.38 to 0.89</td> </tr> <tr> <td class=\"indent1\">Turkey breast</td> <td class=\"centered\">0.60</td> <td class=\"centered\">1.46</td> </tr> <tr> <td class=\"indent1\">Turkey leg, thigh</td> <td class=\"centered\">1.22 to 1.35</td> <td class=\"centered\">2.77 to 2.98</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: U.S. Department of Agriculture, Agricultural Research Service. 2016. USDA National Nutrient Database for Standard Reference, Release 28. Nutrient Data Laboratory Home Page. <A href=\"https://www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/nutrient-data-laboratory/\">https://www.ars.usda.gov/northeast-area/beltsville-md/beltsville-human-nutrition-research-center/nutrient-data-laboratory/</A>.</div><div id=\"graphicVersion\">Graphic 100190 Version 4.0</div></div></div>"},"100192":{"type":"graphic_picture","displayName":"Overhead reverse lunge","title":"Overhead reverse lunge","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Overhead reverse lunge</div><div class=\"cntnt\"><img style=\"width:726px; height:485px;\" src=\"images/EM/100192_Overhead_reverse_lunge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An overhead reverse lunge is an eccentric quadriceps exercise. It starts&nbsp;with a&nbsp;fully upright position (A). The athlete then strides back by extending the hip and flexing the&nbsp;knee of the rear leg&nbsp;in a controlled manner, while holding a ball overhead and maintaining good posture&nbsp;(B). The quadriceps of the forward leg (with foot elevated)&nbsp;is contracting eccentrically.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100192 Version 3.0</div></div></div>"},"100193":{"type":"graphic_picture","displayName":"Dynamic stability exercise","title":"Dynamic stability exercise","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Dynamic stability exercise</div><div class=\"cntnt\"><img style=\"width:727px; height:484px;\" src=\"images/EM/100193_Dynamic_stability_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of a dynamic stability activity that simulates a kicking motion. Tension is place on the contralateral upper and lower extremities to simulate motion across multiple segments.</div><div class=\"graphic_reference\">Courtesy of Timothy J Von Fange, MD.</div><div id=\"graphicVersion\">Graphic 100193 Version 1.0</div></div></div>"},"100194":{"type":"graphic_picture","displayName":"Great toe taping","title":"Great toe taping","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Great toe taping</div><div class=\"cntnt\"><img style=\"width:482px; height:721px;\" src=\"images/SM/100194_Greattoetaping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with soft tissue strains related to the great toe may benefit from additional support during activity, such as that provided by the taping described here:<br />(A) Apply anchors.<br />(B) Apply strip to plantar surface.<br />(C) Apply additional support strips.<br />(D) Apply anchors to close.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100194 Version 5.0</div></div></div>"},"100196":{"type":"graphic_picture","displayName":"Heel contusion taping","title":"Heel contusion taping","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Heel contusion taping</div><div class=\"cntnt\"><img style=\"width:721px; height:414px;\" src=\"images/EM/100196_Heelcontusiontaping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a heel contusion may benefit from additional support, such as that provided by the taping described here:<br />(A) Apply anchors behind and below heel.<br />(B) Using a basket weave technique, apply strips until heel is covered.<br />(C) Reapply anchors to finish.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100196 Version 4.0</div></div></div>"},"100197":{"type":"graphic_table","displayName":"BI-RADS mammographic assessment categories","title":"BI-RADS mammographic assessment categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">BI-RADS mammographic assessment categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\">Management</td> <td class=\"subtitle1\">Likelihood of cancer</td> </tr> <tr class=\"divider_bottom\"> <td>Category 0: Incomplete &ndash; Need additional imaging evaluation and/or prior mammograms for comparison</td> <td>Recall for additional imaging and/or comparison with prior examination(s)</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Category 1: Negative</td> <td>Routine mammography screening</td> <td>Essentially 0 percent&nbsp;likelihood of malignancy</td> </tr> <tr class=\"divider_bottom\"> <td>Category 2: Benign</td> <td>Routine mammography screening</td> <td>Essentially 0 percent&nbsp;likelihood of malignancy</td> </tr> <tr class=\"divider_bottom\"> <td>Category 3: Probably benign</td> <td>Short-interval (6-month) follow-up or continued surveillance mammography</td> <td>&#62;0 but &#8804;2 percent&nbsp;likelihood of malignancy</td> </tr> <tr> <td class=\"sublist1_start\">Category 4: Suspicious</td> <td class=\"divider_bottom\" rowspan=\"4\">Tissue diagnosis</td> <td class=\"sublist1_start\">&#62;2 but &#60;95 percent&nbsp;likelihood of malignancy</td> </tr> <tr> <td class=\"indent1\">Category 4A: <em>Low suspicion</em> for malignancy</td> <td class=\"indent1\">&#62;2 to &#8804;10 percent likelihood of malignancy</td> </tr> <tr> <td class=\"indent1\">Category 4B: <em>Moderate suspicion</em> for malignancy</td> <td class=\"indent1\">&#62;10 to &#8804;50 percent&nbsp;likelihood of malignancy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Category 4C: <em>High suspicion</em> for malignancy</td> <td class=\"indent1\">&#62;50 to &#60;95 percent&nbsp;likelihood of malignancy</td> </tr> <tr class=\"divider_bottom\"> <td>Category 5: Highly suggestive of malignancy</td> <td>Tissue diagnosis</td> <td>&#8805;95 percent&nbsp;likelihood of malignancy</td> </tr> <tr> <td>Category 6: Known biopsy-proven malignancy</td> <td>Surgical excision when clinically appropriate</td> <td>N/A</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission of the American College of Radiology (ACR). No other representation of this material is authorized without expressed, written permission from the ACR. Refer to the ACR website at <a href=\"http://www.acr.org/Quality-Safety/Resources/BIRADS\" target=\"_blank\">www.acr.org/Quality-Safety/Resources/BIRADS</a> for the most current and complete version of the BI-RADS&reg; Atlas.</div><div id=\"graphicVersion\">Graphic 100197 Version 6.0</div></div></div>"},"100198":{"type":"graphic_picture","displayName":"Open basket weave ankle taping","title":"Open basket weave ankle taping","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">Open basket weave ankle taping</div><div class=\"cntnt\"><img style=\"width:731px; height:563px;\" src=\"images/EM/100198_Openbasketweaveankltpng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients in need of additional ankle support, including athletes returning to sport following an ankle sprain, may benefit from taping, as described here:<br />(A) Apply proximal and distal anchors.<br />(B) Apply a stirrup strip.<br />(C) Apply a horseshoe strip.<br />(D) Continue to alternate stirrups and horseshoes, leaving an opening on the anterior aspect, and close the plantar foot with strips of tape.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100198 Version 4.0</div></div></div>"},"100199":{"type":"graphic_picture","displayName":"Closed basket weave ankle taping","title":"Closed basket weave ankle taping","html":"<div class=\"graphic\"><div style=\"width: 789px\" class=\"figure\"><div class=\"ttl\">Closed basket weave ankle taping</div><div class=\"cntnt\"><img style=\"width:769px; height:870px;\" src=\"images/EM/100199_Clsdbasketweaveankltpng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The closed basket weave is a basic taping technique for athletes and others in need of additional ankle support. It is applied as follows:<br />(A) Apply proximal and distal anchors; apply a stirrup strip.<br />(B) Apply a horseshoe strip.<br />(C) Continue to alternate stirrups and horseshoes.<br />(D) Apply figure eight.<br />(E) Apply heel locks.<br />(F) Close with horizontal anchor strips.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100199 Version 4.0</div></div></div>"},"100200":{"type":"graphic_picture","displayName":"Modified ankle taping","title":"Modified ankle taping","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Modified ankle taping</div><div class=\"cntnt\"><img style=\"width:716px; height:580px;\" src=\"images/EM/100200_Modifiedankletaping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients in need of additional ankle support, including athletes returning to sport following an ankle sprain, may benefit from taping, as described here:<br />(A) Apply proximal and distal anchors.<br />(B) Apply three stirrup strips.<br />(C) Apply figure eight with heel locks.<br />(D) Close using successive circular strips around foot, continuing proximal to distal strips.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100200 Version 4.0</div></div></div>"},"100201":{"type":"graphic_picture","displayName":"Achilles tendon taping","title":"Achilles tendon taping","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Achilles tendon taping</div><div class=\"cntnt\"><img style=\"width:728px; height:774px;\" src=\"images/EM/100201_Achillestendontaping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Athletes or others recovering from an Achilles tendon strain may benefit from additional support, such as that described here, while resuming activity:<br />(A) Apply anchors.<br />(B) Apply three to five strips in an X pattern from distal to proximal anchor.<br />(C) Check that dorsiflexion is appropriately limited (ie, does not extend to range that provokes pain).<br />(D) Re-anchor the X distally and proximally.<br />(E-F) Apply a figure eight and heel locks.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100201 Version 4.0</div></div></div>"},"100203":{"type":"graphic_picture","displayName":"Knee lateral collateral ligament taping","title":"Knee lateral collateral ligament taping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee lateral collateral ligament taping</div><div class=\"cntnt\"><img style=\"width:450px; height:725px;\" src=\"images/EM/100203_Kneecollaterallgmntspprt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from an isolated lateral collateral ligament (LCL) strain or who need additional support of the lateral knee can be treated as described:<br />(A) Using elastic tape, apply distal anchor 2-3 in below tibial tuberosity; apply proximal anchor at midpoint of quadriceps.<br />(B) Apply lateral and medial strips in an X fashion.<br />(C) Reinforce with nonelastic tape.<br />(D) Close with strips moving from distal to proximal.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100203 Version 5.0</div></div></div>"},"100204":{"type":"graphic_picture","displayName":"Knee hyperextension taping","title":"Knee hyperextension taping","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Knee hyperextension taping</div><div class=\"cntnt\"><img style=\"width:798px; height:406px;\" src=\"images/EM/100204_Kneehyperextensionstrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Taping of the knee for patients recovering from a hyperextension injury or who need additional support of the posterior knee can be performed as described below and pictured above. The support provided by this taping method would <strong>not</strong> be adequate for a patient returning to full participation in a sport following a significant posterior knee injury (eg, PCL tear).<br />(A) Apply distal and proximal anchors.<br />(B) From the inferior anchor, apply tape strips in an X pattern; pattern should begin wide and become narrow; the last strip should be perpendicular to the anchors.<br />(C) Apply two to three anchors on the lower leg and four to five anchors on the thigh.</div><div class=\"graphic_footnotes\">PCL: posterior cruciate ligament.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100204 Version 5.0</div></div></div>"},"100205":{"type":"graphic_picture","displayName":"Quadriceps wrap","title":"Quadriceps wrap","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Quadriceps wrap</div><div class=\"cntnt\"><img style=\"width:650px; height:514px;\" src=\"images/EM/100205_Quadricepswrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a quadriceps muscle strain may benefit from a thigh wrap like that described here as they return to full activity:<br />(A) Place elastic wrap on the anterior midthigh distal to the painful site.<br />(B) Apply wrap in an upward and lateral direction, encircling the thigh.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100205 Version 4.0</div></div></div>"},"100206":{"type":"graphic_picture","displayName":"Hamstring wrap","title":"Hamstring wrap","html":"<div class=\"graphic\"><div style=\"width: 859px\" class=\"figure\"><div class=\"ttl\">Hamstring wrap</div><div class=\"cntnt\"><img style=\"width:839px; height:224px;\" src=\"images/EM/100206_Hamstringwrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a hamstring muscle strain who are returning to full activity may benefit initially from added support, such as that provided by the wrap described here:<br />(A) Encircle thigh several times, pulling from a medial to lateral direction.<br />(B) Pull wrap up across the greater trochanter, around the lower abdomen to the opposite iliac crest, over the waist and gluteals, cross the greater trochanter, and end on the anterior thigh.<br />(C) Repeat the pattern and reinforce with nonelastic tape.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100206 Version 4.0</div></div></div>"},"100207":{"type":"graphic_picture","displayName":"Groin or adductor wrap","title":"Groin or adductor wrap","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Groin or adductor wrap</div><div class=\"cntnt\"><img style=\"width:793px; height:351px;\" src=\"images/EM/100207_Groinwrap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from an adductor muscle strain may benefit from added support, such as that described here, while they resume activity:<br />(A) Place wrap on the lateral thigh and encircle the thigh in a medial direction.<br />(B) Continue to wrap around the thigh, over the greater trochanter, across the lower abdomen, cover the iliac crest, around the waist and gluteals, cross the greater trochanter, end on the thigh.<br />(C) Reinforce with elastic tape.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100207 Version 4.0</div></div></div>"},"100208":{"type":"graphic_picture","displayName":"Acromioclavicular (AC) joint taping","title":"Acromioclavicular (AC) joint taping","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular (AC) joint taping</div><div class=\"cntnt\"><img style=\"width:726px; height:512px;\" src=\"images/EM/100208_Acromioclaviculartaping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with a mild AC joint injury or recovering from such an injury may benefit from added support while resuming activity. The wrap described here may be used:<br />(A) Place the first anchor at the mid-biceps; place the second anchor below the spine of the scapula over the shoulder through the mid-clavicular line; place the third anchor under the nipple horizontally around the trunk, connecting the two ends of the second anchor.<br />(B) Place tape strips in an X pattern, moving from the biceps, anchoring up and over the acromion process.<br />(C) Repeat the pattern until the acromion process is covered.<br />(D) Reinforce with elastic bandage wrapped as a shoulder spica.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100208 Version 4.0</div></div></div>"},"100209":{"type":"graphic_picture","displayName":"Shoulder spica wrap","title":"Shoulder spica wrap","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Shoulder spica wrap</div><div class=\"cntnt\"><img style=\"width:726px; height:482px;\" src=\"images/EM/100209_Shoulderspica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from rotator cuff strains or a glenohumeral dislocation may benefit from added support during activity. The wrap described here is one approach for providing such support.<br />(A) Encircle the arm in a posterior-to-anterior direction at the mid-biceps.<br />(B) Cross the anterior chest and bring the wrap under the opposite axilla, across the back, and over the acromion process.<br />(C) Continue to wrap through the axilla, around the arm, and again across the anterior chest.<br />(D) Reinforce with nonelastic tape.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100209 Version 4.0</div></div></div>"},"100211":{"type":"graphic_picture","displayName":"Wrist taping - Technique 1","title":"Wrist taping: Technique 1","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Wrist taping: Technique 1</div><div class=\"cntnt\"><img style=\"width:714px; height:462px;\" src=\"images/EM/100211_Wristtapingtechnique1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a wrist sprain may benefit from additional support, such as that described here:<br /><ul>&#xD;&#xA;    <li>Technique 1: Apply three to four circular strips of tape to the wrist.</li>&#xD;&#xA;</ul></div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100211 Version 5.0</div></div></div>"},"100212":{"type":"graphic_picture","displayName":"Wrist taping - Technique 2","title":"Wrist taping: Technique 2","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Wrist taping: Technique 2</div><div class=\"cntnt\"><img style=\"width:713px; height:749px;\" src=\"images/EM/100212_Wristtapingtechnique2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a wrist sprain may benefit from additional support, such as that described here:<br />(A) Place anchor strips around the wrist and metacarpal heads.<br />(B) Place three to four tape strips in an X pattern over the palmar aspect or dorsum of the hand.<br />(C-F) Apply a figure eight beginning on the radial aspect of the proximal anchor.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100212 Version 4.0</div></div></div>"},"100213":{"type":"graphic_picture","displayName":"Thumb spica wrap","title":"Thumb spica wrap","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Thumb spica wrap</div><div class=\"cntnt\"><img style=\"width:854px; height:339px;\" src=\"images/EM/100213_Thumbspica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients recovering from a soft tissue strain involving the thumb may benefit from added support as they resume activity. The method described here may be used:<br />(A) Apply an anchor on the wrist; apply tape on the ulnar aspect of the proximal anchor and continue upward over the palmar aspect of the thenar eminence, cross over the MP join, and encircle the thumb; this line of pull makes an X pattern.<br />(B) Apply three to four Xs; apply an anchor at the wrist to finish.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson MK, Parr GP. Foundations of Athletic Training: Prevention, Assessment, and Management, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100213 Version 4.0</div></div></div>"},"100214":{"type":"graphic_figure","displayName":"Muscles of the anterior wall, superficial dissection","title":"Muscles of the anterior wall, superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior wall, superficial dissection</div><div class=\"cntnt\"><img style=\"width:662px; height:644px;\" src=\"images/EM/100214_Msclantrwllsprfcldssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100214 Version 3.0</div></div></div>"},"100215":{"type":"graphic_figure","displayName":"Muscles of the anterior abdominal wall, deep dissection","title":"Muscles of the anterior abdominal wall, deep dissection","html":"<div class=\"graphic\"><div style=\"width: 706px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior abdominal wall, deep dissection</div><div class=\"cntnt\"><img style=\"width:686px; height:586px;\" src=\"images/EM/100215_Msclantrabdmwlldpdssct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100215 Version 3.0</div></div></div>"},"100216":{"type":"graphic_figure","displayName":"Diaphragm and muscles of the posterior abdominal wall","title":"Diaphragm and muscles of the posterior abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Diaphragm and muscles of the posterior abdominal wall</div><div class=\"cntnt\"><img style=\"width:636px; height:625px;\" src=\"images/EM/100216_Dphrgmmsclpstrabdmnlwll.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100216 Version 3.0</div></div></div>"},"100217":{"type":"graphic_figure","displayName":"Superficial muscles of the back","title":"Superficial muscles of the back","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the back</div><div class=\"cntnt\"><img style=\"width:680px; height:728px;\" src=\"images/EM/100217_Superficialmusclesback.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100217 Version 3.0</div></div></div>"},"100218":{"type":"graphic_figure","displayName":"Deep back muscles, superficial dissection","title":"Deep back muscles, superficial dissection","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Deep back muscles, superficial dissection</div><div class=\"cntnt\"><img style=\"width:678px; height:763px;\" src=\"images/EM/100218_Deepbackmsclssuperficial.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100218 Version 3.0</div></div></div>"},"100219":{"type":"graphic_figure","displayName":"Deep back muscles, deeper dissection","title":"Deep back muscles, deeper dissection","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">Deep back muscles, deeper dissection</div><div class=\"cntnt\"><img style=\"width:705px; height:742px;\" src=\"images/EM/100219_Deepbackmusclsdissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100219 Version 3.0</div></div></div>"},"100229":{"type":"graphic_diagnosticimage","displayName":"Radiograph of mid-shaft fractures of the radius and ulna","title":"Mid-shaft fractures of the radius and ulna on radiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mid-shaft fractures of the radius and ulna on radiography</div><div class=\"cntnt\"><img style=\"width:440px; height:392px;\" src=\"images/RADIOL/100229_Rdgrph_md_shft_frctr_rd_uln.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal radiograph of the forearm shows mid-shaft transverse fractures through the ulna (arrow) and radius (arrowhead). Image B is a magnified view of the fractures of the ulna (arrow) and radius (arrowhead).</div><div id=\"graphicVersion\">Graphic 100229 Version 1.0</div></div></div>"},"100230":{"type":"graphic_diagnosticimage","displayName":"Radiograph of a “nightstick fracture” of the shaft of the ulna","title":"Nightstick fracture of the diaphysis of the ulna","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Nightstick fracture of the diaphysis of the ulna</div><div class=\"cntnt\"><img style=\"width:474px; height:384px;\" src=\"images/RADIOL/100230_Rdgrph_nghtstck_frctr_shft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal radiograph of the radius (A) shows a transverse comminuted fracture through the shaft of the radius (arrow). Image B is a magnified view of the comminuted transverse fracture (arrow). Anatomical alignment is maintained. Image C is a lateral projection of the fracture (arrow).</div><div id=\"graphicVersion\">Graphic 100230 Version 2.0</div></div></div>"},"100232":{"type":"graphic_diagnosticimage","displayName":"Radiography of Monteggia fracture","title":"Monteggia fracture on radiography","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Monteggia fracture on radiography</div><div class=\"cntnt\"><img style=\"width:605px; height:376px;\" src=\"images/RADIOL/100232_Radiography_Monteggia_frctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph of the elbow (A) shows a comminuted fracture of the olecranon process of the ulna (arrow). Image B is an oblique view of the elbow and shows a dislocated (and fractured) radial head (arrowhead) and an olecranon fracture (arrow).</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 100232 Version 1.0</div></div></div>"},"100237":{"type":"graphic_figure","displayName":"Components of a blood salvage system","title":"Flow diagram demonstrating the components of a blood salvage system","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Flow diagram demonstrating the components of a blood salvage system</div><div class=\"cntnt\"><img style=\"width:544px; height:601px;\" src=\"images/ANEST/100237_Blood_salvage_system.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 100237 Version 3.0</div></div></div>"},"100240":{"type":"graphic_algorithm","displayName":"ECV algorithm","title":"Algorithm illustrating the author's approach to external cephalic version (ECV)","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Algorithm illustrating the author's approach to external cephalic version (ECV)</div><div class=\"cntnt\"><img style=\"width:555px; height:760px;\" src=\"images/OBGYN/100240_ECV_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">sc: subcutaneously.</div><div id=\"graphicVersion\">Graphic 100240 Version 1.0</div></div></div>"},"100243":{"type":"graphic_picture","displayName":"PAC","title":"Pulmonary artery catheter","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery catheter</div><div class=\"cntnt\"><img style=\"width:548px; height:380px;\" src=\"images/PULM/100243_PAC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture denotes a typical pulmonary artery catheter (PAC) that has a catheter tip that is naturally curved. This PAC is over 100 cm, indicated with black graduations that occur at 10 cm intervals along the catheter length. A syringe is generally provided with most PAC kits to inflate the balloon located at the catheter tip by no more than 1.5 mL of air. Up to five ports are available for hemodynamic monitoring; this one shows three ports (yellow, red, and blue). The thermistor connector is also shown.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Edwards Lifesciences Corporation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100243 Version 1.0</div></div></div>"},"100244":{"type":"graphic_picture","displayName":"PAC sheath and introducer","title":"Pulmonary artery catheter with protective sleeve and introducer","html":"<div class=\"graphic\"><div style=\"width: 870px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery catheter with protective sleeve and introducer</div><div class=\"cntnt\"><img style=\"width:850px; height:444px;\" src=\"images/PULM/100244_PAC_sheath_and_introducer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel shows a pulmonary artery catheter (PAC) that is inserted through the introducer <em>ex vivo</em>. The right panel shows the PAC inserted <em>in vivo</em>. <em>In vivo</em>, the introducer shaft is located intravenously and the hub is external to the skin. A protective sheath is shown; it is attached to the hub of the introducer and serves to reduce infectious complications. The introducer has one or two side ports that can also be used for the administration of medications and fluids; side attachments can be used to suture it to the skin. The distal portion of the PAC can be seen in the left panel projecting beyond the introducer.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Edwards Lifesciences Corporation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100244 Version 1.0</div></div></div>"},"100245":{"type":"graphic_picture","displayName":"PAC ports","title":"Pulmonary artery catheter ports","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Pulmonary artery catheter ports</div><div class=\"cntnt\"><img style=\"width:534px; height:370px;\" src=\"images/PULM/100245_PAC_ports.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five pulmonary artery catheter (PAC) ports are shown. The thermistor port contains fine wires that lead to a temperature thermistor just proximal to the balloon. It is used to monitor pulmonary artery blood temperature as part of the thermodilution method for cardiac output monitoring. The pulmonary artery (PA) distal pressure monitoring port connects to the distal tip of the PAC and is used to transduce pressure. The proximal drug infusion port, usually 30 cm from the catheter tip, is intended for central venous pressure monitoring as well as for intravenous fluid and drug administration. The balloon inflation port leads to the balloon at the catheter tip and allows the balloon to be inflated and deflated during catheter placement. The right ventricle (RV) infusion port is a fifth port that is available on some catheters. It can be used for infusions and occasionally for pacing the RV.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Edwards Lifesciences Corporation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100245 Version 1.0</div></div></div>"},"100246":{"type":"graphic_picture","displayName":"Dermatophyte infection KOH","title":"Potassium hydroxide (KOH) preparation from dermatophyte infection","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Potassium hydroxide (KOH) preparation from dermatophyte infection</div><div class=\"cntnt\"><img style=\"width:713px; height:534px;\" src=\"images/DERM/100246_Dermatophyte_infection_KOH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple septate hyphae on a background of squamous cells in a potassium hydroxide (KOH) preparation taken from the site of a dermatophyte infection.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 100246 Version 2.0</div></div></div>"},"100248":{"type":"graphic_picture","displayName":"BCC nodular","title":"Nodular basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100248_BCC_nodular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular basal cell carcinoma presenting as a pearly, translucent papule with telangiectasias visible on the surface.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100248 Version 1.0</div></div></div>"},"100249":{"type":"graphic_picture","displayName":"Keratoacanthoma early","title":"Keratoacanthoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Keratoacanthoma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/100249_Keratoacanthoma_early.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early keratoacanthoma presenting as a slightly erythematous papule with a central keratinous plug.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100249 Version 1.0</div></div></div>"},"100252":{"type":"graphic_picture","displayName":"DFSP early","title":"Dermatofibrosarcoma protuberans","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dermatofibrosarcoma protuberans</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100252_DFSP_early.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early lesion of dermatofibrosarcoma protuberans presenting as an indurated skin-colored nodule.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100252 Version 1.0</div></div></div>"},"100255":{"type":"graphic_picture","displayName":"Core strength examination and exercise for spondylolysis","title":"Core strength examination and exercise for spondylolysis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Core strength examination and exercise&nbsp;for spondylolysis</div><div class=\"cntnt\"><img style=\"width:648px; height:488px;\" src=\"images/EM/100255_Cr_strngt_exm_ptnt_spndyl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures demonstrate how&nbsp;the author&nbsp;instructs patients to control their core abdominal muscles. It is a variation of a Williams' flexion exercise, and it can be used to help the patient relieve discomfort. The figure shows the patient in a supine position but beginners may flex both knees, using several pillows to support their lower extremity.<br />(A) The examiner places a hand on the LS spine just above the buttocks, which roughly corresponds to L3-L4.<br />(B) The examiner's hand is&nbsp;at the center of the patient's LS spine.<br />(C-D) A demonstration of how&nbsp;the author&nbsp;instructs the patient to perform the stretch. Tell the patient to \"press my hand against the table using only your back.\" The examiner can place their other hand on the lower abdominal area to assist them with proper technique.</div><div class=\"graphic_reference\">Courtesy of James M Daniels, MD, MPH.</div><div id=\"graphicVersion\">Graphic 100255 Version 1.0</div></div></div>"},"100256":{"type":"graphic_picture","displayName":"Stretches for patients with spondylolysis","title":"Stretches for patients with spondylolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stretches for patients with spondylolysis</div><div class=\"cntnt\"><img style=\"width:327px; height:732px;\" src=\"images/EM/100256_Stretch_patient_spondylolys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures demonstrate stretches used to assist patients with spondylolysis. The patient is asked to grasp their knee and squeeze it up against their abdomen, first one leg and then the other (A and B), and then both together (C).</div><div class=\"graphic_reference\">Courtesy of James M Daniels, MD, MPH.</div><div id=\"graphicVersion\">Graphic 100256 Version 1.0</div></div></div>"},"100260":{"type":"graphic_figure","displayName":"Punch incision technique","title":"Punch incision technique for removal of epidermoid cysts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Punch incision technique for removal of epidermoid cysts</div><div class=\"cntnt\"><img style=\"width:444px; height:603px;\" src=\"images/DERM/100260_Punch_incision_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;A 4 mm punch is used to incise the&nbsp;cyst.<br />(B) The content of the cyst is expressed with strong lateral pressure exerted with the thumbs. This usually releases the cyst wall from the surrounding tissue.<br />(C)&nbsp;The cyst wall is then extracted through the punch opening.</div><div class=\"graphic_reference\">Modified from: Mehrabi D, Leonhardt JM, Brodell RT. Removal of keratinous and pilar cysts with the punch incision technique: Analysis of surgical outcomes. Dermatol Surg 2002; 28:673.</div><div id=\"graphicVersion\">Graphic 100260 Version 2.0</div></div></div>"},"100268":{"type":"graphic_picture","displayName":"Angiolipoma macroscopic features","title":"Macroscopic features of angiolipoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Macroscopic features of angiolipoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100268_Angiolipoma_macroscopic_ftr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiolipoma appearing as a small, well-circumscribed, encapsulated subcutaneous tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100268 Version 1.0</div></div></div>"},"100269":{"type":"graphic_picture","displayName":"Glomus tumor histo","title":"Histologic features of glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Histologic features of glomus tumor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100269_Glomus_tumor_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glomus tumor consists of aggregates of small monomorphous cells with an eosinophilic cytoplasm and a central hyperchromatic nucleous. Numerous dilated blood vessels are present among the glomus cells.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100269 Version 1.0</div></div></div>"},"100270":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 5","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:616px; height:711px;\" src=\"images/DERM/100270_Cutaneous_leiomyomatosis_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental involvement of cutaneous leiomyomatosis. Note additional clusters of lesions on the left forearm.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100270 Version 3.0</div></div></div>"},"100273":{"type":"graphic_picture","displayName":"Capnocytophaga Gram stain","title":"Gram stain of <em>Capnocytophaga canimorsus</em>","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Gram stain of <em>Capnocytophaga canimorsus</em></div><div class=\"cntnt\"><img style=\"width:712px; height:528px;\" src=\"images/ID/100273_Capnocytophaga_gram_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Brichacek M, Blake P, Kao R. Capnocytophaga canimorsus infection presenting with complete splenic infarction and thrombotic thrombocytopenic purpura: a case report. BMC Res Notes 2012; 5:695. Copyright &copy; 2012 Brichacek et al; licensee BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 100273 Version 1.0</div></div></div>"},"100275":{"type":"graphic_table","displayName":"Key findings for major throwing-related upper extremity injuries","title":"Key findings for major throwing-related upper extremity injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key findings for major throwing-related upper extremity injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Shoulder injuries:</td> </tr> <tr> <td class=\"indent1\">Transient shoulder subluxation (\"dead arm\")</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sudden onset of pain accompanied by loss of throwing velocity during arm acceleration or late cocking </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Positive apprehension test </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Rotator cuff injuries</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lateral shoulder pain </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain with overhead motions during activities of daily living </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain in the posterior-superior shoulder, especially at terminal cocking, suggests internal impingement with undersurface rotator cuff tear </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Painful arc of shoulder abduction for 70 to 120 degrees </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Positive impingement tests (Jobe, Hawkins, Neer) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ultrasound or MRI often diagnostic </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Labral tears</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Deep shoulder pain with throwing motions, but not with general activities of daily living </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Mechanical sensations (eg, catching, popping, clicking) within shoulder may occur, especially with overhead motions </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain reproduced by provocative maneuvers (O'Brien's, O'Driscoll's, Jobe relocation, anterior slide, crank) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Can be difficult to diagnose; may need MRI-arthrography IF indicated </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Glenohumeral internal rotation deficiency (GIRD)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain deep in posterior shoulder </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Loss of internal rotation compared with the non-throwing shoulder of at least 20 degrees, and less than 180 degrees total arc of motion with shoulder abducted 90 degrees </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Proximal humeral epiphysiolysis (Little League shoulder)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pitchers between 11 and 16 years old with open growth plates </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Progressively worsening pain in the shoulder with throwing </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain over the lateral proximal humerus </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plain radiographs are useful for confirming presence of open growth plates at the location of pain </li> </ul> </td> </tr> <tr> <td class=\"indent1\">SICK (<strong>S</strong>capular malposition, <strong>I</strong>nferior medial border prominence, <strong>C</strong>oracoid pain and malposition, and dys<strong>K</strong>inesis) scapula syndrome and scapular dyskinesis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Insidious anterior shoulder pain in the coracoid region </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lower scapula with a prominent inferior medial border on affected side </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Abnormal and asymmetric scapular motion with shoulder abduction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Loss of terminal shoulder flexion and coracoid region pain that worsens with passive shoulder flexion </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Elbow injuries:</td> </tr> <tr> <td class=\"indent1\">Ulnar collateral ligament (UCL) sprain or tear</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute onset of medial elbow pain during acceleration with a single pitch </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tenderness over the UCL </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain and laxity with UCL testing (valgus stress, moving stress, milking maneuver) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ultrasound often useful for identifying injury </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Common wrist (forearm) flexor strain</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Insidious onset </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain anterior and lateral to the medial epicondyle; not over UCL </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain with resisted wrist flexion and pronation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>UCL stress testing does not cause pain </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Valgus extension overload (VEO) syndrome</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain in the posterior elbow at ball release </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain when a valgus stress is placed continuously on the elbow while extending the joint from 30 degrees of flexion into terminal extension </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plain radiographs useful for identifying bone spurs and other changes that may occur with VEO </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Olecranon stress fracture</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Focal pain to palpation over the posterior or posteromedial olecranon </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Triceps non-tender on palpation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plain radiographs should be obtained; MRI may be needed if no fracture visible on plain films </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Triceps tendinopathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Insidious onset </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Progressively worsening pain with increased number of pitches thrown </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tenderness at or just proximal to insertion on the olecranon </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pain with resisted elbow extension </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ulnar neuropathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Electric sensation radiating down the forearm with throwing </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Positive ulnar Tinel sign </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Osteochondrosis of elbow</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Child (between 7 and 12 years; with open growth plate)</li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lateral elbow pain</li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plain radiographs show fragmentation of capitellar ossification center</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Osteochondral defect (OCD) of the elbow</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Adolescent </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lateral elbow pain with throwing </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Episodes of locking </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Plain radiographs usually reveal OCD </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Little League elbow</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pitchers between 9 and 12 years old with open growth plates </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Insidious onset </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Medial elbow tenderness and pain with valgus stress </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Plain radiographs useful to confirm presence of open growth plates </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Vascular injury:</td> </tr> <tr> <td class=\"indent1\">Effort thrombosis (Paget-Schroetter syndrome)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Discomfort and swelling of dominant arm </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dilated, visible veins across shoulder and upper arm (Urschel's sign) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Arm discoloration </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Doppler ultrasound critical to rule out this emergent condition </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 100275 Version 2.0</div></div></div>"},"100289":{"type":"graphic_table","displayName":"Anticholinergic activity of medications","title":"Anticholinergic activity of medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticholinergic activity of medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drugs</td> <td class=\"subtitle1\">Relative anticholinergic potency</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antihistamines</td> <td>H<sub>1</sub> receptor antagonists, first-generation: brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, dimenhydrinate, diphenhydramine, doxepin, doxylamine, hydroxyzine, meclizine, triprolidine, others</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td>H<sub>1</sub> receptor antagonists, second-generation: fexofenadine, cetirizine*, loratadine, desloratadine, levocetirizine, others</td> <td>Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Antiparkinson</td> <td>Benztropine, trihexyphenidyl</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td>Amantadine, bromocriptine, entacapone</td> <td>Low</td> </tr> <tr class=\"divider_bottom\"> <td>Analgesic</td> <td>Opioids:&nbsp;codeine, hydrocodone, fentanyl, meperidine, methadone, morphine, oxycodone, tramadol, others</td> <td>Low</td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, overactive bladder</td> <td>Darifenacin, fesoterodine, flavoxate, oxybutynin, solifenacin, tolterodine, trospium</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, spasmolytic</td> <td>Atropine, belladonna-containing medications, clidinium-chlordiazepoxide, dicyclomine, hyoscyamine, glycopyrrolate, homatropine, methscopolamine, propantheline, scopolamine (hyoscine)</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, inhaled bronchodilator</td> <td>Ipratropium, tiotropium</td> <td>High (local effect)</td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, ophthalmic drops (mydriatic/cycloplegic)</td> <td>Atropine, cyclopentolate, homatropine, scopolamine</td> <td>High (local effect)</td> </tr> <tr class=\"divider_bottom\"> <td>Cardiovascular</td> <td>Disopyramide</td> <td>Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Gastrointestinal</td> <td>Antiemetics (eg, hydroxyzine, meclizine, promethazine, scopolamine); also refer to first-generation antihistamines above</td> <td>High</td> </tr> <tr> <td>Domperidone, loperamide, prochlorperazine</td> <td>Low</td> </tr> <tr class=\"divider_bottom\"> <td>H<sub>2</sub> receptor antagonists (ranitidine, cimetidine, famotidine<sup>&#182;</sup>)</td> <td>Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Muscle relaxant</td> <td>Orphenadrine, tizanidine</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclobenzaprine*, baclofen, methocarbamol</td> <td>Low</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Psychotropic</td> <td>Antipsychotics, first-generation: chlorpromazine, fluphenazine, loxapine, methotrimeprazine (levomepromazine), thioridazine, trifluoperazine</td> <td>High</td> </tr> <tr> <td>Antipsychotics, first-generation: haloperidol, perphenazine*, others</td> <td>Low</td> </tr> <tr> <td>Antipsychotics, second-generation: clozapine</td> <td>High</td> </tr> <tr> <td>Antipsychotics, second-generation: olanzapine*, quetiapine*, iloperidone, risperidone, others</td> <td>Low</td> </tr> <tr> <td>Benzodiazepines: chlordiazepoxide, clonazepam, temazepam, triazolam</td> <td>Low</td> </tr> <tr> <td>Selective serotonin reuptake inhibitor (SSRI) antidepressants: citalopram, fluoxetine, fluvoxamine, paroxetine*</td> <td>Low</td> </tr> <tr class=\"divider_bottom\"> <td>Tricyclic antidepressants: amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, others</td> <td>High</td> </tr> <tr> <td>Other neurologic</td> <td>Carbamazepine, lithium, nefazodone, oxcarbazepine, phenelzine, trazodone</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A large number of medicines are reported to have some anticholinergic activity, and considerable variation exists in potency rankings assigned to specific drugs using available anticholinergic risk scales and in expert lists; this list is not exhaustive. Increasing dose and additive effects from simultaneous use of more than one anticholinergic drug can alter the anticholinergic activity rating provided in this table.</div><div class=\"graphic_footnotes\">* Classified as moderate or high anticholinergic potency in some references or variable effects reported.<br />¶ Intravenous famotidine use has been associated with central nervous system effects (eg, delirium and confusion) in hospitalized older adults and patients with renal function impairment; this may be due to a central anticholinergic effect.</div><div class=\"graphic_reference\">Courtesy of Paula A Rochon, MD with additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dur&aacute;n CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013; 69:1485.</li>&#xD;&#xA;    <li>Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc 2015; 63:85.</li>&#xD;&#xA;    <li>United States prescribing information available at US National Library of Medicine DailyMed website (<a href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/index.cfm</a>).</li>&#xD;&#xA;    <li>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63:2227.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 100289 Version 12.0</div></div></div>"},"100290":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 1","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:648px; height:428px;\" src=\"images/DERM/100290_Cutaneous_leiomyomatosis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scattered pink and light brown papules on the chest.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100290 Version 1.0</div></div></div>"},"100291":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 2","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:499px; height:648px;\" src=\"images/DERM/100291_Cutaneous_leiomyomatosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pink/red variably sized and shaped papules and nodules.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100291 Version 1.0</div></div></div>"},"100292":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 3","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:648px; height:558px;\" src=\"images/DERM/100292_Cutaneous_leiomyomatosis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical ovoid pink banal appearance of single cutaneous leiomyomatosis lesion.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100292 Version 1.0</div></div></div>"},"100293":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 4","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:728px; height:307px;\" src=\"images/DERM/100293_Cutaneous_leiomyomatosis_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clustered pink cutaneous leiomyomatosis nodules on the central and upper back.<br />(B) Close-up image of nodules in panel A.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100293 Version 1.0</div></div></div>"},"100295":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 6","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:648px; height:489px;\" src=\"images/DERM/100295_Cutaneous_leiomyomatosis_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tumor-like exophytic cutaneous leiomyomatosis (CL) nodule within a plaque of confluent smaller CL nodules.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100295 Version 1.0</div></div></div>"},"100296":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis 7","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:648px; height:414px;\" src=\"images/DERM/100296_Cutaneous_leiomyomatosis_7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized cutaneous leiomyomatosis. Hundreds of painful small red papules and nodules on the leg.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100296 Version 1.0</div></div></div>"},"100297":{"type":"graphic_picture","displayName":"Cutaneous leiomyomatosis histo","title":"Cutaneous leiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Cutaneous leiomyomatosis</div><div class=\"cntnt\"><img style=\"width:728px; height:260px;\" src=\"images/DERM/100297_Cutaneous_leiomyomatosis_8.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Histology of cutaneous leiomyomatosis (CL): Broad fascicles of smooth muscle fibers in the dermis.<br />(B) Histology of CL (high power): Bundles of smooth muscle cells with square-shaped nuclei and intervening entrapped collagen fibers.</div><div class=\"graphic_reference\">Courtesy of Edward W Cowen, MD, MHSc.</div><div id=\"graphicVersion\">Graphic 100297 Version 1.0</div></div></div>"},"100302":{"type":"graphic_figure","displayName":"Obturator nerve motor and sensory function","title":"Obturator nerve motor and sensory function","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Obturator nerve motor and sensory function</div><div class=\"cntnt\"><img style=\"width:572px; height:633px;\" src=\"images/EM/100302_Obturatornerve.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100302 Version 3.0</div></div></div>"},"100308":{"type":"graphic_picture","displayName":"Nail psoriasis nail plate crumbling","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100308_Nail_psoriasi_nail_plt_crmb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crumbling of the nail plate resulting in loss of part of the dystrophic nail in a patient with nail psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100308 Version 2.0</div></div></div>"},"100311":{"type":"graphic_picture","displayName":"Psoas muscle palpation","title":"Psoas muscle palpation","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Psoas muscle palpation</div><div class=\"cntnt\"><img style=\"width:708px; height:531px;\" src=\"images/EM/100311_Psoas_muscle_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpation of the psoas muscle is an important part of the musculoskeletal examination of the pelvis. The patient must relax their abdominal musculature for palpation to be effective.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100311 Version 1.0</div></div></div>"},"100314":{"type":"graphic_picture","displayName":"Palpation of adductor longus origin","title":"Palpation of adductor longus origin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of adductor longus origin</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/EM/100314_Plpt_addctr_lngs_insrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The proximal adductor longus is palpated from the musculotendinous portion to its&nbsp;origin on the pubis bone.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100314 Version 1.0</div></div></div>"},"100317":{"type":"graphic_picture","displayName":"Passive stretching of adductor muscles","title":"Passive stretching of adductor muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passive stretching of adductor muscles</div><div class=\"cntnt\"><img style=\"width:316px; height:237px;\" src=\"images/EM/100317_Pssv_strtch_addctr_mscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When assessing the adductor muscles, increase the stretch gradually to avoid causing undue pain.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100317 Version 1.0</div></div></div>"},"100318":{"type":"graphic_figure","displayName":"Psoas muscle anatomy","title":"Psoas muscle anatomy","html":"<div class=\"graphic\"><div style=\"width: 823px\" class=\"figure\"><div class=\"ttl\">Psoas muscle anatomy</div><div class=\"cntnt\"><img style=\"width:803px; height:638px;\" src=\"images/EM/100318_Psoas.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100318 Version 3.0</div></div></div>"},"100319":{"type":"graphic_picture","displayName":"Hip adduction against resistance","title":"Hip adduction against resistance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip adduction against resistance</div><div class=\"cntnt\"><img style=\"width:316px; height:237px;\" src=\"images/EM/100319_Hip_adduction_aganst_rsstnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adduction against resistance is an important test of hip adductor muscle function.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100319 Version 1.0</div></div></div>"},"100326":{"type":"graphic_picture","displayName":"Functional assessment of abdominal muscles","title":"Functional assessment of abdominal muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional assessment of abdominal muscles</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/EM/100326_Funct_assess_abdom_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To assess abdominal strength more completely, testing is performed with and without a rotational component. The photograph above shows testing without rotation.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100326 Version 1.0</div></div></div>"},"100327":{"type":"graphic_picture","displayName":"Functional assessment of the iliopsoas muscle","title":"Functional assessment of the iliopsoas muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Functional assessment of the iliopsoas muscle</div><div class=\"cntnt\"><img style=\"width:320px; height:240px;\" src=\"images/EM/100327_Funct_assess_iliopsoas_musc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Iliopsoas function can be tested grossly by having the patient flex their hip against resistance.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100327 Version 1.0</div></div></div>"},"100328":{"type":"graphic_picture","displayName":"Modified Thomas test for iliopsoas","title":"Modified Thomas test for iliopsoas","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Modified Thomas test for iliopsoas</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/EM/100328_Mod_Thomas_test_iliopsoas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tightness of the iliopsoas muscle can be assessed using a modified version of the Thomas test pictured above.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100328 Version 2.0</div></div></div>"},"100329":{"type":"graphic_picture","displayName":"Ultrasound probe position for imaging adductors","title":"Ultrasound probe position for imaging adductors","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Ultrasound probe position for imaging adductors</div><div class=\"cntnt\"><img style=\"width:538px; height:655px;\" src=\"images/EM/100329_US_probe_pos_imag_adductors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For this examination, the patient is supine with their leg slightly abducted and knee bent approximately 20 degrees.<br />(A) The transducer is positioned at the level of the pubic bone and oriented to provide a transverse view. From this position, the probe is gradually swept inferiorly along the adductor tendons and myotendinous junction and then along the muscle bellies.<br />(B) The transducer is positioned at the level of the pubic bone and oriented to provide a longitudinal view. From this position, the probe is gradually swept medially and laterally across the adductor tendons and muscles.</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 100329 Version 2.0</div></div></div>"},"100337":{"type":"graphic_algorithm","displayName":"Treatment algorithm for neonatal seizures","title":"Antiseizure drug therapy for neonatal seizures","html":"<div class=\"graphic\"><div style=\"width: 932px\" class=\"figure\"><div class=\"ttl\">Antiseizure drug therapy for neonatal seizures</div><div class=\"cntnt\"><img style=\"width:912px; height:618px;\" src=\"images/NEURO/100337_Treatment_neonatal_seizures.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EEG: electroencephalography; IV: intravenous; PE: phenytoin equivalents.<br />* There are limited data on comparative efficacy and best dosing strategies for second-line therapies.<br />&para; Low body weight (&lt;2.5 kg) and newborns undergoing hypothermia treatment are at risk for accumulation of lidocaine. Adjust dose for low body weight or if using concurrent therapeutic hypothermia<sup>[1]</sup>. Refer to accompanying text and separate table of lidocaine dosing for neonatal seizures.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>van den Broek MP, Rademaker CM, van Straaten HL, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed 2013; 98:F341.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 100337 Version 5.0</div></div></div>"},"100339":{"type":"graphic_picture","displayName":"Pityriasis amiantacea","title":"Pityriasis amiantacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis amiantacea</div><div class=\"cntnt\"><img style=\"width:441px; height:442px;\" src=\"images/DERM/100339_Pityriasis_amiantacea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pityriasis amiantacea. Masses of sticky silvery scales adhere to the scalp and cause matting of hairs.</div><div class=\"graphic_reference\">Reproduced with permission from: Collins CD, Hivnor C. Seborrheic dermatitis. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith L, Katz S, Gilchrest B, et al (Eds), McGraw-Hill, New York 2012. Copyright &copy; 2012 McGraw-Hill Education.</div><div id=\"graphicVersion\">Graphic 100339 Version 2.0</div></div></div>"},"100340":{"type":"graphic_table","displayName":"Causes of postoperative ocular complaints","title":"Causes of postoperative ocular complaints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of postoperative ocular complaints</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Associated factors<br /> (not necessarily causal)</td> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Duration of POVL</td> <td class=\"subtitle1\">Workup</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Visual loss with pain</td> </tr> <tr> <td class=\"indent1\">Corneal abrasion<sup>[1-4]</sup></td> <td> <ul> <li>Any type of surgery </li> <li>Prolonged surgery </li> <li>Exposure of cornea </li> <li>Trauma </li> </ul> </td> <td> <ul> <li>Onset immediate after emergence from anesthesia </li> <li>Usually unilateral </li> <li>Painful </li> <li>Foreign body sensation </li> <li>Conjunctival erythema, tearing, photophobia </li> <li>Normal pupillary reflexes </li> <li>Blurred vision to no visual deficit </li> </ul> </td> <td>24 to 48 hours</td> <td> <ul> <li>History </li> <li>Symptoms </li> <li>External eye exam </li> <li>Fluorescein stain and slit lamp exam </li> </ul> </td> <td>Prophylactic antibiotic and lubricant eye drops</td> </tr> <tr> <td class=\"indent1\">Acute angle closure glaucoma<sup>[5-8]</sup></td> <td> <ul> <li>Any type of surgery </li> <li>General anesthesia </li> <li>Drugs: adrenergic, anticholinergic, antihistamines, antiparkinsonian, mydriatic, cholinergic, antidepressants </li> <li>Genetic/anatomic predisposition </li> <li>Female </li> <li>Hypermetropia </li> </ul> </td> <td> <ul> <li>Onset may be delayed &#62;12 hours postop </li> <li>Unilateral &#62; bilateral </li> <li>Pain: boring quality with ipsilateral headache </li> <li>Intermittent blurring of vision with halos </li> <li>Nausea, vomiting </li> <li>Mid-dilated nonreactive pupil </li> <li>Conjunctival erythema </li> <li>Corneal epithelial edema </li> <li>IOP &#62;21 mmHg </li> </ul> </td> <td> <ul> <li>Until IOP controlled </li> <li><strong>Treatment required within a few hours of onset to prevent permanent vision loss</strong> </li> </ul> </td> <td> <ul> <li>History </li> <li>Symptoms </li> <li>External eye exam </li> <li>IOP &#62;21 mmHg </li> <li>Avoid dilated funduscopic exam as it may worsen symptoms </li> </ul> </td> <td> <ul> <li>Topical and systemic medication to reduce IOP </li> <li>Iridotomy for refractory &#8593; IOP </li> <li>Temporizing maneuvers (ie, anterior chamber paracentesis) </li> <li>Avoid eye patch or other Rx that dilates pupils </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Retrobulbar hematoma<sup>[9-13]</sup></td> <td> <ul> <li>Orbital trauma </li> <li>Head and neck procedures </li> <li>May occur (rarely) with other surgical procedures when other associated risk factors are present: orbital floor fracture and s/p repair, anticoagulation, uncontrolled hypertension, straining or Valsalva, sneezing, vomiting </li> </ul> </td> <td> <ul> <li>Most vision loss within 3 to 24 hours, but may be delayed up to seven to nine days </li> <li>Unilateral </li> <li>Severe, stabbing pain; pressure </li> <li>Visual loss from hematoma causing optic nerve ischemia, direct compression, or central retinal artery occlusion </li> <li>Nausea, vomiting </li> <li>Diplopia, ophthalmoplegia </li> <li>Visual flashes </li> <li>Relative afferent pupillary defect or absent pupillary reflex </li> <li>Eyelid hematoma/ecchymosis </li> <li>Subconjunctival hemorrhage </li> <li>Proptosis </li> </ul> </td> <td> <ul> <li>Depends on time to effective treatment </li> <li><strong>Treatment required within a few hours of onset to prevent permanent vision loss</strong> </li> </ul> </td> <td> <ul> <li>History </li> <li>External eye exam with pupillary light reflexes </li> <li>Imaging if necessary, but may delay Rx </li> </ul> </td> <td> <ul> <li>Surgical emergency if visual loss present </li> <li>Lateral canthotomy or inferior cantholysis </li> <li>May give topical medications to lower IOP if surgery delayed </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pituitary apoplexy<sup>[14-16]</sup></td> <td> <ul> <li>Cardiac surgery; one case report after transurethral prostate surgery </li> <li>Reduced blood flow to pituitary: severe hemorrhagic hypotension, head trauma, pituitary irradiation </li> <li>Sudden increase in blood flow to the pituitary </li> <li>Stimulation of the pituitary </li> <li>Anticoagulation </li> </ul> </td> <td> <ul> <li>Onset immediate to delayed by three months </li> <li>Severe headache </li> <li>Blurred vision to visual field defect to blindness </li> <li>Cranial nerve III commonly involved with dilated, nonreactive pupil </li> <li>Ophthalmoplegia </li> <li>Altered mental status </li> <li>Possible Addisonian crisis </li> </ul> </td> <td>Full recovery to permanent blindness (especially for chiasmal injuries)</td> <td> <ul> <li>CT/MRI imaging of head </li> <li>Lab: electrolytes, glucose, pituitary hormones </li> </ul> </td> <td> <ul> <li>Surgical decompression for visual changes or altered mental status </li> <li>Endocrine replacement as necessary including high-dose corticosteroids </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Posterior reversible encephalopathy<sup>[17-21]</sup></td> <td> <ul> <li>Preeclampsia, eclampsia </li> <li>Not commonly associated with surgery </li> <li>Immunosuppressants </li> <li>Chemotherapy </li> <li>Infection </li> <li>Vascular disease </li> <li>Renal disease </li> </ul> </td> <td> <ul> <li>Three postoperative cases: onset immediate after emergence from anesthesia </li> <li>May have diffuse headache </li> <li>Blurred vision, homonymous hemianopia, blindness </li> <li>Nausea, vomiting </li> <li>Seizures </li> <li>Brainstem symptoms </li> <li>Hemiplegia </li> <li>Altered mental status </li> <li>Normal pupillary light reflexes </li> <li>Normal funduscopic exam </li> <li>Brisk DTRs </li> <li>Positive Babinski </li> </ul> </td> <td>Average seven days; range from one day to permanent if progresses to infarction</td> <td>DWI MRI brain showing vasogenic edema posterior circulation, especially subcortical white matter</td> <td> <ul> <li>Antihypertensives </li> <li>Anticonvulsants for seizures </li> <li>Mannitol for cerebral edema </li> <li>Magnesium sulfate&nbsp;for preeclampsia/eclampsia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Visual loss without pain</td> </tr> <tr> <td class=\"indent1\">Anterior ischemic optic neuropathy<sup>[22-27]</sup></td> <td> <ul> <li>Cardiac surgery </li> <li>Prone spine surgery </li> <li>Head and neck surgery </li> <li>Older age </li> <li>Vascular risk factors </li> <li>Anemia </li> <li>Vasopressor use </li> <li>Hypotension </li> <li>Small optic nerve cup-to-disc ratio </li> <li>Aberrant physiology or anatomy in the setting of reduced perfusion pressure </li> </ul> </td> <td> <ul> <li>Onset immediate; may be delayed to POD one to three </li> <li>Bilateral &#62; unilateral </li> <li>Progresses for a few days before stabilizing </li> <li>Altitudinal field cuts, scotoma to complete loss of vision with no light perception </li> <li>Relative afferent pupillary defect if asymmetric or amaurotic pupils </li> <li>Funduscopic examination: optic disc swelling, attenuated vessels, splinter hemorrhages </li> </ul> </td> <td>Usually permanent; may have small degree of recovery</td> <td> <ul> <li>History </li> <li>Symptoms </li> <li>Pupillary light reflexes </li> <li>External eye exam </li> <li>Dilated funduscopic exam </li> </ul> </td> <td> <ul> <li>None proven </li> <li>Theoretical: optimized hemodynamics, glucocorticoids, mannitol, hyperbaric O<sub>2</sub> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Posterior ischemic optic neuropathy<sup>[22-28]</sup></td> <td> <ul> <li>Prone spinal procedures </li> <li>Bilateral head and neck procedures </li> <li>Cardiac surgery </li> <li>Prolonged duration in position with increased venous pressure in head: prone, Trendelenburg, Wilson frame </li> <li>Large blood loss </li> <li>Large fluid resuscitation, high crystalloid/colloid ratio </li> <li>Wilson frame </li> <li>Male sex </li> <li>Obesity in prone position </li> </ul> </td> <td> <ul> <li>Onset usually immediate after emergence from anesthesia, no progression </li> <li>Bilateral &#62;&#62; unilateral </li> <li>Altitudinal field cuts, scotoma to complete loss of vision with no light perception </li> <li>Relative afferent pupillary defect if asymmetric or amaurotic pupils </li> <li>Funduscopic exam normal </li> </ul> </td> <td>Usually permanent; may have small degree of recovery</td> <td> <ul> <li>History </li> <li>Symptoms </li> <li>Pupillary light reflexes </li> <li>External eye exam </li> <li>Dilated funduscopic exam </li> </ul> </td> <td> <ul> <li>None proven </li> <li>Theoretical: optimized hemodynamics, glucocorticoids, mannitol, hyperbaric O<sub>2</sub> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cerebral or cortical visual loss<sup>[22,23,26,27]</sup></td> <td> <ul> <li>Spine fusion </li> <li>Cardiac surgery </li> <li>Nonfusion orthopedic surgery </li> <li>&#60;18 years old </li> <li>Charlson risk index &#62;0 </li> <li>Infarction due to emboli or hypotension </li> </ul> </td> <td> <ul> <li>Onset immediate after emergence from anesthesia </li> <li>Bilateral: total blindness or small area preserved central vision </li> <li>Unilateral: contralateral homonymous hemianopia </li> <li>Pupillary light reflexes normal </li> <li>Funduscopic exam normal </li> </ul> </td> <td>Some recovery possible; rarely complete</td> <td> <ul> <li>CT or MRI </li> </ul> </td> <td> <ul> <li>Normalization of blood pressure, cardiac output, oxygenation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Central retinal artery occlusion<sup>[22-24,26,29,30]</sup></td> <td> <ul> <li>Prone procedures, especially spine </li> <li>Cardiac surgery </li> <li>Head and neck surgery </li> <li>Emboli </li> <li>Horseshoe headrest </li> <li>Intraocular gas bubbles within two months of GA with nitrous oxide </li> </ul> </td> <td> <ul> <li>Onset immediate after emergence from anesthesia </li> <li>Unilateral </li> <li>Complete or nearly complete loss of vision in the affected eye </li> <li>Pupillary light reflex sluggish to absent; relative afferent pupillary if caused by globe compression; may have signs of periorbital trauma </li> <li>Retinal whitening on funduscopic exam </li> </ul> </td> <td>Usually permanent, severe visual loss in affected eye</td> <td> <ul> <li>External eye exam </li> <li>IOP measurement </li> <li>Pupillary light reflexes </li> <li>Funduscopic exam </li> </ul> </td> <td> <ul> <li>None proven </li> <li>Theoretical: inhaled O<sub>2</sub> with 5% CO<sub>2</sub>, acetazolamide </li> <li>Controversial, especially in postoperative setting: thrombolysis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Glycine-induced visual loss<sup>[31-36]</sup></td> <td> <ul> <li>Transurethral prostate surgery </li> <li>Hysteroscopy </li> <li>Long operative time </li> <li>Large irrigant absorption </li> <li>Increased height of irrigation bag </li> <li>High-pressure irrigation </li> <li>Head-down position </li> </ul> </td> <td> <ul> <li>Onset intraoperative if awake; up to several hours postoperatively </li> <li>Blurred vision </li> <li>Sluggish to fixed and dilated pupils </li> <li>Funduscopic exam normal </li> </ul> </td> <td>&#60;24 hours; may be longer if severe hyponatremia and other neurological/cardiac dysfunction</td> <td> <ul> <li>History </li> <li>Lab: serum glycine and ammonia levels </li> </ul> </td> <td> <ul> <li>Correct volume overload and electrolyte abnormalities </li> <li>Supportive </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IOP: intraocular pressure; Rx: treatment; CT: computerized tomography; MRI: magnetic resonance imaging; DWI: diffused weighted&nbsp;imaging; GA: general anesthesia.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Roth S, Thisted RA, Erickson JP, et al. Eye injuries after nonocular surgery. A study of 60,965 anesthetics from 1988 to 1992. Anesthesiology 1996; 85:1020.</li>&#xD;&#xA;    <li>Vetter TR, Ali NM, Boudreaux AM. A case-control study of an intraoperative corneal abrasion prevention program: Holding the gains made with a continuous quality improvement effort. Jt Comm J Qual Patient Saf 2012; 38:490.</li>&#xD;&#xA;    <li>Cucchiara RF, Black S. Corneal abrasion during anesthesia and surgery. Anesthesiology 1988; 69:978.</li>&#xD;&#xA;    <li>Wipperman JL1, Dorsch JN. Evaluation and management of corneal abrasions. Am Fam Physician. 2013 Jan 15; 87:114.</li>&#xD;&#xA;    <li>Lentschener C, Ghimouz A, Bonnichon P, et al. Acute postoperative glaucoma after nonocular surgery remains a diagnostic challenge. Anesth Analg 2002; 94:1034.</li>&#xD;&#xA;    <li>Fazio DT, Bateman JB, Christensen RE. Acute angle-closure glaucoma associated with surgical anesthesia. Arch Ophthalmol 1985; 103:360.</li>&#xD;&#xA;    <li>Eldor J, Admoni M. Acute glaucoma following nonophthalmic surgery. Isr J Med Sci 1989; 25:652.</li>&#xD;&#xA;    <li>Gayat E, Gabison E, Devys JM. Case report: Bilateral angle closure glaucoma after general anesthesia. Anesth Analg 2011; 112:126.</li>&#xD;&#xA;    <li>DeMere M, Wood T, Austin W. Eye complications with blepharoplasty or other eyelid surgery. A national survey. Plast Reconstr Surg 1974; 53:634.</li>&#xD;&#xA;    <li>Stankiewicz JA, Chow JM. Two faces of orbital hematoma in intranasal (endoscopic) sinus surgery. Otolaryngol Head Neck Surg 1999; 120:841.</li>&#xD;&#xA;    <li>Gosau M, Sch&ouml;neich M, Draenert FG, et al. Retrospective analysis of orbital floor fractures--complications, outcome, and review of literature. Clin Oral Investig 2011; 15:305.</li>&#xD;&#xA;    <li>Hass AN, Penne RB, Stefanyszyn MA, Flanagan JC. Incidence of postblepharoplasty orbital hemorrhage and associated visual loss. Ophthal Plast Reconstr Surg 2004; 20:426.</li>&#xD;&#xA;    <li>Teng CC, Reddy S, Wong JJ, Lisman RD. Retrobulbar hemorrhage nine days after cosmetic blepharoplasty resulting in permanent visual loss. Ophthal Plast Reconstr Surg 2006; 22:388.</li>&#xD;&#xA;    <li>Mattke AF, Vender JR, Anstadt MR. Pituitary apoplexy presenting as Addisonian crisis after coronary artery bypass grafting. Tex Heart Inst J 2002; 29:193.</li>&#xD;&#xA;    <li>Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry 2001; 71:542.</li>&#xD;&#xA;    <li>Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: Clinical features, management and outcome. Clin Endocrinol (Oxf) 1999; 51:181.</li>&#xD;&#xA;    <li>Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.</li>&#xD;&#xA;    <li>Lysandropoulos AP, Rossetti AO. Postictal cortical visual impairment: A symptom of posterior reversible encephalopathy. Epilepsy Behav 2010; 17:276.</li>&#xD;&#xA;    <li>Eran A, Barak M. Posterior reversible encephalopathy syndrome after combined general and spinal anesthesia with intrathecal morphine. Anesth Analg 2009; 108:609.</li>&#xD;&#xA;    <li>Yi JH, Ha SH, Kim YK, Choi EM. Posterior reversible encephalopathy syndrome in an untreated hypertensive patient after spinal surgery under general anesthesia -A case report-. Korean J Anesthesiol 2011; 60:369.</li>&#xD;&#xA;    <li>Kim TK, Yoon JU, Park SC, et al. Postoperative blindness associated with posterior reversible encephalopathy syndrome: A case report. J Anesth 2010; 24:783.</li>&#xD;&#xA;    <li>Shen Y, Drum M, Roth S. The prevalence of perioperative visual loss in the United States: A 10-year study from 1996 to 2005 of spinal, orthopedic, cardiac, and general surgery. Anesth Analg 2009; 109:1534.</li>&#xD;&#xA;    <li>Roth S. Postoperative blindness. In: Miller's Anesthesia, 6th ed, Miller RD (Ed), Elsevier, New York 2004. p.3001.</li>&#xD;&#xA;    <li>Postoperative Visual Loss Study Group. Risk factors associated with ischemic optic neuropathy after spinal fusion surgery. Anesthesiology 2012; 116:15.</li>&#xD;&#xA;    <li>Ho VT, Newman NJ, Song S, et al. Ischemic optic neuropathy following spine surgery. J Neurosurg Anesthesiol 2005; 17:38.</li>&#xD;&#xA;    <li>Newman NJ. Perioperative visual loss after nonocular surgeries. Am J Ophthalmol 2008; 145:604.</li>&#xD;&#xA;    <li>Lee LA, Newman NJ, Wagner TA, et al. Postoperative ischemic optic neuropathy. Spine (Phila Pa 1976) 2010; 35:S105.</li>&#xD;&#xA;    <li>Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:743.</li>&#xD;&#xA;    <li>Hollenhorst RW, Svien HJ, Benoit CF. Unilateral blindness occurring during anesthesia for neurosurgical operations. AMA Arch Ophthalmol 1954; 52:819.</li>&#xD;&#xA;    <li>Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. Retinal survival time. Exp Eye Res 2004; 78:723.</li>&#xD;&#xA;    <li>Mizutani AR, Parker J, Katz J, Schmidt J. Visual disturbances, serum glycine levels and transurethral resection of the prostate. J Urol 1990; 144:697.</li>&#xD;&#xA;    <li>Radziwill AJ, Vuadens P, Borruat FX, Bogousslavsky J. Visual disturbances and transurethral resection of the prostate: The TURP syndrome. Eur Neurol 1997; 38:7.</li>&#xD;&#xA;    <li>Karci A, Erkin Y. Transient blindness following hysteroscopy. J Int Med Res 2003; 31:152.</li>&#xD;&#xA;    <li>Wang JM, Creel DJ, Wong KC. Transurethral resection of the prostate, serum glycine levels, and ocular evoked potentials. Anesthesiology 1989; 70:36.</li>&#xD;&#xA;    <li>Hahn RG. Dose-dependent half-life of glycine. Urol Res 1993; 21:289.</li>&#xD;&#xA;    <li>Hawary A, Mukhtar K, Sinclair A, Pearce I. Transurethral resection of the prostate syndrome: Almost gone but not forgotten. J Endourol 2009; 23:2013.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 100340 Version 1.0</div></div></div>"},"100349":{"type":"graphic_table","displayName":"Concerning signs vomiting child","title":"Concerning signs in an infant or child with nausea or vomiting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concerning signs in an infant or child with nausea or vomiting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"27\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"> <p>Increased possibility of an underlying systemic or metabolic disorder: Concerning signs</p> </td> <td class=\"subtitle1\">Comments or diagnostic considerations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nonspecific symptoms</td> </tr> <tr> <td class=\"indent1\">Prolonged vomiting <ul class=\"decimal_heading\"> <li>&#62;12 hours in a neonate </li> <li>&#62;24 hours in children &#60;2 years </li> <li>&#62;48 hours in older children </li> </ul> </td> <td> <ul> <li>Concerns for fluid and electrolyte abnormalities </li> <li>Increased possibility of underlying systemic or metabolic disorder </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Profound lethargy</td> <td> <ul> <li>Increased possibility of an underlying systemic or metabolic disorder&nbsp; </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Significant weight loss</td> <td> <ul> <li>Increased possibility of an underlying systemic or metabolic disorder </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Symptoms of GI obstruction or disease</td> </tr> <tr> <td class=\"indent1\">Bilious vomiting</td> <td>Intestinal obstruction, especially in a neonate</td> </tr> <tr> <td class=\"indent1\">Projectile vomiting</td> <td> <ul> <li>Pyloric stenosis in a young infant (3 to 6 weeks of age) </li> <li>Intestinal obstruction, cyclic vomiting syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hematemesis</td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Severe hematemesis suggests&nbsp;esophageal varices. </li> <li>Milder hematemesis may be due to&nbsp;injury to the esophagus (Mallory-Weiss tear) or stomach (prolapse gastropathy),&nbsp;due to&nbsp;recurrent vomiting. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hematochezia</td> <td>Intussusception (especially in infants and toddlers), infectious colitis, or IBD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Marked abdominal distension, peritoneal signs</td> <td>Intestinal obstruction or intra-abdominal process (eg, appendicitis, obstruction)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Symptoms or signs suggesting neurologic or systemic disease</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bulging fontanelle (infant)</td> <td>Hydrocephalus or meningitis</td> </tr> <tr> <td class=\"indent1\">Headache, positional triggers for vomiting or vomiting on awakening, lack of nausea</td> <td>Increased intracranial pressure (eg, CNS mass, hydrocephalus, or pseudotumor cerebri)</td> </tr> <tr> <td class=\"indent1\">Altered consciousness, seizures, or focal neurologic abnormalities</td> <td>Toxic ingestion, diabetic ketoacidosis, CNS mass, or inborn error of metabolism</td> </tr> <tr> <td class=\"indent1\">History or physical signs of trauma</td> <td>Intracranial or intra-abdominal injury (eg, duodenal hematoma)</td> </tr> <tr> <td class=\"indent1\">Hypotension disproportionate to apparent illness, and/or hyponatremia with hyperkalemia</td> <td>Adrenal crisis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; IBD: inflammatory bowel disease; CNS: central nervous system.</div><div class=\"graphic_reference\">Courtesy of Dr. Carlo Di Lorenzo.</div><div id=\"graphicVersion\">Graphic 100349 Version 3.0</div></div></div>"},"100350":{"type":"graphic_table","displayName":"History and PE vomiting child","title":"Key elements of the history and physical examination in a pediatric patient with nausea or vomiting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of the history and physical examination in a pediatric patient with nausea or vomiting</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Diagnostic considerations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">History</td> </tr> <tr> <td class=\"indent1\">Contacts with vomiting or diarrhea</td> <td> <ul> <li>Gastroenteritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Acute onset of diarrhea and fever</td> <td> <ul> <li>Viral gastroenteritis (if typical features) </li> <li>Infection (sepsis, infectious enteritis/colitis, appendicitis, IBD) </li> <li>Hirschsprung-associated enterocolitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Early morning vomiting</td> <td> <ul> <li>Pregnancy (adolescent females),&nbsp;increased ICP, or cyclic vomiting syndrome&nbsp; </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Vomiting without nausea</td> <td> <ul> <li>Increased ICP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Effortless vomiting</td> <td> <ul> <li>Gastroesophageal reflux </li> <li>Rumination syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Chronic or recurrent infections</td> <td> <ul> <li>Immunodeficiency </li> <li>Tracheoesophageal fistula (infant with recurrent pneumonia) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Periodic episodes of vomiting</td> <td> <ul> <li>Cyclic vomiting syndrome </li> <li>Inborn error of metabolism </li> <li>Migraine (usually with headache and family history) </li> <li>Porphyria, carcinoid, pheochromocytoma, familial dysautonomia </li> </ul> </td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Vomiting triggered by specific foods</td> </tr> <tr> <td class=\"sublist2\">Vomiting begins within minutes to two hours of ingesting the food, usually with cutaneous or respiratory symptoms</td> <td class=\"sublist_other\"> <ul> <li>Food allergy (eg, anaphylaxis) </li> </ul> </td> </tr> <tr> <td class=\"sublist2\">Subacute or chronic, with diarrhea</td> <td class=\"sublist_other\"> <ul> <li>Food protein-induced enteropathy or FPIES </li> </ul> </td> </tr> <tr> <td class=\"sublist2\">Triggered by introduction of lactose</td> <td class=\"sublist_other\"> <ul> <li>Galactosemia </li> </ul> </td> </tr> <tr> <td class=\"sublist2\">Triggered by introduction of fructose or sucrose</td> <td class=\"sublist_other\"> <ul> <li>Hereditary fructose intolerance </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Undigested food in vomitus</td> <td> <ul> <li>Achalasia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Heartburn</td> <td> <ul> <li>Esophagitis (peptic or eosinophilic) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Physical examination</td> </tr> <tr> <td class=\"indent1\">Marked abdominal distension; visible bowel loops; bilious vomitus (green or yellow); absent bowel sounds or increased high-pitched bowel sounds (\"borborygmi\"); or feculent (with the odor of feces)</td> <td> <ul> <li>Intestinal obstruction </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Focal tenderness</td> <td> <ul> <li>RLQ: Appendicitis or Crohn disease </li> <li>RUQ: Gallbladder disease, pancreatitis </li> <li>Costovertebral angle: Pyelonephritis </li> <li>Epigastric: Pancreatitis, peptic ulcer disease/gastritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hepatomegaly, splenomegaly, jaundice</td> <td> <ul> <li>Hepatitis, viral infection (eg, EBV), metabolic disorders </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ataxia, dizziness, nystagmus</td> <td> <ul> <li>Vestibular neuronitis or acute cerebellar ataxia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Papilledema</td> <td> <ul> <li>Increased ICP </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ambiguous genitalia</td> <td> <ul> <li>Congenital adrenal hyperplasia with vomiting due to adrenal crisis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Unusual odor</td> <td> <ul> <li>Inborn error of metabolism </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Enlarged parotid glands</td> <td> <ul> <li>Bulimia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; ICP: intracranial pressure; FPIES: food protein-induced enterocolitis syndrome; RLQ: right lower quadrant; RUQ: right upper quadrant; EBV: Epstein-Barr virus.</div><div class=\"graphic_reference\">Courtesy of Dr. Carlo Di Lorenzo.</div><div id=\"graphicVersion\">Graphic 100350 Version 4.0</div></div></div>"},"100351":{"type":"graphic_table","displayName":"Antinausea and antiemetic medications","title":"Antinausea, antiemetic, and related medications used for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antinausea, antiemetic, and related medications used for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class and drug</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr> <td class=\"subtitle2_left\">Antihistamines</td> <td class=\"subtitle2_left\">Minimal antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Diphenhydramine</td> <td class=\"divider_bottom\" rowspan=\"4\">Vestibular suppression, anti-ACh effect, and H<sub>1</sub> antagonist</td> <td class=\"divider_bottom\" rowspan=\"4\">Motion sickness</td> <td class=\"divider_bottom\" rowspan=\"4\">Sedation, anti-ACh effects*</td> </tr> <tr> <td class=\"indent1\">Hydroxyzine</td> </tr> <tr> <td class=\"indent1\">Dimenhydrinate</td> </tr> <tr> <td class=\"divider_bottom indent1\">Meclizine</td> </tr> <tr> <td class=\"subtitle2_left\">Phenothiazines</td> <td class=\"subtitle2_left\">Mild-moderate antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Promethazine</td> <td>D<sub>2</sub> antagonist at CTZ and H<sub>1</sub> antagonist</td> <td class=\"divider_bottom\" rowspan=\"3\">Chemotherapy-induced vomiting</td> <td class=\"divider_bottom\" rowspan=\"3\">Anti-ACh effects,* extrapyramidal reactions</td> </tr> <tr> <td class=\"indent1\">Prochlorperazine</td> <td class=\"divider_bottom\" rowspan=\"2\">D<sub>2</sub> antagonist at CTZ</td> </tr> <tr> <td class=\"divider_bottom indent1\">Chlorpromazine</td> </tr> <tr> <td class=\"subtitle2_left\">Substituted benzamides</td> <td class=\"subtitle2_left\">Moderate antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Metoclopramide</td> <td>D<sub>2</sub> antagonist at CTZ and 5-HT<sub>4</sub> agonist in gut</td> <td rowspan=\"2\">GERD, gastroparesis, chemotherapy-induced vomiting</td> <td rowspan=\"2\">Irritability and extrapyramidal reactions</td> </tr> <tr> <td class=\"indent1\">Trimethobenzamide</td> <td>D<sub>2</sub> antagonist at CTZ</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cisapride</td> <td>5-HT<sub>4</sub> agonist, ACh release in gut</td> <td>GERD, gastroparesis</td> <td>Diarrhea, abdominal pain, headache, QT prolongation</td> </tr> <tr> <td class=\"subtitle2_left\">Benzimidazole derivatives</td> <td class=\"subtitle2_left\">Moderate antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Domperidone</td> <td>D<sub>2</sub> antagonist in gut</td> <td>Gastroparesis, chemotherapy-induced vomiting</td> <td>Headaches. This drug is not available in United States.</td> </tr> <tr> <td class=\"subtitle2_left\">5-HT<sub>3</sub> receptor antagonists</td> <td class=\"subtitle2_left\">High antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ondansetron</td> <td class=\"divider_bottom\" rowspan=\"3\">5-HT<sub>3</sub> antagonist at CTZ and &#8595; vagal afferents from gut</td> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Chemotherapy- and postoperative-induced vomiting, cyclic vomiting.</p> <p>Ondansetron as also been used in the treatment of acute gastroenteritis.</p> </td> <td class=\"divider_bottom\" rowspan=\"3\">Headache</td> </tr> <tr> <td class=\"indent1\">Granisetron</td> </tr> <tr> <td class=\"divider_bottom indent1\">Tropisetron</td> </tr> <tr> <td class=\"subtitle2_left\">Tachykinin receptor antagonists</td> <td class=\"subtitle2_left\">High antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aprepitant</td> <td>NK<sub>1</sub> antagonist on emesis program</td> <td>Chemotherapy-induced vomiting, effecting on delayed phase</td> <td>Fatigue, dizziness, diarrhea</td> </tr> <tr> <td class=\"subtitle2_left\">Anticholinergics</td> <td class=\"subtitle2_left\">Minimal-mild antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scopolamine</td> <td>Vestibular suppression, anti-ACh</td> <td>Motion sickness</td> <td>Sedation, anti-ACh effects*</td> </tr> <tr> <td class=\"subtitle2_left\">Butyrophenones</td> <td class=\"subtitle2_left\">Moderate antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Droperidol</td> <td>D<sub>2</sub> antagonist at CTZ; anxiolytic action and sedation</td> <td>Chemotherapy- and postoperative-induced vomiting</td> <td>Hypotension, sedation, extrapyramidal effects</td> </tr> <tr> <td class=\"subtitle2_left\">Benzodiazepines </td> <td class=\"subtitle2_left\">Minimal antiemetic activity</td> <td class=\"subtitle2_left\" colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td class=\"divider_bottom\" rowspan=\"2\">Enhanced central GABA-ergic induction of anxiolysis, sedation, and amnesia</td> <td class=\"divider_bottom\" rowspan=\"2\">Adjunctive therapy (sedation) for chemotherapy-induced vomiting and cyclic vomiting</td> <td class=\"divider_bottom\" rowspan=\"2\">Sedation, respiratory depression</td> </tr> <tr> <td class=\"divider_bottom indent1\">Diazepam</td> </tr> <tr> <td class=\"subtitle2_left\">Antimigraine-abortive triptans</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sumatriptan</td> <td class=\"divider_bottom\" rowspan=\"3\">5-HT<sub>1B1D</sub> agonist; induces cerebral vasoconstriction, relaxes gastric fundus</td> <td>Abortive approach for migraine, abdominal migraine, cyclic vomiting; subcutaneous, PO, and nasal forms</td> <td class=\"divider_bottom\" rowspan=\"3\">Transient burning sensation in chest and neck</td> </tr> <tr> <td class=\"indent1\">Zolmitriptan</td> <td>PO, nasal forms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Frovatriptan</td> <td>PO, longer half-life</td> </tr> <tr> <td class=\"subtitle2_left\">Other - NSAIDS</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketorolac</td> <td>Cyclooxygenase inhibitor of prostaglandin synthesis</td> <td>Abortive approach for migraine, cyclic vomiting</td> <td>Gastrointestinal bleeding</td> </tr> <tr> <td class=\"subtitle2_left\">Antimigraine - prophylactic medication</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cyproheptadine</td> <td>H<sub>1</sub> antagonist and 5-HT<sub>2</sub> antagonist</td> <td rowspan=\"2\">Prevention of migraine, abdominal migraine, cyclic vomiting</td> <td>Sedation, anti-ACh effects,* weight gain due to appetite stimulation</td> </tr> <tr> <td class=\"indent1\">Pizotyline</td> <td>5-HT<sub>2</sub> antagonist</td> <td>Not available in United States</td> </tr> <tr> <td class=\"indent1\">Propranolol</td> <td>&#946;<sub>1</sub>, &#946;<sub>2</sub> adrenergic antagonist</td> <td>Prevention of abdominal migraine, cyclic vomiting</td> <td>Hypotension, bradycardia, fatigability; monitor pulse</td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>5-HT<sub>2</sub> antagonist, &#8593; synaptic norepinephrine</td> <td>Prevention of migraine, abdominal migraine, cyclic vomiting</td> <td>Sedation, anti-ACh effects,* QT prolongation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phenobarbital</td> <td>GABA<sub>A</sub> inhibition; results in &#8593; chloride ion current</td> <td>Prevention of cyclic vomiting</td> <td>Sedation, cognitive learning difficulties</td> </tr> <tr> <td class=\"subtitle2_left\">Corticosteroids</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dexamethasone</td> <td>Unknown</td> <td>Adjunctive therapy for chemotherapy- and postoperative-induced vomiting</td> <td>Adrenal suppression</td> </tr> <tr> <td class=\"subtitle2_left\">Cannabinoids</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dronabinol</td> <td rowspan=\"2\">Acts on CB1R receptors on vagus</td> <td rowspan=\"2\">Chemotherapy-induced vomiting</td> <td rowspan=\"2\">Disorientation, vertigo, hallucinations</td> </tr> <tr> <td class=\"indent1\">Nabilone</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACh: acetylcholine; CB1R: cannabinoid receptor 1; CTZ: chemoreceptor trigger zone; D: dopamine; GERD: gastroesophageal reflux disease; H: histamine; 5-HT: 5-hydroxytryptamine (serotonin); GABA: gamma aminobutyric acid; NK: neurokinin; QT: Q-T interval; NSAID: nonsteroidal antiinflammatory drug.<br />* Anticholinergic effects include blurred vision, dry mouth, hypotension, palpitations, urinary retention.</div><div class=\"graphic_reference\">From B U K. Li, \"Vomiting and pyloric stenosis.\" In Walker's Pediatric Gastrointestinal Disease, 5th Edition. Kleinman RE, Sanderson IR, Goulet O, Sherman PM, Mieli-Vergani G, and Shneider BL, Eds. B.C. Decker Inc. Hamilton, Ontario, 2008. Used with permission from People's Medical Publishing House&mdash;USA (PMPH-USA), Shelton, CT.</div><div id=\"graphicVersion\">Graphic 100351 Version 3.0</div></div></div>"},"100356":{"type":"graphic_table","displayName":"Approach to the assessment of decision-making capacity","title":"The decision-making abilities, their definitions, and questions to assess them","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The decision-making abilities, their definitions, and questions to assess them</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Decision-making ability</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Sample questions</td> </tr> <tr class=\"divider_bottom\"> <td>Understanding</td> <td>The ability to state the meaning of the relevant information (eg, diagnosis, risks and benefits of a treatment or procedure, indications, and options of care).</td> <td>After disclosing a piece of information, pause and ask the patient: \"Can you tell me in your own words what I just said about [fill in the topic disclosed]?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Expressing a choice</td> <td>The ability to state a decision.</td> <td>\"Based on what we've just discussed about [insert the topic], what would you choose?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Appreciation</td> <td>The ability to explain how information applies to oneself.</td> <td> <p>To assess appreciation of diagnosis: \"Can you tell me in your own words what you see as your medical problem?\"</p> <p>To assess appreciation of benefit: \"Regardless of what your choice is, do you think that it is possible the medication can benefit you?\"</p> To assess appreciation of risk: \"Regardless of what your choice is, do you think it is possible the medication can harm you?\"</td> </tr> <tr> <td>Reasoning</td> <td>The ability to compare information and infer consequences of choices.</td> <td> <p>To assess comparative reasoning: \"How is X better than Y?\"</p> To assess consequential reasoning: \"How could X affect your daily activities?\"</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Instructions: The usual flow of a capacity assessment begins with the clinician disclosing the relevant facts for a decision and an assessment of the patient's understanding of those facts. Next, the clinician asks for the person's choice, followed by an assessment of their appreciation and reasoning about the choice, and concluding with a reassessment of choice. During the reassessment of choice, pay attention to the logical consistency of the choice based on the reasoning provided.</div><div id=\"graphicVersion\">Graphic 100356 Version 3.0</div></div></div>"},"100357":{"type":"graphic_table","displayName":"Examples of performance on measures of decision-making abilities","title":"Examples of adequate, marginal, and inadequate performance on measures of the four decision-making abilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of adequate, marginal, and inadequate performance on measures of the four decision-making abilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Adequate</td> <td class=\"subtitle1\">Marginal</td> <td class=\"subtitle1\">Inadequate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Understanding</strong></td> <td>Patient recalls the content of the item and offers a fairly clear version of it. Specific use of all the terms supplied in the description is not required as long as there is no loss of meaning.</td> <td>Incomplete or vague response. The patient shows some recollection of the item content, but describes it in a way that renders understanding uncertain, even after the clinician has made efforts to obtain clarification. This includes responses that could indicate understanding but are too broad or vague to be sure, or responses that contain some correct pieces of information, but lack key features.</td> <td>Clearly inaccurate response with serious distortion. For example, the patient does not recall the content of the item; describes it in a way that is clearly inaccurate; describes it in a way that seriously alters its meaning even after efforts to obtain clarification; or offers a response that is unrelated to the question or unintelligible. Responses citing the material verbatim with no other accompanying description do not constitute adequate understanding.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Expressing a choice</strong></td> <td>Patient states a clear, single choice.</td> <td>Patient states more than one choice or ambivalence.</td> <td>Patient is unable to state a choice at all.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Appreciation of the problem</strong></td> <td>Patient acknowledges that he or she manifests a problem based on sound reasoning. Alternatively, the patient may disagree with the claim, but must offer reasons that are not delusional and have some reasonable or verifiable explanation.</td> <td>Patient acknowledges manifesting a problem but denies some features that may be considered critical for understanding or solving the problem. For example, a person who admits she only needs help with opening her medications, when her problem is known to be remembering to take her medications. This rating may also be given if the patient disagrees or is ambivalent about the existence of the problem, but provides reasons that are vague or not clearly defined.</td> <td>Patient clearly does not believe that he or she has a problem with the disclosed activity. Reasoning is seriously flawed and is not based on reality or known facts.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Appreciation of the options</strong></td> <td>Patient acknowledges at least some potential benefit (or adverse effect) of the option on his or her situation that is not based on delusional or distorted thinking. Alternatively, the patient sees no benefit (or does not believe the option will have an adverse effect) and offers reasons that are not delusional or distorted to support the claim. The patient may be ambivalent, but must give a clear and logical reason for being ambivalent.</td> <td>Patient may or may not believe that the option will benefit (or have an adverse effect on) his or her situation, but the reason is vague or may represent delusional or distorted versions of reality. Alternatively, the patient is ambivalent as to the potential benefit (or harm) and the reasoning is vague.</td> <td>Patient offers reasons that are delusional or a serious distortion of reality, or cannot answer the question.</td> </tr> <tr> <td><strong>Reasoning</strong></td> <td> <p>Comparative: Patient provides a clear and vivid statement that compares the consequences of one option with another.</p> <p>Consequential: Patient provides a clear and vivid statement of how continuing with the current situation could or could not affect the patient's life.</p> Logical consistency: The patient's final choice follows logically and consistently based on reasoning provided.</td> <td> <p>Comparative: Patient provides a comparison statement without a statement of specific consequences.</p> <p>Consequential: Patient provides a general statement without details of how the current situation could or could not affect the patient's life.</p> Logical consistency: It is unclear whether the patient's final choice follows logically from the reasoning provided.</td> <td> <p>Comparative: Patient provides no comparative statements or an illogical comparison.</p> <p>Consequential: Patient provides no everyday consequences or an otherwise illogical answer.</p> Logical consistency: The patient's final choice does not follow logically from the reasoning provided.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Assessment of Capacity for Everyday Decision-Making (ACED) Volume I, developed by Jason Karlawish, MD and James Lai, MD.</div><div id=\"graphicVersion\">Graphic 100357 Version 2.0</div></div></div>"},"100359":{"type":"graphic_algorithm","displayName":"Model of GERD pathogenesis in adults","title":"Model of gastroesophageal reflux disease (GERD) pathogenesis in adults","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Model of gastroesophageal reflux disease (GERD) pathogenesis in adults</div><div class=\"cntnt\"><img style=\"width:668px; height:512px;\" src=\"images/GAST/100359_Model_GERD_pathogen_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EGJ: esophagogastric junction; LES-CD: lower esophageal sphincter-crural diphragm; TLESR: transient lower esophageal sphincter relaxation crural diagphram; SCJ: squamocolumnar junction.</div><div class=\"graphic_reference\">Reproduced with permission from: Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: The present, the past and the future. Gut 2014; 63:1185. Copyright &copy; 2014 BMJ Publishing Group Ltd &amp; British Society of Gastroenterology.</div><div id=\"graphicVersion\">Graphic 100359 Version 1.0</div></div></div>"},"100360":{"type":"graphic_algorithm","displayName":"Approach to disclosing serious news intellectually disabled","title":"Algorithmic approach to disclosure versus non-disclosure of serious news to individuals with intellectual disability","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to disclosure versus non-disclosure of serious news to individuals with intellectual disability</div><div class=\"cntnt\"><img style=\"width:442px; height:652px;\" src=\"images/PALC/100360_Appr_discl_seri_news_dsbld.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* These do not necessarily mean that disclosure is harmful, but careful consideration is needed.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Tuffrey-Wijne I. How to Break Bad News to People with Intellectual Disabilities: A Guide for Carers and Professionals. Jessica Kingsley Publishers, London 2012.</li>&#xD;&#xA;    <li>Tuffrey-Wijne I. A new model for breaking bad news to people with intellectual disabilities. Palliat Med 2013; 27:5.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Tuffrey-Wijne I, Giatras N, Butler G, et al. Developing guidelines for disclosure or non-disclosure of bad news around life-limiting illness and death to people with intellectual disabilities. J Appl Res Intellect Disabil 2013; 26:231. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/jar.12026/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/jar.12026/abstract</a>. Copyright &copy; 2013. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 100360 Version 1.0</div></div></div>"},"100362":{"type":"graphic_table","displayName":"Drugs that may unmask or worsen myasthenia gravis","title":"Drugs that may unmask or worsen myasthenia gravis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that may unmask or worsen myasthenia gravis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs that may unmask or worsen myasthenia gravis</td> </tr> <tr> <td class=\"subtitle2_single\">Anesthetic agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Neuromuscular blocking agents<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Antibiotics</td> </tr> <tr> <td class=\"indent2\">Aminoglycosides<sup>&#182;</sup> (eg, gentamicin, neomycin, tobramycin)</td> </tr> <tr> <td class=\"indent2\">Clindamycin</td> </tr> <tr> <td class=\"indent2\">Fluoroquinolones (eg, ciprofloxacin, levofloxacin, norfloxacin)</td> </tr> <tr> <td class=\"indent2\">Ketolides<sup>&#9674;</sup> (eg, telithromycin)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Vancomycin</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiovascular drugs</td> </tr> <tr> <td class=\"indent2\">Beta blockers (eg, atenolol, labetalol, metoprolol, propranolol)</td> </tr> <tr> <td class=\"indent2\">Procainamide</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Quinidine</td> </tr> <tr> <td class=\"subtitle2_single\">Other drugs</td> </tr> <tr> <td class=\"indent2\">Anti-PD-1 monoclonal antibodies (eg, nivolumab and pembrolizumab)</td> </tr> <tr> <td class=\"indent2\">Botulinum toxin</td> </tr> <tr> <td class=\"indent2\">Chloroquine</td> </tr> <tr> <td class=\"indent2\">Hydroxychloroquine</td> </tr> <tr> <td class=\"indent2\">Magnesium</td> </tr> <tr> <td class=\"indent2\">Penicillamine</td> </tr> <tr> <td class=\"indent2\">Quinine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs usually well-tolerated in myasthenia gravis but occasionally associated with an exacerbation*</td> </tr> <tr> <td class=\"subtitle2_single\">Anesthetic agents</td> </tr> <tr> <td class=\"indent2\">Inhalation anesthetics (eg, isoflurane, halothane)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Local anesthetics<sup>&#916;</sup> (eg, bupivacaine, lidocaine, procaine)</td> </tr> <tr> <td class=\"subtitle2_single\">Antibiotics and antiviral agents</td> </tr> <tr> <td class=\"indent2\">Antiretroviral agents (eg, ritonavir)</td> </tr> <tr> <td class=\"indent2\">Tetracyclines (eg, doxycycline, tetracycline)</td> </tr> <tr> <td class=\"indent2\">Macrolides (eg, azithromycin, clarithromycin, erythromycin)</td> </tr> <tr> <td class=\"indent2\">Metronidazole</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Nitrofurantoin</td> </tr> <tr> <td class=\"subtitle2_single\">Anticonvulsants</td> </tr> <tr> <td class=\"indent2\">Carbamazepine</td> </tr> <tr> <td class=\"indent2\">Ethosuximide</td> </tr> <tr> <td class=\"indent2\">Gabapentin</td> </tr> <tr> <td class=\"indent2\">Phenobarbital</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Phenytoin</td> </tr> <tr> <td class=\"subtitle2_single\">Antipsychotics and other psychiatric drugs</td> </tr> <tr> <td class=\"indent2\">Butyrophenones (eg, haloperidol)</td> </tr> <tr> <td class=\"indent2\">Lithium</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Phenothiazines<sup>&#167;</sup> (eg, chlorpromazine, prochlorperazine)</td> </tr> <tr> <td class=\"subtitle2_single\">Glucocorticoids<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent2\">Dexamethasone</td> </tr> <tr> <td class=\"indent2\">Methylprednisolone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Prednisone</td> </tr> <tr> <td class=\"subtitle2_single\">Ophthalmic drugs</td> </tr> <tr> <td class=\"indent2\">Betaxolol</td> </tr> <tr> <td class=\"indent2\">Echothiophate</td> </tr> <tr> <td class=\"indent2\">Proparacaine</td> </tr> <tr> <td class=\"indent2\">Timolol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Tropicamide</td> </tr> <tr> <td class=\"subtitle2_single\">Other drugs</td> </tr> <tr> <td class=\"indent2\">Cisplatinum</td> </tr> <tr> <td class=\"indent2\">Emetine (Ipecac syrup)</td> </tr> <tr> <td class=\"indent2\">Fludarabine</td> </tr> <tr> <td class=\"indent2\">Glatiramer acetate</td> </tr> <tr> <td class=\"indent2\">Interferon alpha</td> </tr> <tr> <td class=\"indent2\">Interleukin-2</td> </tr> <tr> <td class=\"indent2\">Iodinated contrast agents</td> </tr> <tr> <td class=\"indent2\">Riluzole</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PD-1: programmed death receptor-1; MG: myasthenia gravis; IVIG: intravenous immune globulin.<br />* This is not a complete list of all drugs that may, in individual patients, adversely affect neuromuscular transmission. Please refer to the text for further information. <br />&para; Only when necessary in hospitalized patients and with caution for respiratory muscle weakness.<br />&Delta; When inadvertently administered intravenously.<br /><span class=\"lozenge\">&loz;</span> <strong>Contraindicated</strong> in myasthenia gravis.<br />&sect; Also used as antiemetics. <br />&yen; Although glucocorticoids are a common treatment for MG, at high doses they may cause a significant exacerbation of MG symptoms during early stages of treatment. For this reason, glucocorticoids should be started in high doses only in hospitalized patients who are receiving concurrent plasmapheresis or IVIG for myasthenic crisis.</div><div id=\"graphicVersion\">Graphic 100362 Version 4.0</div></div></div>"},"100363":{"type":"graphic_picture","displayName":"Granular cell tumor tongue","title":"Granular cell tumor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Granular cell tumor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100363_Granular_cell_tmr_tng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granular cell tumors typically present as a nodule on the dorsum of the tongue.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100363 Version 1.0</div></div></div>"},"100364":{"type":"graphic_picture","displayName":"Granular cell tumor tongue histo","title":"Histopathologic features of granular cell tumor of the tongue​","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of granular cell tumor of the tongue​</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100364_Grnlr_cell_tmr_tng_hst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sheets, cords, and nests of large cells with small round or oval nuclei and abundant granular eosinophilic cytoplasm are dispersed between collagen bundles.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100364 Version 1.0</div></div></div>"},"100366":{"type":"graphic_table","displayName":"Drugs usually well-tolerated but potentially exacerbating MG","title":"Drugs usually well-tolerated in myasthenia gravis but occasionally associated with an exacerbation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs usually well-tolerated in myasthenia gravis but occasionally associated with an exacerbation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anesthetic agents</td> </tr> <tr> <td class=\"indent1\">Inhalation anesthetics - eg, isoflurane, halothane</td> </tr> <tr> <td class=\"indent1\">Local anesthetics<sup>&#182;</sup> - eg, bupivacaine, lidocaine, procaine</td> </tr> <tr> <td class=\"subtitle1_single\">Antibiotics and antiviral agents</td> </tr> <tr> <td class=\"indent1\">Antiretroviral agents - eg, ritonavir</td> </tr> <tr> <td class=\"indent1\">Tetracyclines - eg, doxycycline, tetracycline</td> </tr> <tr> <td class=\"indent1\">Macrolides - eg, azithromycin, clarithromycin, erythromycin</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> </tr> <tr> <td class=\"indent1\">Ethosuximide</td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> </tr> <tr> <td class=\"indent1\">Phenobarbital</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> </tr> <tr> <td class=\"subtitle1_single\">Antipsychotics and other psychiatric drugs</td> </tr> <tr> <td class=\"indent1\">Butyrophenones - eg, haloperidol</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Phenothiazines<sup>&#916;</sup> - eg, chlorpromazine, prochlorperazine</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular drugs</td> </tr> <tr> <td class=\"indent1\">Bretylium</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers - eg, verapamil</td> </tr> <tr> <td class=\"indent1\">Statins</td> </tr> <tr> <td class=\"subtitle1_single\">Glucocorticoids<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Dexamethasone</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> </tr> <tr> <td class=\"subtitle1_single\">Ophthalmic drugs</td> </tr> <tr> <td class=\"indent1\">Betaxolol</td> </tr> <tr> <td class=\"indent1\">Echothiophate</td> </tr> <tr> <td class=\"indent1\">Proparacaine</td> </tr> <tr> <td class=\"indent1\">Timolol</td> </tr> <tr> <td class=\"indent1\">Tropicamide</td> </tr> <tr> <td class=\"subtitle1_single\">Other drugs</td> </tr> <tr> <td class=\"indent1\">Cisplatinum</td> </tr> <tr> <td class=\"indent1\">Emetine (Ipecac syrup)</td> </tr> <tr> <td class=\"indent1\">Fludarabine</td> </tr> <tr> <td class=\"indent1\">Glatiramer acetate</td> </tr> <tr> <td class=\"indent1\">Interferon alpha</td> </tr> <tr> <td class=\"indent1\">Interleukin-2</td> </tr> <tr> <td class=\"indent1\">Iodinated contrast agents</td> </tr> <tr> <td class=\"indent1\">Riluzole</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MG: myasthenia gravis; IVIG: intravenous immune globulin.<br />* This is not a complete list of all drugs that may, in individual patients, adversely affect neuromuscular transmission. Please refer to the text for further information.<br />¶ When inadvertently administered intravenously.<br />∆ Also used as antiemetics.<br /><FONT class=lozenge>◊</FONT> Although glucocorticoids are a common treatment for MG, at high doses they may cause a significant exacerbation of MG symptoms during early stages of treatment. For this reason, glucocorticoids should be started in high doses only in hospitalized patients who are receiving concurrent plasmapheresis or IVIG for myasthenic crisis.</div><div id=\"graphicVersion\">Graphic 100366 Version 2.0</div></div></div>"},"100370":{"type":"graphic_diagnosticimage","displayName":"Radiographs of Galeazzi fracture in adult","title":"Galeazzi fracture on radiography in adult","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Galeazzi fracture on radiography in adult</div><div class=\"cntnt\"><img style=\"width:725px; height:402px;\" src=\"images/RADIOL/100370_Radiogrph_galeazzi_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal radiograph of the right forearm (A) shows an oblique fracture through the mid-shaft of the radius (arrow). Image B confirms the fracture of the radius (arrow) with dislocation of the distal ulna and styloid fracture (arrowhead). Image C is a magnified view of the wrist shown in image B and shows the dislocated distal ulna (arrowhead) with ulna styloid fracture. Image D is a magnified lateral radiograph showing the normal position of the ulna (arrowhead).</div><div class=\"graphic_reference\">Images A, B, and C courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 100370 Version 1.0</div></div></div>"},"100371":{"type":"graphic_table","displayName":"Classification of OHSS: Clinical and biochemical features","title":"Classification of OHSS: Clinical and biochemical features<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of OHSS: Clinical and biochemical features<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Biochemical features</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mild</strong></td> <td> <ul> <li>Abdominal distention/discomfort </li> <li>Mild nausea/vomiting </li> <li>Diarrhea </li> <li>Enlarged ovaries </li> </ul> </td> <td> <ul> <li>No clinically important laboratory findings </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Moderate</strong></td> <td> <ul> <li>Presence of mild features plus: <ul> <li>Ultrasonographic evidence of ascites </li> </ul> </li> </ul> </td> <td> <ul> <li>Elevated Hct (&#62;41%) </li> <li>Elevated WBC (&#62;15,000/microL) </li> <li>Hypoproteinemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Severe</strong></td> <td> <ul> <li>Presence of mild and moderate features plus: <ul> <li>Clinical evidence of ascites (can be tense ascites) </li> <li>Severe abdominal pain </li> <li>Intractable nausea and vomiting </li> <li>Rapid weight gain (&#62;1 kg in 24 hours) </li> <li>Pleural effusion </li> <li>Severe dyspnea </li> <li>Oliguria/anuria </li> <li>Low blood/central venous pressure </li> <li>Syncope </li> <li>Venous thrombosis </li> </ul> </li> </ul> </td> <td> <ul> <li>Hemoconcentration (Hct &#62;55%) </li> <li>WBC &#62;25,000/microL </li> <li>Serum creatinine &#62;1.6 mg/dL </li> <li>Creatinine clearance &#60;50 mL/min </li> <li>Hyponatremia (Na<sup>+</sup> &#60;135 mEq/L) </li> <li>Hyperkalemia (K<sup>+</sup> &#62;5 mEq/L) </li> <li>Elevated liver enzymes </li> </ul> </td> </tr> <tr> <td><strong>Critical</strong></td> <td> <ul> <li>Presence of severe features plus: <ul> <li>Anuria/acute renal failure </li> <li>Arrhythmia </li> <li>Pericardial effusion </li> <li>Massive hydrothorax </li> <li>Thromboembolism </li> <li>Arterial thrombosis </li> <li>ARDS </li> <li>Sepsis </li> </ul> </li> </ul> </td> <td> <ul> <li>Worsening of biochemical findings seen with severe OHSS </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OHSS: ovarian hyperstimulation syndrome; Hct: hematocrit; WBC: white blood cell; Na: sodium; K: potassium; ARDS: acute respiratory distress syndrome.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil steril 1992; 58:249.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012; 10:32. Copyright &copy; 2012 Fiedler and Ezcurra. Reproduced from BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 100371 Version 4.0</div></div></div>"},"100372":{"type":"graphic_table","displayName":"Complications vertebral osteo","title":"Complications of vertebral osteomyelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of vertebral osteomyelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Short-term complications</td> <td class=\"subtitle1\">Longer-term complications</td> </tr> <tr> <td> <ul> <li>Epidural abscess, subdural abscess, meningitis </li> <li>Paraspinal abscess and extension (including psoas, retropharyngeal, mediastinal, subphrenic, retroperitoneal abscesses, or empyema)</li> <li>Extension of infection involving the aorta and/or vena cava</li> <li>Spinal cord and/or nerve root impingement with neurological consequences </li> <li>Vertebral body collapse </li> <li>Endocarditis*</li> </ul> </td> <td> <ul> <li>Residual neurological deficit(s) </li> <li>Chronic back pain </li> <li>Depression </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In general, vertebral osteomyelitis is a complication of bacteremia; associated endocarditis may or may not be present.</div><div id=\"graphicVersion\">Graphic 100372 Version 2.0</div></div></div>"},"100373":{"type":"graphic_table","displayName":"Suggested treatment schema for permanent prostate brachytherapy","title":"Suggested treatment schema for low-, intermediate-, and high-risk disease for permanent prostate brachytherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested treatment schema for low-, intermediate-, and high-risk disease for permanent prostate brachytherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk group per NCCN</td> <td class=\"subtitle1\">Brachytherapy alone?</td> <td class=\"subtitle1\">Combined with EBRT?</td> <td class=\"subtitle1\">Combined with androgen deprivation?</td> </tr> <tr> <td>Low</td> <td>Yes</td> <td>Not favored</td> <td>Not favored</td> </tr> <tr> <td>Intermediate</td> <td>Optional</td> <td>Optional</td> <td>Optional</td> </tr> <tr> <td>High</td> <td>No</td> <td>Yes</td> <td>Favored</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NCCN: National Comprehensive Cancer Network; EBRT: external beam radiation therapy.</div><div class=\"graphic_reference\">Reproduced from: Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11:6. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100373 Version 1.0</div></div></div>"},"100375":{"type":"graphic_picture","displayName":"Multiple neurofibromas 2","title":"Neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neurofibroma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/100375_Multiple_neurofibromas_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple neurofibromas in a patient with neurofibromatosis type I.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100375 Version 1.0</div></div></div>"},"100379":{"type":"graphic_picture","displayName":"Isometric hip adduction with bent knees","title":"Isometric hip adduction with bent knees","html":"<div class=\"graphic\"><div style=\"width: 738px\" class=\"figure\"><div class=\"ttl\">Isometric hip adduction with bent knees</div><div class=\"cntnt\"><img style=\"width:718px; height:658px;\" src=\"images/EM/100379_Ismtrc_hp_addctn_bnt_kns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric adduction performed with a ball between bent knees is an exercise used early in the rehabilitation of patients with an adductor muscle or tendon strain.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100379 Version 1.0</div></div></div>"},"100380":{"type":"graphic_picture","displayName":"Isometric hip adduction with straight legs","title":"Isometric hip adduction with straight legs","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Isometric hip adduction with straight legs</div><div class=\"cntnt\"><img style=\"width:722px; height:748px;\" src=\"images/EM/100380_Ismtrc_hp_addct_strght_lg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isometric hip adduction against a ball placed between the ankles is an exercise used early in the rehabilitation of patients with adductor muscle or tendon strains.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100380 Version 1.0</div></div></div>"},"100381":{"type":"graphic_table","displayName":"PACU discharge criteria","title":"A commonly used postanesthesia care unit (PACU) discharge criteria score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A commonly used postanesthesia care unit (PACU) discharge criteria score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Postanesthetic discharge scoring system</td> </tr> <tr> <td class=\"subtitle2_single\">Vital signs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <p>2 = BP + pulse within 20% preop baseline</p> <p>1 = BP + pulse within 20-40% preop baseline</p> 0 = BP + pulse &#62;40% preop baseline</td> </tr> <tr> <td class=\"subtitle2_single\">Activity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <p>2 = Steady gait, no dizziness, or meets preop level</p> <p>1 = Requires assistance</p> 0 = Unable to ambulate</td> </tr> <tr> <td class=\"subtitle2_single\">Nausea and vomiting</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <p>2 = Minimal/treated with PO medication</p> <p>1 = Moderate/treated with parenteral medication</p> 0 = Severe/continues despite treatment</td> </tr> <tr> <td class=\"subtitle2_single\">Pain</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <p>Controlled with oral analgesics and acceptable to patient:</p> <p>2 = Yes</p> 1 = No</td> </tr> <tr> <td class=\"subtitle2_single\">Surgical bleeding</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <p>2 = Minimal/no dressing changes</p> <p>1 = Moderate/up to two dressing changes required</p> 0 = Severe/more than three dressing changes required</td> </tr> <tr> <td><strong>Score &#8805;9 for discharge</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; PO: oral.</div><div class=\"graphic_reference\">Modified with permission from: Fowler MA, Spiess BD. Postanesthesia recovery. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100381 Version 6.0</div></div></div>"},"100384":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of minor adductor strain","title":"Ultrasound of minor adductor strain","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Ultrasound of minor adductor strain</div><div class=\"cntnt\"><img style=\"width:724px; height:505px;\" src=\"images/EM/100384_US_minor_adductor_strain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a small intramuscular bleed and tissue irregularities around the musculotendinous junction consistent with an adductor strain. To the right of the image is an example of anisotropy: a hypoechoic region that appears when sound waves are not aligned with the ultrasound probe. This may be due to loss of contact between the ultrasound probe and curved areas of the body. Anisotropy can be confused with signs of injury.</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 100384 Version 2.0</div></div></div>"},"100385":{"type":"graphic_figure","displayName":"PMN defects","title":"Polymorphonuclear neutrophil (PMN) defects","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Polymorphonuclear neutrophil (PMN)&nbsp;defects</div><div class=\"cntnt\"><img style=\"width:536px; height:647px;\" src=\"images/HEME/100385_PMN_defects.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal neutrophil functions in the circulation (pink background) and the tissues (gray background) are illustrated, along with inherited defects in each of the&nbsp;stages in response to&nbsp;pathogens (adhesion, chemotaxis, phagocytosis, and killing). Refer to UpToDate topics on individual syndromes and laboratory testing for these defects for additional information.</div><div class=\"graphic_footnotes\">LAD: Leukocyte adhesion defect; CGD: chronic granulomatous disease.</div><div class=\"graphic_reference\">Courtesy of Thomas Coates, MD</div><div id=\"graphicVersion\">Graphic 100385 Version 1.0</div></div></div>"},"100386":{"type":"graphic_diagnosticimage","displayName":"Ultrasound appearance of normal and injured muscle tissue","title":"Ultrasound appearance of normal and injured muscle tissue","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Ultrasound appearance of normal and injured muscle tissue</div><div class=\"cntnt\"><img style=\"width:625px; height:414px;\" src=\"images/EM/100386_US_normal_injured_muscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image on the left shows the smooth, regular appearance of normal muscle tissue. In contrast, the image on the right shows an irregular, slightly hyperechoic (bright) area with a swirling appearance (arrows) consistent with intramuscular bleeding and hypoechoic (dark) areas (arrowheads) consistent with a tissue deficit. The deficit may be due to missing muscle or tendon tissue from a tear.</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 100386 Version 2.0</div></div></div>"},"100387":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of adductor tendon avulsion","title":"Ultrasound of adductor tendon avulsion","html":"<div class=\"graphic\"><div style=\"width: 970px\" class=\"figure\"><div class=\"ttl\">Ultrasound of adductor tendon avulsion</div><div class=\"cntnt\"><img style=\"width:950px; height:548px;\" src=\"images/EM/100387_US_adductor_tendon_avulsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a complete adductor tendon tear. The tendon stump is the hyperechoic (white) area seen to the right of the image and is notable for the irregular appearance of the tissue; the hypoechoic (dark) region represents the tissue defect. A small part of the pubic bone can be seen to the left (arrow).</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 100387 Version 2.0</div></div></div>"},"100388":{"type":"graphic_picture","displayName":"Biodex machine","title":"Biodex machine","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Biodex machine</div><div class=\"cntnt\"><img style=\"width:763px; height:700px;\" src=\"images/EM/100388_Biodex_machine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biodex machine is&nbsp;used for&nbsp;isokinetic assessment or training of specific muscle groups.&nbsp;</div><div class=\"graphic_reference\">Photo courtesy of Biodex Medical Systems, Inc.</div><div id=\"graphicVersion\">Graphic 100388 Version 2.0</div></div></div>"},"100390":{"type":"graphic_picture","displayName":"Single leg squat exercise","title":"Single leg squat exercise","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Single leg squat exercise</div><div class=\"cntnt\"><img style=\"width:793px; height:407px;\" src=\"images/EM/100390_Single_leg_squat_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When descending during a single leg squat, sit back as if sitting down on a chair and maintain a neutral spine (ie, flat lumbar spine) throughout the motion. The torso will incline forward from the hip (not the spine). The arms may be held straight ahead for balance, and&nbsp;a light weight may be held&nbsp;for additional assistance.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100390 Version 2.0</div></div></div>"},"100391":{"type":"graphic_table","displayName":"Lab testing for disorders of neutrophil number or function","title":"Laboratory testing for disorders of neutrophil number or function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing for disorders of neutrophil number or function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Initial testing</td> <td class=\"subtitle1\">Genetic testing*</td> <td class=\"subtitle1\">Additional details</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Disorders of neutrophil number</td> </tr> <tr> <td class=\"indent1\">Severe congenital neutropenia (SCN)</td> <td>CBC, BM evaluation</td> <td>ELANE (mutation in approximately 60%), TCIRG1, G6PC3, GFI1, WAS, CSF3R, HAX1<sup>&#182;</sup>; 20 to 30% do not have a mutation identified</td> <td> <p>CBC shows isolated neutropenia</p> BM shows promyelocytic (progranulocyte) arrest</td> </tr> <tr> <td class=\"indent1\">Cyclic neutropenia (CN)</td> <td>Serial CBCs (eg, two times per week)</td> <td>ELANE mutation in approximately 90%</td> <td>CBC shows isolated neutropenia with a characteristic periodicity (eg, absolute neutrophil count &#60;200/microL for two to four days). BM not helpful.</td> </tr> <tr> <td class=\"indent1\">MonoMAC</td> <td>CBC, lymphocyte subsets</td> <td>GATA2 mutation in approximately 80%</td> <td>Varying neutropenia, severe monocytopenia, NK cell cytopenia, B cell lymphopenia</td> </tr> <tr> <td class=\"indent1\">Shwachman-Diamond syndrome (SDS)</td> <td>CBC, tests of exocrine pancreatic function, BM evaluation</td> <td>SBDS mutation in approximately 80%</td> <td> <p>CBC shows isolated neutropenia or pancytopenia</p> BM shows decreased cellularity; laboratory tests show exocrine pancreatic dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Disorders of neutrophil function</td> </tr> <tr> <td class=\"indent1\">Chediak-Higashi syndrome (CHS)</td> <td>CBC, BM evaluation</td> <td>LYST mutation in approximately 80%</td> <td>Characteristic very large granules in leukocytes</td> </tr> <tr> <td class=\"indent1\">Leukocyte adhesion deficiency-I (LAD-I)</td> <td>CBC, flow cytometry for deficiency of CD11b/CD18</td> <td>ITGB2 mutation in over 90%</td> <td>Neutrophilic leukocytosis, omphalitis in newborn period</td> </tr> <tr> <td class=\"indent1\">Leukocyte adhesion deficiency-II (LAD-II)</td> <td>CBC, flow cytometry for deficiency of CD15a/SLeX</td> <td>GDP-fucose transporter</td> <td>Dysmorphic, neuro development problems</td> </tr> <tr> <td class=\"indent1\">Chronic granulomatous disease (CGD)</td> <td>Flow cytometry using dihydrorhodamine (DHR) fluorescence; NBT slide test</td> <td>CYBB, NCF1, CYBA, or NCF2 mutation in most cases</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Neutrophil specific granule deficiency</td> <td>CBC</td> <td>C/EBP-epsilon</td> <td>Bilobed neutrophils (pseudo Pelger-Huet anomaly) that lack granules</td> </tr> <tr> <td class=\"indent1\">Hyperimmunoglobulin E (IgE) syndrome (Job syndrome)</td> <td>CBC, IgE levels, Th-17 cell count</td> <td>STAT3</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on laboratory testing of neutrophil function and on specific disorders for further details.</div><div class=\"graphic_footnotes\">CBC: complete blood count with exam of smear; BM: bone marrow; ANC: absolute neutrophil count; NBT: nitro blue tetrazolium.<br />* The genetic disorders associated with neutropenia or neutrophil dysfunction syndromes can be diagnosed with reasonable certainty by combinations of the tests listed above, which are available through certified clinical reference laboratories. Refer to UpToDate topics on neutropenia and neutrophil dysfunction for details and caveats regarding testing and additional clinical features of these syndromes.<br />¶ HAX1 mutation is rare and essentially only seen in consanguineous pairings.</div><div id=\"graphicVersion\">Graphic 100391 Version 4.0</div></div></div>"},"100392":{"type":"graphic_picture","displayName":"Side lunge exercise","title":"Side lunge exercise","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Side lunge exercise</div><div class=\"cntnt\"><img style=\"width:792px; height:473px;\" src=\"images/EM/100392_Side_lunge_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the side lunge, step directly to the side while maintaining good posture (flat lower back). Particularly early during rehabilitation, do not stride further than is comfortable.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100392 Version 1.0</div></div></div>"},"100393":{"type":"graphic_picture","displayName":"Side-lying hip adduction","title":"Side-lying hip adduction","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Side-lying hip adduction</div><div class=\"cntnt\"><img style=\"width:669px; height:665px;\" src=\"images/EM/100393_Side_lying_hip_adduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adduction of the hip against gravity while lying on one's side is a basic exercise that can be used early in the rehabilitation of an adductor injury.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100393 Version 1.0</div></div></div>"},"100395":{"type":"graphic_diagnosticimage","displayName":"Radiography proximal radial fracture rotational displacement","title":"Proximal radial shaft fracture with rotational displacement on radiography","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Proximal radial shaft fracture with rotational displacement on radiography</div><div class=\"cntnt\"><img style=\"width:763px; height:490px;\" src=\"images/RADIOL/100395_Rdgr_prx_rdl_frct_rttnl_dsp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anteroposterior view of the radius and ulna shows a fracture of the proximal radius (arrow) and an altered position of the bicipital tuberosity (arrowhead) when compared to the normal position of the bicipital tuberosity in this view (B, arrowhead). Image C is a lateral view of the proximal fracture of the radius (arrow), bicipital tuberosity, and the eccentric soft tissue swollen muscle mass (asterisk) compared to the normal (D) where there is a paucity of muscle mass in this location (asterisk). In this lateral projection, the altered position of the bicipital tuberosity in C (arrowhead) is not as well appreciated when compared to its position in the normal (D, arrowhead).</div><div class=\"graphic_reference\">Images A and C courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 100395 Version 1.0</div></div></div>"},"100398":{"type":"graphic_picture","displayName":"Side plank with hip adduction","title":"Side plank with hip adduction","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Side plank with hip adduction</div><div class=\"cntnt\"><img style=\"width:710px; height:703px;\" src=\"images/EM/100398_Side_plank_hip_adduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The side plank with hip adduction exercise develops both core and adductor muscle strength. Maintain a straight torso throughout the exercise.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100398 Version 1.0</div></div></div>"},"100400":{"type":"graphic_picture","displayName":"Single leg hop onto unstable surface","title":"Single leg hop onto unstable surface","html":"<div class=\"graphic\"><div style=\"width: 827px\" class=\"figure\"><div class=\"ttl\">Single leg hop onto unstable surface</div><div class=\"cntnt\"><img style=\"width:807px; height:798px;\" src=\"images/EM/100400_Sngl_lg_hp_unstbl_srfc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hopping onto an unstable surface develops balance and stability during the final phase of rehabilitation.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100400 Version 1.0</div></div></div>"},"100403":{"type":"graphic_picture","displayName":"Single leg stance catching a ball","title":"Single leg stance catching a ball","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Single leg stance catching a ball</div><div class=\"cntnt\"><img style=\"width:794px; height:554px;\" src=\"images/EM/100403_Single_leg_stanc_catch_ball.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Catching a ball while balancing on a single leg is an exercise used during the final stages of a rehabilitation. Such functional exercises more closely approximate the demands of sport than standard strength exercises.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100403 Version 1.0</div></div></div>"},"100404":{"type":"graphic_picture","displayName":"Jumping on and off unstable surface","title":"Jumping on and off unstable surface","html":"<div class=\"graphic\"><div style=\"width: 810px\" class=\"figure\"><div class=\"ttl\">Jumping on and off unstable surface</div><div class=\"cntnt\"><img style=\"width:790px; height:455px;\" src=\"images/EM/100404_Jump_on_off_unstable_surfac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Jumping on and off an unstable surface using one leg develops balance and stability. This advanced exercise is performed during the final stage of rehabilitation.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100404 Version 1.0</div></div></div>"},"100405":{"type":"graphic_picture","displayName":"Single leg hops in four quadrants","title":"Single leg hops in four quadrants","html":"<div class=\"graphic\"><div style=\"width: 889px\" class=\"figure\"><div class=\"ttl\">Single leg hops in four quadrants</div><div class=\"cntnt\"><img style=\"width:869px; height:366px;\" src=\"images/EM/100405_Single_leg_hops_four_qdrnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single leg hops develop strength, stability, and balance. Hops are performed clockwise, counterclockwise, and diagonally from one quadrant to another. Patients are instructed to land softly with each hop.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100405 Version 1.0</div></div></div>"},"100407":{"type":"graphic_picture","displayName":"Isokinetic testing of hip adduction and abduction","title":"Isokinetic testing of hip adduction and abduction","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Isokinetic testing of hip adduction and abduction</div><div class=\"cntnt\"><img style=\"width:794px; height:387px;\" src=\"images/EM/100407_Iskntc_tst_hp_addct_abdct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the photograph above, the athlete's hip adduction and abduction strength are being tested isokinetically in a Biodex machine.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100407 Version 1.0</div></div></div>"},"100409":{"type":"graphic_table","displayName":"Neonatal sepsis differential diagnosis","title":"Differential diagnosis of neonatal sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of neonatal sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Distinguishing features</td> <td class=\"subtitle1\">Diagnostic tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other systemic neonatal infections</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Viral infections:</td> </tr> <tr> <td class=\"indent2\">Herpes simplex virus</td> <td>Mucocutaneous vesicles, CSF pleocytosis, elevated CSF protein, thrombocytopenia, hepatitis</td> <td>Viral culture; HSV PCR</td> </tr> <tr> <td class=\"indent2\">Enteroviruses</td> <td>Fulminant systemic disease, myocarditis, hepatitis, encephalitis</td> <td>Viral culture; EV PCR</td> </tr> <tr> <td class=\"indent2\">Parechovirus</td> <td>Encephalitis/meningitis, rash on palms and soles</td> <td>HPeV PCR (available through CDC)</td> </tr> <tr> <td class=\"indent2\">Cytomegalovirus</td> <td>Thrombocytopenia, periventricular intracranial calcifications, microcephaly, sensorineural hearing loss, chorioretinitis</td> <td>Viral culture; CMV PCR</td> </tr> <tr> <td class=\"indent2\">Influenza viruses</td> <td>Respiratory symptoms, rhinorrhea, gastrointestinal symptoms</td> <td>Viral culture; influenza-specific antigen detection or immunofluorescence assay</td> </tr> <tr> <td class=\"indent2\">Respiratory syncytial virus</td> <td>Respiratory symptoms, rhinorrhea, cough, apnea, pneumonia</td> <td>Viral culture; RSV-specific antigen detection or immunofluorescence assay</td> </tr> <tr> <td class=\"indent1\">Spirochetal infections &ndash; Syphilis</td> <td>Skeletal abnormalities (osteochondritis and periostitis), pseudoparalysis, persistent rhinitis, maculopapular rash (particularly on palms and soles or in diaper area)</td> <td>RPR or VDRL</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Parasitic infections:</td> </tr> <tr> <td class=\"indent2\">Congenital malaria</td> <td>Anemia, splenomegaly, jaundice</td> <td>Detection of parasitemia on blood smear</td> </tr> <tr> <td class=\"indent2\">Toxoplasmosis</td> <td>Intracranial calcifications (diffuse), hydrocephalus, chorioretinitis, mononuclear CSF pleocytosis, elevated CSF protein</td> <td><em>Toxoplasma gondii</em> serology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fungal infection &ndash; Candidiasis</td> <td>Persistent hyperglycemia, thrombocytopenia, multiorgan failure</td> <td>Isolation of Candida in blood, urine, or CSF culture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Noninfectious causes of temperature instability in neonates</td> </tr> <tr> <td class=\"indent1\">Altered environmental temperature</td> <td colspan=\"2\">Transient; no other systemic symptoms; resolves with simple nonpharmacologic measures</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> <td colspan=\"2\">Clinical history of poor feeding or fluid losses (eg, vomiting and/or diarrhea)</td> </tr> <tr> <td class=\"indent1\">Neonatal abstinence syndrome</td> <td>History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning</td> <td>Positive drug screening tests</td> </tr> <tr> <td class=\"indent1\">CNS insult (eg, anoxia or hemorrhage)</td> <td>History of perinatal asphyxia; focal neurologic findings or seizures</td> <td>Abnormal neuroimaging studies</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> <td>Hypotonia, lethargy, hypothermia, large fontanels</td> <td>Abnormal T4 or TSH level on newborn screen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Congenital adrenal hyperplasia</td> <td>Ambiguous genitalia (females), adrenal insufficiency and salt-wasting (hyponatremia, hyperkalemia, dehydration)</td> <td>Abnormal 17a-hydroxyprogesterone level on newborn screen</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Noninfectious causes of respiratory and cardiocirculatory symptoms in neonates</td> </tr> <tr> <td class=\"indent1\">Transient tachypnea of the newborn</td> <td>Onset of symptoms within two hours after delivery; symptoms usually resolve within 24 hours</td> <td>CXR findings include increased lung volumes, mild cardiomegaly, prominent vascular markings, fluid in the interlobar fissures, and pleural effusions</td> </tr> <tr> <td class=\"indent1\">Respiratory distress syndrome</td> <td>Most common in preterm infants; rare in term infants; onset of symptoms within first few hours after delivery, progressively worsens over first 48 hours of life</td> <td>CXR findings include low lung volume and diffuse reticulogranular ground glass appearance with air bronchograms</td> </tr> <tr> <td class=\"indent1\">Meconium aspiration</td> <td>History of meconium-stained amniotic fluid; respiratory distress occurs immediately after birth</td> <td>Initial CXR may show streaky, linear densities; as the disease progresses, the lungs may appear hyperinflated with diffuse patchy densities</td> </tr> <tr> <td class=\"indent1\">Pneumothorax</td> <td>Asymmetric chest rise, decreased breath sounds on affected side; hypotension (in cases of tension pneumothorax)</td> <td>CXR will usually detect symptomatic pneumothoraces</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies (including tracheal-esophageal fistula, choanal atresia, and diaphragmatic hernia)</td> <td>Often occur with other congenital anomalies including VACTERL and CHARGE associations; choanal atresia is characterized by noisy labored breathing while feeding</td> <td>CDH is often diagnosed by routine antenatal ultrasound screening; postnatal CXR shows herniation of abdominal contents into hemithorax; TEF is diagnosed with upper gastrointestinal series and/or bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Neonatal abstinence syndrome</td> <td>History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning</td> <td>Positive drug screening tests</td> </tr> <tr> <td class=\"indent1\">Cardiac arrhythmias (eg, supraventricular tachycardia)</td> <td>Abrupt onset and termination of rapid heart rate</td> <td>Abnormal ECG</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Congenital heart disease</td> <td>Infants with ductal-dependent lesions may initially lack symptoms then develop cyanosis and rapid clinical deterioration as the PDA closes in the first few days of life</td> <td>Abnormal hyperoxia test; abnormal echocardiography</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Noninfectious causes of neurologic symptoms in neonates</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> <td>Common in infants who are large for gestational age and/or infants of diabetic mothers</td> <td>Abnormal blood glucose level</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> <td>Increased neuromuscular irritability and seizures; associated with prematurity, maternal diabetes, and perinatal asphyxia</td> <td>Abnormal serum calcium level</td> </tr> <tr> <td class=\"indent1\">Hypermagnesemia</td> <td>Generalized hypotonia, respiratory depression and apnea; typically results from maternal treatment with magnesium sulfate</td> <td>Abnormal serum magnesium level</td> </tr> <tr> <td class=\"indent1\">CNS insult (eg, anoxia or hemorrhage)</td> <td>History of perinatal asphyxia; focal neurologic findings or seizures</td> <td>Abnormal neuroimaging studies</td> </tr> <tr> <td class=\"indent1\">Congenital CNS malformations (eg, hydrocephalus)</td> <td>Abnormal head circumference</td> <td>Abnormal neuroimaging studies</td> </tr> <tr> <td class=\"indent1\">Neonatal abstinence syndrome</td> <td>History of maternal drug use; sweating, sneezing, nasal stuffiness, and yawning</td> <td>Positive drug screening tests</td> </tr> <tr> <td class=\"indent1\">Inborn errors of metabolism</td> <td>Otherwise unexplained acid-base disorders, hyperammonemia, hypoglycemia, hematologic abnormalities, liver dysfunction, and renal disease</td> <td>Positive newborn screen for inborn errors of metabolism</td> </tr> <tr> <td class=\"indent1\">Pyridoxine deficiency</td> <td>Refractory seizures</td> <td>Abnormal plasma pyridoxal-5-phophate level</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebral spinal fluid; HSV: herpes simplex virus; PCR: polymerase chain reaction; EV: enterovirus; HPeV: human parechovirus; CMV: cytomegalovirus; RSV: respiratory syncytial virus; RPR: rapid plasma reagin; VDRL: venereal disease research laboratory; CNS: central nervous system; T4: thyroxine; TSH: thyrotropin; CXR: chest radiograph; CDH: congenital diaphragmatic hernia; VACTERL: malformations of the vertebrae, anus, cardiac structures, trachea, esophagus, renal system, and limbs; CHARGE: coloboma of the iris or choroid, heart defect, atresia of the choanae, retarded growth and development, genitourinary abnormalities, and ear defects; TEF: tracheoesophageal fistula; ECG: electrocardiogram; PDA: patent ductus arteriosus.</div><div class=\"graphic_reference\">Adapted from: Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the fetus and newborn infant, 7<SUP>th</SUP> ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010.</div><div id=\"graphicVersion\">Graphic 100409 Version 2.0</div></div></div>"},"100410":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of intramuscular hematoma","title":"Ultrasound image of intramuscular hematoma","html":"<div class=\"graphic\"><div style=\"width: 894px\" class=\"figure\"><div class=\"ttl\">Ultrasound image of intramuscular hematoma</div><div class=\"cntnt\"><img style=\"width:874px; height:376px;\" src=\"images/EM/100410_US_intramuscular_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image on the left shows normal muscle tissue. Note the regular linear pattern and homogeneous appearance. In contrast, the image on the right shows an intramuscular hematoma, with its swirling, irregular appearance.</div><div class=\"graphic_reference\">Courtesy of Bev Roos.</div><div id=\"graphicVersion\">Graphic 100410 Version 2.0</div></div></div>"},"100420":{"type":"graphic_algorithm","displayName":"Patient with undifferentiated shock (ongoing resuscitation)","title":"Approach to the patient with undifferentiated hypotension or shock: Ongoing resuscitation","html":"<div class=\"graphic\"><div style=\"width: 1000px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with undifferentiated hypotension or shock: Ongoing resuscitation</div><div class=\"cntnt\"><img style=\"width:980px; height:784px;\" src=\"images/PULM/100420_Undiff_shock_ongoing_resus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shaded boxes indicate the points in the process at which no further action needs to be taken, a diagnosis has been made, or continued resuscitation is required.</div><div class=\"graphic_footnotes\">JVD: jugular venous distension; PE: pulmonary embolus; P2: pulmonic second heart sound; ABG: arterial blood gas; CBC: complete blood count; CXR: chest radiograph; ECG: electrocardiography; DIC: disseminated intravascular coagulation; CT: computed tomography; CTPA: computed tomographic pulmonary angiography; PAC: pulmonary artery catheter; RV: right ventricle; LV: left ventricle; IVC: inferior vena cava; Pcwp: pulmonary capillary wedge pressure; CO: cardiac output; SVR: systemic vascular resistance; SvO<SUB>2</SUB>: mixed venous oxyhemoglobin saturation.<br />* Timing and availability depends on institutional resources. Point-of-care ultrasonography may also be used in those in whom routine imaging is unsafe.<br />¶ Myocardial contractility may be depressed in some forms of distributive shock.<br />Δ The presence of B lines on lung ultrasound may suggest pulmonary edema to support cardiogenic shock.<br /><FONT class=lozenge>◊</FONT> Detection of fluid in the peritoneal cavity and an aortic aneurysm may support hemorrhagic shock from aneurysm rupture.<br />§ Absence of lung sliding may support obstructive shock from tension pneumothorax.<br />¥ These findings are typical of PE, pulmonary hypertension, and tension pneumothorax. In cardiac tamponade, PAC reading are similar to those in cardiogenic shock; however, right atrial, right ventricular end-diastolic, and pulmonary artery wedge pressures are equal.</div><div id=\"graphicVersion\">Graphic 100420 Version 1.0</div></div></div>"},"100421":{"type":"graphic_algorithm","displayName":"Peeling skin syndrome","title":"Clinical, histopathologic, and molecular manifestations of the different subtypes of peeling skin syndrome","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Clinical, histopathologic, and molecular manifestations of the different subtypes of peeling skin syndrome</div><div class=\"cntnt\"><img style=\"width:555px; height:558px;\" src=\"images/DERM/100421_Peeling_skin_syndrome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PSS: peeling skin syndrome; SC: stratum corneum; SG: stratum granulosum; <EM>CHST8</EM>: carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8; FTT: failure to thrive; IgE: immunoglobulin E; <EM>CDSN</EM>: corneodesmosin; <EM>TGM5</EM>: transglutaminase 5; <EM>CSTA</EM>: cystatin A.</div><div class=\"graphic_reference\">Courtesy of Eli Sprecher, MD, PhD, and Liat Samuelov, MD.</div><div id=\"graphicVersion\">Graphic 100421 Version 1.0</div></div></div>"},"100422":{"type":"graphic_table","displayName":"Immunization before, during, and after pregnancy","title":"Immunizations that may be administered before, during, and after pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunizations that may be administered before, during, and after pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Before pregnancy</td> <td class=\"subtitle1\">During pregnancy</td> <td class=\"subtitle1\">After pregnancy</td> <td class=\"subtitle1\">Type of vaccine</td> </tr> <tr> <td>Hepatitis A</td> <td>Yes, if indicated</td> <td>Yes, if indicated</td> <td>Yes, if indicated</td> <td>Inactivated</td> </tr> <tr> <td>Hepatitis B</td> <td>Yes, if indicated</td> <td>Yes, if indicated</td> <td>Yes, if indicated</td> <td>Inactivated</td> </tr> <tr> <td>Human papillomavirus (HPV)</td> <td>Yes, if indicated, through 26 years of age</td> <td>No, under study</td> <td>Yes, if indicated, through 26 years of age</td> <td>Inactivated</td> </tr> <tr> <td>Influenza IIV</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Inactivated</td> </tr> <tr> <td>Influenza LAIV</td> <td>Yes, if less than 50 years of age and healthy; avoid conception for 4 weeks</td> <td>No</td> <td>Yes, if less than 50 years of age and healthy; avoid conception for 4 weeks</td> <td>Live</td> </tr> <tr> <td>MMR</td> <td>Yes, if indicated, avoid conception for 4 weeks</td> <td>No</td> <td>Yes, if indicated, give immediately postpartum if susceptible to rubella</td> <td>Live</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Meningococcal:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Polysaccharide </li> </ul> </td> <td>If indicated</td> <td>If indicated</td> <td>If indicated</td> <td>Inactivated</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Conjugate </li> </ul> </td> <td>If indicated</td> <td>If indicated</td> <td>If indicated</td> <td>Inactivated</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\">Pneumococcal:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Polysaccharide </li> </ul> </td> <td>If indicated</td> <td>If indicated</td> <td>If indicated</td> <td>Inactivated</td> </tr> <tr> <td>Tdap</td> <td>Yes, if indicated</td> <td>Yes, vaccinate during each pregnancy ideally between 27 and 36 weeks of gestation</td> <td>Yes, immediately postpartum, if not received previously</td> <td>Toxoid/inactivated</td> </tr> <tr> <td>Tetanus/diphtheria Td</td> <td>Yes, if indicated</td> <td>Yes, if indicated, Tdap preferred</td> <td>Yes, if indicated</td> <td>Toxoid</td> </tr> <tr> <td>Varicella</td> <td>Yes, if indicated, avoid conception for 4 weeks</td> <td>No</td> <td>Yes, if indicated, give immediately postpartum if susceptible</td> <td>Live</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Vaccines for Pregnant Women. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/vaccines/adults/rec-vac/pregnant.html\" target=\"_blank\">http://www.cdc.gov/vaccines/adults/rec-vac/pregnant.html</a> (Accessed on March 19, 2015).</div><div id=\"graphicVersion\">Graphic 100422 Version 2.0</div></div></div>"},"100433":{"type":"graphic_diagnosticimage","displayName":"Embolization  of multiple pulmonary AVMs","title":"Multiple pulmonary AVMs with embolization","html":"<div class=\"graphic\"><div style=\"width: 690px\" class=\"figure\"><div class=\"ttl\">Multiple pulmonary AVMs with embolization</div><div class=\"cntnt\"><img style=\"width:670px; height:333px;\" src=\"images/RADIOL/100433_Emblztn_mltpl_plmnry_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A diagnostic angiogram (A) shows a left apical AVM (arrowhead) and a larger medial right-sided basal segmental AVM (arrow). Image B shows coils in a successfully embolized AVM in the left apex (arrowhead) and right lower lobe (arrows). Image C is a magnified view of the coils in the left apex and image D shows a series of coils in the medial branch of the right lower lobe artery (arrows).</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation.</div><div id=\"graphicVersion\">Graphic 100433 Version 1.0</div></div></div>"},"100434":{"type":"graphic_diagnosticimage","displayName":"Imaging and treatment of pulmonary AVM","title":"Pulmonary AVM treated with coil embolization","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Pulmonary AVM treated with coil embolization</div><div class=\"cntnt\"><img style=\"width:469px; height:367px;\" src=\"images/RADIOL/100434_Imaging_trtmnt_plmnry_AVM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reconstructed CTA of the pulmonary circulation in LAO projection shows a small feeding artery (arrow) with a large draining vein (arrowhead). Image B is also a reconstructed CTA in the LAO projection and shows a large draining vein entering the left atrium. Image C is a venous phase of a right pulmonary arteriogram and shows a large draining varicosity (between arrowheads). Image D shows the coils used to embolize the right lower lobe AVM.</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation; LA: left atrium; CTA: computed tomographic angiogram; LAO: left anterior oblique.</div><div class=\"graphic_reference\">Images C and D courtesy of Scott Sequeira, MD.</div><div id=\"graphicVersion\">Graphic 100434 Version 1.0</div></div></div>"},"100435":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of mitral stenosis","title":"Chest radiograph showing features of mitral stenosis with left atrial enlargement and pulmonary edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing features of mitral stenosis with left atrial enlargement and pulmonary edema</div><div class=\"cntnt\"><img style=\"width:369px; height:384px;\" src=\"images/RADIOL/100435_Chst_rdgrph_mtrl_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posteroanterior chest radiograph of a patient with mitral stenosis with left atrial enlargement causing a straight heart border (arrowhead) and double density (arrow). There is also cephalization of the pulmonary vessels (dashed arrow) consistent with cardiogenic pulmonary edema.</div><div id=\"graphicVersion\">Graphic 100435 Version 1.0</div></div></div>"},"100437":{"type":"graphic_diagnosticimage","displayName":"Imaging left mainstem bronchus in mitral stenosis","title":"Chest radiograph and computed tomography showing elevation of left mainstem bronchus caused by left atrial enlargement in a patient with mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Chest radiograph and computed tomography showing elevation of left mainstem bronchus caused by left atrial enlargement in a patient with mitral stenosis</div><div class=\"cntnt\"><img style=\"width:721px; height:344px;\" src=\"images/RADIOL/100437_Img_lft_mnst_brnch_mtrl_stn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posteroanterior chest radiograph (A) shows widening of the carinal angle (asterisk) and elevation of the left mainstem bronchus (arrow) in a patient with mitral stenosis. Image B is a corresponding coronal computed tomography reconstruction shown to illustrate the anatomy underlying the appearance on chest radiograph; it shows the elevated left bronchus (arrow), a prominent left atrial appendage (arrowhead), and an enlarged left atrium (la).</div><div id=\"graphicVersion\">Graphic 100437 Version 1.0</div></div></div>"},"100439":{"type":"graphic_diagnosticimage","displayName":"Radiography of left atrial enlargement in mitral stenosis","title":"Chest radiograph showing displacement of the esophagus by left atrial enlargement in a patient with mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Chest radiograph showing displacement of the esophagus by left atrial enlargement in a patient with mitral stenosis</div><div class=\"cntnt\"><img style=\"width:607px; height:351px;\" src=\"images/RADIOL/100439_Rdgr_lft_atrl_enlrg_mtrl_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A posteroanterior radiograph (A) shows a straightened left heart border with a prominent left atrial appendage (arrow) in a patient with left atrial enlargement caused by mitral stenosis. Image B is a lateral radiograph taken after the patient swallowed radiopaque contrast and shows compression of the lower esophagus by the enlarged left atrium (arrow).</div><div id=\"graphicVersion\">Graphic 100439 Version 1.0</div></div></div>"},"100440":{"type":"graphic_diagnosticimage","displayName":"Radiograph of calcified mitral valve in mitral stenosis","title":"Radiograph showing calcification of a mitral valve with rheumatic mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Radiograph showing calcification of a mitral valve with rheumatic mitral stenosis</div><div class=\"cntnt\"><img style=\"width:669px; height:344px;\" src=\"images/RADIOL/100440_Rdg_clcf_mtrl_vlv_mtrl_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral radiograph (A) shows calcification of the mitral valve (arrow). Image B is a magnified view of the calcification of the mitral valve (arrow).</div><div id=\"graphicVersion\">Graphic 100440 Version 1.0</div></div></div>"},"100441":{"type":"graphic_diagnosticimage","displayName":"Imaging pulmonary hypertension in mitral stenosis","title":"Chest radiography and computed tomogram showing mitral stenosis with pulmonary hypertension on radiography and computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Chest radiography and computed tomogram showing mitral stenosis with pulmonary hypertension on radiography and computed tomography scan</div><div class=\"cntnt\"><img style=\"width:662px; height:380px;\" src=\"images/RADIOL/100441_Img_plmnry_hyprt_mtrl_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anteroposterior radiograph (A) shows a \"mitralized\" heart with an enlarged pulmonary artery (arrow), a straight mid-portion of the left heart border (consistent with left atrial enlargement) and a steep left heart border (indicating a normal-sized left ventricle), and a small aorta. Image B is a coronal reconstruction of a computed tomography scan illustrating the underlying anatomy, including an enlarged main pulmonary artery (arrow) and&nbsp;calcified mitral valve (arrowhead). In this patient, right atrial enlargement is also seen in some patients with mitral stenosis, particularly when significant tricuspid regurgitation is present.</div><div id=\"graphicVersion\">Graphic 100441 Version 1.0</div></div></div>"},"100442":{"type":"graphic_algorithm","displayName":"Management approach for patients with extensive stage SCLC","title":"Management approach for patients with extensive stage small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Management approach for patients with extensive stage small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:500px; height:280px;\" src=\"images/ONC/100442_Patients_extensive_stg_SCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCLC: small cell lung cancer; PCI: prophylactic cranial irradiation; TRT: thoracic radiation therapy.<br />* Four to six cycles of platinum-based chemotherapy.</div><div id=\"graphicVersion\">Graphic 100442 Version 2.0</div></div></div>"},"100443":{"type":"graphic_algorithm","displayName":"Management approach for patients with limited stage SCLC","title":"Management approach for patients with limited stage small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Management approach for patients with limited stage small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:610px; height:458px;\" src=\"images/ONC/100443_Patients_limited_stage_SCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SCLC: small cell lung cancer; N: node; pN: pathologic node; cN: clinical node.<br />* Chemotherapy typically consists of four cycles of cisplatin plus etoposide.</div><div id=\"graphicVersion\">Graphic 100443 Version 2.0</div></div></div>"},"100446":{"type":"graphic_picture","displayName":"Standing hip adduction against resistance","title":"Standing hip adduction against resistance","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Standing hip adduction against resistance</div><div class=\"cntnt\"><img style=\"width:676px; height:644px;\" src=\"images/EM/100446_Stnd_hp_addct_agnst_rsstnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hip adduction against resistance while standing is a basic exercise performed early during the rehabilitation of adductor injuries. As the injury heals and strength improves, resistance is gradually increased.</div><div class=\"graphic_reference\">Courtesy of Jon Patricios, MBBCh, MMedSci, FACSM, FFSEM (UK).</div><div id=\"graphicVersion\">Graphic 100446 Version 1.0</div></div></div>"},"100447":{"type":"graphic_algorithm","displayName":"Evaluation of a child with EDMD phenotype","title":"Evaluation of a child with Emery-Dreifuss muscular dystrophy phenotype","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Evaluation of a child with&nbsp;Emery-Dreifuss muscular dystrophy phenotype</div><div class=\"cntnt\"><img style=\"width:485px; height:639px;\" src=\"images/NEURO/100447_Evltn_chld_EDMD_phntyp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for the evaluation of a patient with an EDMD phenotype.</div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; CM: congenital myopathy; CMD: congenital muscular dystrophy; EDMD: Emery-Dreifuss muscular dystrophy; EMD: emerin gene; FHL1: four-and-a-half LIM domains 1 gene; IHC: immunohistochemistry; LMNA: lamin A/C gene; NGS: next generation sequencing; RSS: rigid spine syndrome; SEPN1: selenoprotein N 1 gene; SYNE1: spectrin repeat containing, nuclear envelope 1 gene; SYNE2: spectrin repeat containing, nuclear envelope 2 gene; TMEM43: transmembrane protein 43 gene.</div><div id=\"graphicVersion\">Graphic 100447 Version 1.0</div></div></div>"},"100449":{"type":"graphic_picture","displayName":"Popliteal cyst in a child","title":"Asymptomatic popliteal (Baker's) cyst in a child","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Asymptomatic popliteal (Baker's) cyst in a child</div><div class=\"cntnt\"><img style=\"width:712px; height:472px;\" src=\"images/RHEUM/100449_Popliteal_cyst_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a posterior view of the knees of a healthy four-year-old boy with an asymptomatic left popliteal cyst and no arthritis.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 100449 Version 6.0</div></div></div>"},"100456":{"type":"graphic_algorithm","displayName":"Differential diagnosis of delusions","title":"Differential diagnosis of delusions","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Differential diagnosis of delusions</div><div class=\"cntnt\"><img style=\"width:782px; height:906px;\" src=\"images/PSYCH/100456_Decision_tree_delusions.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th Ed: DSM-5. Washington, D.C.: American Psychiatric Association, 2013.</div><div id=\"graphicVersion\">Graphic 100456 Version 2.0</div></div></div>"},"100457":{"type":"graphic_table","displayName":"Differential diagnosis of RLS during pregnancy","title":"Differential diagnosis of RLS during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of RLS during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common mimics</td> </tr> <tr> <td class=\"indent1\">Positional discomfort</td> </tr> <tr> <td class=\"indent1\">Venous stasis</td> </tr> <tr> <td class=\"indent1\">Leg edema</td> </tr> <tr> <td class=\"indent1\">Leg cramps</td> </tr> <tr> <td class=\"indent1\">Compression and stretch neuropathies</td> </tr> <tr> <td class=\"indent1\">Sore leg muscles</td> </tr> <tr> <td class=\"indent1\">Ligament sprain/tendon strain</td> </tr> <tr> <td class=\"indent1\">Positional ischemia (numbness)</td> </tr> <tr> <td class=\"indent1\">Dermatitis</td> </tr> <tr> <td class=\"indent1\">Bruises</td> </tr> <tr> <td class=\"subtitle1_single\">Less common mimics</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> </tr> <tr> <td class=\"indent1\">Other orthopedic disorders</td> </tr> <tr> <td class=\"indent1\">Peripheral neuropathy</td> </tr> <tr> <td class=\"indent1\">Radiculopathy</td> </tr> <tr> <td class=\"indent1\">Myopathy</td> </tr> <tr> <td class=\"indent1\">Myelopathy</td> </tr> <tr> <td class=\"indent1\">Fibromyalgia</td> </tr> <tr> <td class=\"indent1\">Complex regional pain syndrome</td> </tr> <tr> <td class=\"indent1\">Drug-induced akathisia</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS:&nbsp;restless legs syndrome.</div><div class=\"graphic_reference\">Reproduced from: Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev 2015; 22:64. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100457 Version 3.0</div></div></div>"},"100458":{"type":"graphic_algorithm","displayName":"Diagnosis and management RLS during pregnancy and lactation","title":"Diagnosis and management of RLS during pregnancy and lactation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Diagnosis and management of RLS during pregnancy and lactation</div><div class=\"cntnt\"><img style=\"width:584px; height:683px;\" src=\"images/SLEEP/100458_DgnsmngRLSWEDprgnlctt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dashed arrows: Consider medication only after assessment of severity, risks, and benefits by provider and patient, in patients who have significant impact on quality of life.</div><div class=\"graphic_footnotes\">RLS: restless legs syndrome; TIBC: total iron binding capacity; % saturation: percent iron saturation; IV: intravenous; ER: extended release.<br />* For more detailed information, refer to UpToDate topics on restless legs syndrome during pregnancy and lactation.<br />¶ After the first trimester.<br />Δ Avoid concurrent use with diphenhydramine or anticonvulsants.<br /><FONT class=lozenge>◊</FONT> Refractory: An inadequate response to at least one nonpharmacologic intervention and iron (if ferritin &lt;75 mcg/L) tried over an adequate period of time.<br />§ Very severe, very refractory: A score of &gt;30 on the International Restless Legs Syndrome Study Group rating scale and failure to respond to at least one nonpharmacologic treatment, iron (if ferritin &lt;75 mcg/L), and one non-opioid pharmacologic treatment.</div><div class=\"graphic_reference\">Original figure modified for this publication. Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev 2015; 22:64. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100458 Version 5.0</div></div></div>"},"100459":{"type":"graphic_algorithm","displayName":"Treatment of potentially resectable NSCLC","title":"Treatment of potentially resectable non-small cell lung cancer","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Treatment of potentially resectable non-small cell lung cancer</div><div class=\"cntnt\"><img style=\"width:552px; height:364px;\" src=\"images/ONC/100459_Trtmnt__ptntl_rsctbl_NSCLC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; RT: radiation therapy; SBRT: stereotactic body radiation therapy.<br />* Based upon comorbidities, age, or refusal of surgery.<br />¶ SBRT preferred for tumors &lt;5 cm; definitive RT with conventional fractionation for larger lesions.<br />Δ Adjuvant chemotherapy is administered if high-risk features are present. Refer to UpToDate topic on adjuvant systemic therapy in resectable non-small cell lung cancer for further details.<br /><FONT class=lozenge>◊</FONT> Consultation with medical oncology, radiation oncology, and thoracic surgery indicated prior to definitive therapy. Concurrent chemoradiotherapy, surgery,&nbsp;or induction therapy followed by resection in carefully selected patients.</div><div id=\"graphicVersion\">Graphic 100459 Version 4.0</div></div></div>"},"100461":{"type":"graphic_table","displayName":"Causes of hypoparathyroidism","title":"Causes of hypoparathyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypoparathyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"indent1\">Genetic disorders</td> </tr> <tr> <td class=\"indent2\">Abnormal parathyroid gland development</td> </tr> <tr> <td class=\"indent2\">Abnormal PTH synthesis</td> </tr> <tr> <td class=\"indent2\">Activating mutations of calcium-sensing receptor (autosomal dominant hypocalcemia or sporatic isolated hypoparathyroidism)</td> </tr> <tr> <td class=\"indent1\">Post-surgical (thyroidectomy, parathyroidectomy, radical neck dissection)</td> </tr> <tr> <td class=\"indent1\">Autoimmune</td> </tr> <tr> <td class=\"indent2\">Autoimmune polyglandular syndrome (associated with chronic mucocutaneous candidiasis and primary adrenal insufficiency)</td> </tr> <tr> <td class=\"indent2\">Isolated hypoparathyroidism due to activating antibodies to calcium-sensing receptor</td> </tr> <tr> <td class=\"indent1\">Infiltration of the parathyroid gland (granulomatous, iron overload, metastases)</td> </tr> <tr> <td class=\"indent1\">Radiation-induced destruction parathyroid glands</td> </tr> <tr> <td class=\"indent1\">Hungry bone syndrome (post parathyroidectomy)</td> </tr> <tr> <td class=\"indent1\">HIV infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Data from: Thakker RV. Hypocalcemia: Pathogenesis, differential diagnosis, and management. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edition, American Society of Bone and Mineral Research 2006; 35:213.</div><div id=\"graphicVersion\">Graphic 100461 Version 2.0</div></div></div>"},"100465":{"type":"graphic_diagnosticimage","displayName":"Radiography of DIOS in cystic fibrosis","title":"Cystic fibrosis and distal intestinal obstruction syndrome on radiography","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Cystic fibrosis and distal intestinal obstruction syndrome on radiography</div><div class=\"cntnt\"><img style=\"width:592px; height:708px;\" src=\"images/PEDS/100465_Rdgrphy_DIOS_cystc_fbrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solid arrow indicates \"bubbly-granular\" mass in right lower quadrant suggestive of distal intestinal obstruction syndrome (DIOS). Arrowhead indicates scybalas of stool. DIOS often co-occurs with constipation.</div><div class=\"graphic_reference\">Courtesy of Drucy Borowitz, MD.</div><div id=\"graphicVersion\">Graphic 100465 Version 1.0</div></div></div>"},"100466":{"type":"graphic_picture","displayName":"Placental site nodules","title":"Placental site nodules","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Placental site nodules</div><div class=\"cntnt\"><img style=\"width:711px; height:533px;\" src=\"images/ONC/100466_Placental_site_nodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\"><EM>Courtesy of Rebecca Baergen, MD.</EM></div><div id=\"graphicVersion\">Graphic 100466 Version 1.0</div></div></div>"},"100467":{"type":"graphic_picture","displayName":"Epithelioid trophoblastic tumor","title":"Epithelioid trophoblastic tumor","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Epithelioid trophoblastic tumor</div><div class=\"cntnt\"><img style=\"width:711px; height:528px;\" src=\"images/ONC/100467_Epithelioid_trphblstc_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\"><EM>Courtesy of Rebecca Baergen, MD.</EM></div><div id=\"graphicVersion\">Graphic 100467 Version 1.0</div></div></div>"},"100470":{"type":"graphic_picture","displayName":"Malaria and brain MRI","title":"Brain MRI: A two-year-old Malawian boy with cerebral malaria and retinopathy","html":"<div class=\"graphic\"><div style=\"width: 795px\" class=\"figure\"><div class=\"ttl\">Brain MRI: A two-year-old Malawian boy with cerebral malaria and retinopathy</div><div class=\"cntnt\"><img style=\"width:775px; height:491px;\" src=\"images/ID/100470_Malaria_brain_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T2 view: Diffuse brain swelling with complete loss of sulcal markings. The T2 signal in gray and white matter is diffuse, and the ventricles are effaced.<br />(B) Sagittal T1 FLAIR: Diffuse brain swelling with effacement of basilar cisterns and fourth ventricle, brainstem compression, and tonsillar herniation below the foramen magnum. There is complete loss of sulcal markings in cerebrum and cerebellum and downward herniation of the diaphragmatic sella.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Terrie Taylor, DO.</div><div id=\"graphicVersion\">Graphic 100470 Version 1.0</div></div></div>"},"100471":{"type":"graphic_algorithm","displayName":"Rising PSA after definitive RT","title":"Rising PSA after definitive radiation therapy*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rising PSA after definitive radiation therapy*</div><div class=\"cntnt\"><img style=\"width:341px; height:328px;\" src=\"images/ONC/100471_Rsng_PSA_aftr_definitive_RT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PSA: prostate specific antigen; RT: radiation therapy; ADT: androgen deprivation therapy.<br />* PSA rise of 2 ng/mL or more above the nadir PSA (Phoenix criterion).<br />&para; Options include radical prostatectomy, cryotherapy, brachytherapy.<br />&Delta; Factors to consider include age, comorbidity, PSA kinetics, Gleason grade, and prognostic factors at original diagnosis.</div><div id=\"graphicVersion\">Graphic 100471 Version 2.0</div></div></div>"},"100472":{"type":"graphic_algorithm","displayName":"Rising PSA after radical prostatectomy","title":"Rising PSA after radical prostatectomy*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rising PSA after radical prostatectomy*</div><div class=\"cntnt\"><img style=\"width:366px; height:214px;\" src=\"images/ONC/100472_Rsng_PSA_aft_rdcl_prsttctmy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PSA: prostate specific antigen; ADT: androgen deprivation therapy; RT: radiation therapy.<br />* Definition: Two determinations of PSA &gt;0.20 ng/mL.<br />&para; Factors to consider include age, comorbidity, PSA kinetics, Gleason grade, and prognostic factors at original diagnosis.<br />&Delta; Minimum dose 64 Gy to prostate bed; the role of ADT with RT remains experimental.</div><div id=\"graphicVersion\">Graphic 100472 Version 2.0</div></div></div>"},"100474":{"type":"graphic_diagnosticimage","displayName":"Brain injury patterns of neonatal HIE on MRI","title":"Patterns of brain injury on MRI in neonates with hypoxic-ischemic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Patterns of brain injury on MRI in neonates with hypoxic-ischemic encephalopathy</div><div class=\"cntnt\"><img style=\"width:486px; height:738px;\" src=\"images/PEDS/100474_Brn_injr_pttrn_nntl_HIE_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patterns of brain injury in neonates with hypoxic-ischemic encephalopathy on T1-weighted, T2-weighted, and DWI.</div><div class=\"graphic_footnotes\">HIE: hypoxic-ischemic encephalopathy; MRI: magnetic resonance imaging; DWI: diffusion-weighted images; BGT: basal ganglia/thalamic predominant injury; WS: watershed with cortical laminar necrosis and subcortical white matter injury; Global: global pattern with total cerebral injury.</div><div class=\"graphic_reference\">Reproduced from: Massaro AN. MRI for neurodevelopmental prognostication in the high-risk term infant. Semin Perinatol 2015; 39:159. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100474 Version 2.0</div></div></div>"},"100475":{"type":"graphic_algorithm","displayName":"Level of care matching using 2014 ASAM criteria","title":"Matching patient substance use disorder treatment needs to levels care using ASAM criteria","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Matching patient substance use disorder treatment needs to levels care using ASAM criteria</div><div class=\"cntnt\"><img style=\"width:704px; height:378px;\" src=\"images/PSYCH/100475_Lvl_mtch_2014_ASAM_crtr.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: The American Society of Addiction Medicine Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, 3rd ed., Mee-Lee D, Shulman GD, Fishman MJ, et al. (Eds), The Change Company, Carson City, NV 2013.</div><div id=\"graphicVersion\">Graphic 100475 Version 1.0</div></div></div>"},"100482":{"type":"graphic_table","displayName":"Knee injuries by mechanism in skeletally immature patients","title":"Knee injuries by mechanism in skeletally immature patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Knee injuries by mechanism in skeletally immature patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism of injury</td> <td class=\"subtitle1\">Likely diagnosis</td> <td class=\"subtitle1\">Other possible conditions</td> </tr> <tr> <td>Twisting or pivoting maneuvers</td> <td> <ul> <li>Anterior cruciate ligament injury with or without meniscus tear </li> <li>Medial collateral ligament injury </li> <li>Patellar dislocation </li> </ul> </td> <td> <ul> <li>Posterior lateral corner injury </li> </ul> </td> </tr> <tr> <td>Hyperextension (eg, landing a jump)</td> <td> <ul> <li>Anterior cruciate ligament injury with or without meniscus tear </li> <li>Posterior cruciate&nbsp;ligament injury&nbsp;</li> <li>Distal femoral physeal fracture </li> <li>Proximal tibial physeal fracture </li> <li>Meniscal tear </li> </ul> </td> <td> <ul> <li>Posterior capsule tear </li> <li>Posterior lateral corner injury </li> </ul> </td> </tr> <tr> <td>Valgus stress (direct force to the lateral knee)</td> <td> <ul> <li>Medial collateral ligament injury with or without meniscus tear </li> <li>Anterior cruciate ligament injury </li> <li>Distal femoral physeal fracture </li> <li>Proximal tibial physeal fracture </li> <li>Tibial eminence (spine) fracture </li> <li>Patellar dislocation </li> </ul> </td> <td> <ul> <li>Posterior lateral corner injury </li> </ul> </td> </tr> <tr> <td>Direct blow to the anterior knee</td> <td> <ul> <li>Patellar fracture </li> <li>Chondral fracture (articular cartilage) </li> <li>Posterior cruciate ligament injury </li> </ul> </td> <td> <ul> <li>Prepatellar bursitis </li> <li>Chondral contusion </li> <li>Posterior capsule tear </li> <li>Posterior lateral corner injury </li> </ul> </td> </tr> <tr> <td>Varus stress (direct force to the medial knee)</td> <td> <ul> <li>Lateral collateral ligament tear </li> <li>Distal femoral physeal fracture </li> <li>Posterior lateral corner tear </li> <li>Tibiofemoral dislocation </li> </ul> </td> <td> <ul> <li>Tibial eminence (spine) fracture </li> <li>Peroneal nerve injury </li> </ul> </td> </tr> <tr> <td>Hyperflexion (taking off from a jump)</td> <td> <ul> <li>Meniscus tear </li> <li>Proximal tibial physeal fracture </li> <li>Tibial tuberosity avulsion fracture </li> <li>Patellar sleeve fracture </li> </ul> </td> <td> <ul> <li>Tibial eminence (spine) fracture </li> <li>Osteochondral fracture </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 100482 Version 1.0</div></div></div>"},"100483":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation of hydrops fetalis","title":"Diagnostic evaluation of nonimmune hydrops fetalis<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 1010px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation of nonimmune hydrops fetalis<SUP>[1-3]</SUP></div><div class=\"cntnt\"><img style=\"width:990px; height:838px;\" src=\"images/OBGYN/100483_Algoevalhydropsfetalis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe fetal anemia can be treated by in utero fetal transfusion.</div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; MCA: middle cerebral artery; PSV: peak systolic velocity; MoM: multiples of the median; IgM: immunoglobulin M; IgG: immunoglobulin G; MCV: mean corpuscular volume; RBC: red blood cell.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Society for Maternal-Fetal Medicine (SMFM), Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: Nonimmune hydrops fetalis. Am J Obstet Gynecol 2015; 212:127.</LI>&#xD;&#xA;<LI>Zhang EG, Regan F, Layton M, et al. Managing the difficult case of fetal anemia. J Matern Fetal Neonatal Med 2011; 24:1498.</LI>&#xD;&#xA;<LI>Stone DL, Sidransky E. Hydrops fetalis: Lysosomal storage disorders in extremis. Adv Pediatr 1999; 46:409.</LI></OL></div><div id=\"graphicVersion\">Graphic 100483 Version 2.0</div></div></div>"},"100489":{"type":"graphic_table","displayName":"Pediatric Crohn disease activity index","title":"Pediatric Crohn disease activity index (PCDAI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric Crohn disease activity index (PCDAI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">History (Recall, 1 week)</td> </tr> <tr> <td class=\"subtitle2_left\">Abdominal pain:&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">None</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">Mild&nbsp;&#8212;&nbsp;Brief, does not interfere with activities</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Moderate or severe&nbsp;&#8212;&nbsp;Daily, longer lasting, affects activities, nocturnal</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Stools: (per day)</td> </tr> <tr> <td class=\"indent1\">0 to 1 liquid stools, no blood</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">Up to 2 semi-formed stools with small blood, or 2 to 5 liquid stools without blood</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gross bleeding, or &#8805;6 liquid stools, or nocturnal diarrhea</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Patient functioning, general well-being (recall, 1 week)</td> </tr> <tr> <td class=\"indent1\">No limitations of activities, well</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">Occasional difficulty in maintaining age appropriate activities, below par</td> <td>____(5)</td> </tr> <tr> <td class=\"indent1\">Frequent limitation of activity, very poor</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Laboratory</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">HCT (%)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">&#60;10 years:</td> </tr> <tr> <td class=\"indent2\">&#62;33</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">28 to 32</td> <td>____(2.5)</td> </tr> <tr> <td class=\"indent2\">&#60;28</td> <td>____(5)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">11 to 19 years (females)</td> </tr> <tr> <td class=\"indent2\">&#8805;34</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">29 to 33</td> <td>____(2.5)</td> </tr> <tr> <td class=\"indent2\">&#60;29</td> <td>____(5)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">11 to 14 years (males)</td> </tr> <tr> <td class=\"indent2\">&#8805;35</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">30 to 34</td> <td>____(2.5)</td> </tr> <tr> <td class=\"indent2\">&#60;30</td> <td>____(5)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">15 to 19 years (males)</td> </tr> <tr> <td class=\"indent2\">&#8805;37</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">32 to 36</td> <td>____(2.5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">&#60;32</td> <td>____(5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">ESR (mm/hr)</td> </tr> <tr> <td class=\"indent1\">&#60;20</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">20 to 50</td> <td>____(2.5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;50</td> <td>____(5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Albumin (g/dL)</td> </tr> <tr> <td class=\"indent1\">&#8805;3.5</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">3.1 to 3.4</td> <td>____(5)</td> </tr> <tr> <td class=\"indent1\">&#8804;3</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Examination</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Weight</td> </tr> <tr> <td class=\"indent1\">Weight gain, weight stable,&nbsp;or voluntary weight loss</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">Involuntary weight stable, or weight loss 1 to 9 percent</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Weight loss &#8805;10 percent</td> <td>____(0)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Height</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">At diagnosis:</td> </tr> <tr> <td class=\"indent2\">&#60;1 channel decrease*</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">1 to&nbsp;2 channel decrease</td> <td>____(5)</td> </tr> <tr> <td class=\"indent2\">&#8805;2 channel decrease</td> <td>____(10)</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>or</strong></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Follow-up<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">High velocity &#8805; &ndash;1 SD</td> <td>____(0)</td> </tr> <tr> <td class=\"indent2\">High velocity&nbsp;between &ndash;1 SD and &ndash;2 SD</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">High velocity &#8804;&ndash;2 SD</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">No tenderness, no mass</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">Tenderness, or mass without tenderness</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tenderness, involuntary guarding, definite mass</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Perirectal disease</td> </tr> <tr> <td class=\"indent1\">None, asymptomatic tags</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">1 to 2 indolent fistula(e), scant drainage, no tenderness</td> <td>____(5)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Active fistula, drainage, tenderness, or abscess</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Extraintestinal manifestations</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">(Fever &#8805;38.5&#176;C for&nbsp;3 days over past week, definite arthritis, uveitis, E. nodosum, P. gangrenosum)</td> </tr> <tr> <td class=\"indent1\">None</td> <td>____(0)</td> </tr> <tr> <td class=\"indent1\">One</td> <td>____(5)</td> </tr> <tr> <td class=\"indent1\">&#8805;Two</td> <td>____(10)</td> </tr> <tr> <td class=\"subtitle1_left\">Total score</td> <td class=\"subtitle1_left\">________</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The PCDAI is interpreted as follows:&nbsp;a score of 0-10&nbsp;indicates inactive disease, 11-30 indicates mild disease activity, and &gt;30 indicates moderate to severe disease activity. A decrease in PCDAI of ≥12.5 points reflects a clinical response (improvement from moderate/severe to mild/inactive disease).<SUP>[1]</SUP></LI></UL>&#xD;&#xA;<UL>&#xD;&#xA;<LI>A weighted version of the PCDAI (wPCDAI) has also been developed (not shown here), with a maximum score of 125.<SUP>[2]</SUP>&nbsp;For the&nbsp;wPCDAI, a score of &lt;12.5 indicates remission; 12.5-40 indicates mild disease activity; 40-57.5 indicates moderate disease activity; and &gt;57.5 indicates severe disease activity.</LI></UL></div><div class=\"graphic_footnotes\">HCT: hematocrit; ESR: erythrocyte sedimentation rate; SD: standard deviation; E. nodosum: erythema&nbsp;nodosum; P. gangrenosum: pyoderma&nbsp;gangrenosum.<br />* A \"channel decrease\" refers to serial height measurements that deviate across the width of a major curve on a standard height-for-age chart. For example,&nbsp;decreasing from the 40<SUP>th</SUP> to 20<SUP>th</SUP> percentile is a one-channel decrease.&nbsp;<br />¶ Height velocity is measured against population standards, eg, Tanner JM, Davies S. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.</div><div class=\"graphic_reference\">References:&nbsp;<br /><OL>&#xD;&#xA;<LI>Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41:416.</LI>&#xD;&#xA;<LI>Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012; 18:55.</LI></OL>Table from: Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12:439. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 1991 ESPGHAN and NASPGHAN. Unauthorized reproduction of this material is prohibited.<br /></div><div id=\"graphicVersion\">Graphic 100489 Version 3.0</div></div></div>"},"100492":{"type":"graphic_table","displayName":"Secondary screening versus diagnostic testing","title":"Advantages and disadvantages of secondary screening with a cell free DNA test versus a diagnostic test in women who screen positive for trisomy 21","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of secondary screening with a cell free DNA test versus a diagnostic test in women who screen positive for trisomy 21</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Secondary screening with cell free DNA test</td> <td class=\"subtitle1\">Diagnostic test (chorionic villus sampling or genetic amniocentesis)</td> </tr> <tr> <td>Noninvasive</td> <td>Invasive</td> </tr> <tr> <td>Screen-positive requires confirmatory diagnostic test.</td> <td>Definitive</td> </tr> <tr> <td>Will detect trisomy 21, 18, 13, some sex chromosome aneuploidies, and some microdeletions</td> <td>Conventional G-banding will detect all numerical and all large structural chromosomal abnormalities. Microdeletions and microduplications are detected by microarray.</td> </tr> <tr> <td>Does not screen for open neural tube defects</td> <td>Amniotic fluid is tested for alpha-fetoprotein to screen for open neural tube defects.</td> </tr> <tr> <td>Not well validated in twin pregnancy</td> <td>Validated in twin pregnancy</td> </tr> <tr> <td>Screen negative patients do not undergo further diagnostic testing, thus unexpected chromosomal abnormalities that can be identified by an invasive test will be missed.</td> <td>Unexpected chromosomal abnormalities that can be identified by an invasive test will be detected.</td> </tr> <tr> <td>Costly</td> <td>Less costly</td> </tr> <tr> <td>May delay definitive diagnosis and management&nbsp;since a positive&nbsp;screen requires further testing</td> <td>Direct route to a definitive diagnosis&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 100492 Version 2.0</div></div></div>"},"100493":{"type":"graphic_diagnosticimage","displayName":"Transvaginal and laparoscopic images of an endometrioma","title":"Transvaginal and laparoscopic images of an endometrioma​","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Transvaginal and laparoscopic images of an endometrioma​</div><div class=\"cntnt\"><img style=\"width:797px; height:333px;\" src=\"images/OBGYN/100493_Trnsvgnl_lprscpc_img_endmtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasonogram of a 6 cm (diameter), left ovarian endometrioma and its corresponding laparoscopic image.</div><div class=\"graphic_reference\">Reprinted with permission of the Society of Laparoendoscopic Surgeons. Maul LV, Morrision JE, Schollmeyer T, et al. Surgical therapy of ovarian endometrioma: recurrence and pregnancy rates. JSLS 2014; 18. Copyright &copy; 2014 Society of Laparoendoscopic Surgeons.</div><div id=\"graphicVersion\">Graphic 100493 Version 1.0</div></div></div>"},"100496":{"type":"graphic_picture","displayName":"Plank exercise","title":"Plank exercise","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Plank exercise</div><div class=\"cntnt\"><img style=\"width:715px; height:239px;\" src=\"images/EM/100496_Plank.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plank is a sound exercise for developing basic core strength. Although there are several variations, the photograph above shows a standard plank. Note the straight torso and neutral spine (ie, without flexion or extension). As their strength increases, patients can hold this position for longer periods.</div><div class=\"graphic_reference\">Reproduced with permission from: Escamilla RF. Core trunk stabilization. In: Sports Medicine of Baseball, Dines JS, Altchek DW, Andrews J, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100496 Version 5.0</div></div></div>"},"100497":{"type":"graphic_picture","displayName":"Core strengthening exercises","title":"Core strengthening exercises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Core strengthening exercises</div><div class=\"cntnt\"><img style=\"width:357px; height:722px;\" src=\"images/EM/100497_Core_strengthening_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When properly performed, the plank (A), side plank (B), and bird dog (C) exercises above are effective and safe methods for developing core strength. Note the neutral position of the spine (ie, no flexion or extension) in all three exercises.</div><div class=\"graphic_reference\">Reproduced with permission from: Moir G, Bladen TL. Kinesiology, anatomy, and biomechanics. In: ACSM's Resources for the Group Exercise Instructor, DeSimone G (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100497 Version 1.0</div></div></div>"},"100500":{"type":"graphic_table","displayName":"Listeriosis foods","title":"Foods associated with listeriosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods associated with listeriosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Common causes or causes of large outbreaks</td> <td class=\"subtitle1\">Less common causes</td> </tr> <tr> <td>Processed/delicatessen meats</td> <td>Milk</td> </tr> <tr> <td>Hot dogs</td> <td>Ice cream</td> </tr> <tr> <td>Soft cheeses</td> <td>Caramel apples</td> </tr> <tr> <td>P&#226;t&#233;s</td> <td>Stone fruit (eg, nectarines)</td> </tr> <tr> <td>Canteloupe</td> <td>Smoked seafood</td> </tr> <tr> <td rowspan=\"4\">&nbsp;</td> <td>Corn salad</td> </tr> <tr> <td>Rice salad</td> </tr> <tr> <td>Hog head cheese</td> </tr> <tr> <td>Packaged salad greens</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cartwright EJ, Jackson KA, Johnson SD, et al. Listeriosis outbreaks and associated food vehicles, United States, 1998-2008. Emerg Infect Dis 2013; 19:1.</LI>&#xD;&#xA;<LI>Interagency Food Safety Analytics Collaboration (IFSAC) Project. Foodborne illness source attribution estimates for Salmonella, Escherichia coli O157 (E. coli O157), Listeria monocytogenes (Lm), and Campylobacter using outbreak surveillance data - February 2015. http://www.cdc.gov/foodsafety/pdfs/ifsac-project-report-508c.pdf (Accessed on March 23, 2015).</LI>&#xD;&#xA;<LI>Frye DM, Zweig R, Sturgeon J, et al. An outbreak of febrile gastroenteritis associated with delicatessen meat contaminated with Listeria monocytogenes. Clin Infect Dis 2002; 35:943.</LI>&#xD;&#xA;<LI>Olsen SJ, Patrick M, Hunter SB, et al. Multistate outbreak of Listeria monocytogenes infection linked to delicatessen turkey meat. Clin Infect Dis 2005; 40:962.</LI>&#xD;&#xA;<LI>Gottlieb SL, Newbern EC, Griffin PM, et al. Multistate outbreak of Listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. Clin Infect Dis 2006; 42:29.</LI>&#xD;&#xA;<LI>Cartwright EJ, Jackson KA, Johnson SD, et al. Listeriosis outbreaks and associated food vehicles, United States, 1998-2008. Emerg Infect Dis 2013; 19:1.</LI>&#xD;&#xA;<LI>Linnan MJ, Mascola L, Lou XD, et al. Epidemic listeriosis associated with Mexican-style cheese. N Engl J Med 1988; 319:823.</LI>&#xD;&#xA;<LI>Büla CJ, Bille J, Glauser MP. An epidemic of food-borne listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis 1995; 20:66.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Outbreak of listeriosis associated with homemade Mexican-style cheese--North Carolina, October 2000-January 2001. MMWR Morb Mortal Wkly Rep 2001; 50:560.</LI>&#xD;&#xA;<LI>MacDonald PD, Whitwam RE, Boggs JD, et al. Outbreak of listeriosis among Mexican immigrants as a result of consumption of illicitly produced Mexican-style cheese. Clin Infect Dis 2005; 40:677.</LI>&#xD;&#xA;<LI>Choi MJ, Jackson KA, Medus C, et al. Notes from the field: multistate outbreak of listeriosis linked to soft-ripened cheese--United States, 2013. MMWR Morb Mortal Wkly Rep 2014; 63:294.</LI>&#xD;&#xA;<LI>Cartwright EJ, Jackson KA, Johnson SD, et al. Listeriosis outbreaks and associated food vehicles, United States, 1998-2008. Emerg Infect Dis 2013; 19:1.</LI>&#xD;&#xA;<LI>McCollum JT, Cronquist AB, Silk BJ, et al. Multistate outbreak of listeriosis associated with cantaloupe. N Engl J Med 2013; 369:944.</LI>&#xD;&#xA;<LI>Dalton CB, Austin CC, Sobel J, et al. An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk. N Engl J Med 1997; 336:100.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Outbreak of Listeria monocytogenes infections associated with pasteurized milk from a local dairy--Massachusetts, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1097.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. FDA investigates Listeria monocytogenes in ice cream products from Blue Bell Creameries. http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm438104.htm (Accessed on March 23, 2015).</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Multistate outbreak of listeriosis linked to commercially produced, prepackaged caramel apples. http://www.cdc.gov/listeria/outbreaks/caramel-apples-12-14/index.html (Accessed on March 23, 2015).</LI>&#xD;&#xA;<LI>Jackson BR, Salter M, Tarr C, et al. Notes from the field: listeriosis associated with stone fruit - United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:282.</LI>&#xD;&#xA;<LI>Gillesberg Lassen S, Ethelberg S, Bjorkman JT, et al. Two listeria outbreaks caused by smoked fish consumption-using whole-genome sequencing for outbreak investigations. Clin Microbiol Infect 2016; 22:620.</LI>&#xD;&#xA;<LI>Aureli P, Fiorucci GC, Caroli D, et al. An outbreak of febrile gastroenteritis associated with corn contaminated by Listeria monocytogenes. N Engl J Med 2000; 342:1236.</LI>&#xD;&#xA;<LI>Salamina G, Dalle Donne E, Niccolini A, et al. A foodborne outbreak of gastroenteritis involving Listeria monocytogenes. Epidemiol Infect 1996; 117:429.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention (CDC). Outbreak of invasive listeriosis associated with the consumption of hog head cheese--Louisiana, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:401.</LI>&#xD;&#xA;<LI>Self JL, Conrad A, Stroika S, et al. Notes from the field: Outbreak of Listeriosis associated with consumption of packaged salad - United States and Canada, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65:879. </LI></OL></div><div id=\"graphicVersion\">Graphic 100500 Version 3.0</div></div></div>"},"100501":{"type":"graphic_picture","displayName":"Bridge exercises","title":"Bridge exercises","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Bridge exercises</div><div class=\"cntnt\"><img style=\"width:585px; height:570px;\" src=\"images/EM/100501_Bridgeexercises.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bridge exercises are useful for developing strength in the posterior chain, including the musculature of the low back, hips (eg, gluteals), and hamstrings. A number of variations are pictured above. Those involving an unstable base (eg, exercise ball) are more challenging and should only be introduced after the patient demonstrates adequate strength with exercises performed on a stable base.<br />(A) Floor bridge.<br />(B) Floor bridge with marching.<br />(C) Ball bridge.<br />(D) Ball bridge with single leg.<br />(E) Bridge with feet on ball.<br />(F) Hamstring bridge with feet on ball.</div><div class=\"graphic_reference\">Reproduced with permission from: Chapman SA, DeFranca CL. Rehabilitation of the low back pain patient. In: Low Back Pain: Mechanism, Diagnosis, and Treatment, 7th Ed, Cox, JM (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100501 Version 5.0</div></div></div>"},"100503":{"type":"graphic_picture","displayName":"Back squat with barbell","title":"Back squat with barbell","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Back squat with barbell</div><div class=\"cntnt\"><img style=\"width:766px; height:421px;\" src=\"images/EM/100503_Backsquatbarbell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When properly performed, the back squat is an excellent exercise for developing the strength of the torso and lower extremities. Throughout the movement, the spine should be maintained in a neutral position (without flexion or excessive extension) and the hips, knees, and ankles should travel in the same sagittal plane. Squats should be performed to proper depth&nbsp;(ie, femurs below a parallel&nbsp;relationship with the ground)&nbsp;in order to engage the hamstrings and adductor muscle groups and to develop mobility.</div><div class=\"graphic_reference\">Reproduced with permission from: Graham JF. Resistance exercise techniques and spotting. In: Conditioning for Strength and Human Performance, 2nd Ed, Chandler TJ, Brown LE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100503 Version 3.0</div></div></div>"},"100504":{"type":"graphic_picture","displayName":"Front squat with barbell","title":"Front squat with barbell","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Front squat with barbell</div><div class=\"cntnt\"><img style=\"width:751px; height:381px;\" src=\"images/EM/100504_Frontsquatbarbell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The front squat is performed with the barbell in a racked position, resting on the proximal deltoids. Elbows and arms remain up and the spine is maintained in a neutral position throughout the squatting motion.</div><div class=\"graphic_reference\">Reproduced with permission from: Graham JF. Resistance exercise techniques and spotting. In: Conditioning for Strength and Human Performance, 2nd Ed, Chandler TJ, Brown LE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100504 Version 3.0</div></div></div>"},"100505":{"type":"graphic_table","displayName":"Pediatric dysfunctional voiding symptom survey","title":"Dysfunctional voiding symptom survey in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dysfunctional voiding symptom survey in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Over the last month</td> <td class=\"subtitle1\">Almost never</td> <td class=\"subtitle1\">Less than half the time</td> <td class=\"subtitle1\">About half the time</td> <td class=\"subtitle1\">Almost every time</td> <td class=\"subtitle1\">Not available</td> </tr> <tr> <td>1. I have had wet clothes or wet underwear during the day.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>2. When I wet myself, my underwear is soaked.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>3. I miss having a bowel movement every day.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>4. I have to push for my bowel movements to come out.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>5. I only go to the bathroom one or two times each day.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>6. I can hold onto my pee by crossing my legs, squatting or doing the \"pee dance\".</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>7. When I have to pee, I cannot wait.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>8. I have to push to pee.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr> <td>9. When I pee it hurts.</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">NA</td> </tr> <tr class=\"divider_bottom\"> <td>10. Parents to answer. Has your child experienced something stressful including the following: new baby at home, new home, new school, school or home problems, abuse, special events (birthday), or accident/injury?</td> <td class=\"centered\" colspan=\"3\">No (0)</td> <td class=\"centered\" colspan=\"2\">Yes (3)</td> </tr> <tr> <td><strong>Total</strong></td> <td colspan=\"5\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The questionnaire has been used in several pediatric urologic centers to assess for bladder dysfunction. In girls, the threshold score suggestive of bladder dysfunction is &gt;6 and in boys, the threshold score is &gt;9.</div><div class=\"graphic_reference\">Reproduced from: Farhat W, B&auml;gli DJ, Capolicchio G, et al. The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 2000; 164:1011. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100505 Version 1.0</div></div></div>"},"100519":{"type":"graphic_figure","displayName":"Cyclospora life cycle","title":"<em>Cyclospora</em> infection – Life cycle","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\"><em>Cyclospora</em> infection &ndash; Life cycle</div><div class=\"cntnt\"><img style=\"width:456px; height:632px;\" src=\"images/ID/100519_Cyclospora_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When freshly passed in stool <STRONG innerHtml>(1)</STRONG>, the oocyst is not infective. Therefore, direct fecal-oral transmission cannot occur; this differentiates <EM>Cyclospora </EM>from another important coccidian parasite, <EM>Cryptosporidium</EM>. In the environment <STRONG innerHtml>(2)</STRONG>, sporulation occurs after days or weeks at temperatures between 22° and 32°C, resulting in division of the sporont into two sporocysts, each containing two elongated sporozoites <STRONG>(3)</STRONG>. Fresh produce and water can serve as vehicles for transmission <STRONG innerHtml>(4)</STRONG>, and the sporulated oocysts are ingested (in contaminated food or water) <STRONG>(5)</STRONG>. The oocysts excyst in the gastrointestinal tract, freeing the sporozoites, which invade the epithelial cells of the small intestine <STRONG>(6)</STRONG>. Inside the cells, they undergo asexual multiplication and sexual development to mature into oocysts, which will be shed in stool <STRONG>(7)</STRONG>. The potential mechanisms of food and water contamination are still under investigation.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Parasites - Cyclosporiasis (Cyclospora Infection). Available at: <a href=\"http://www.cdc.gov/parasites/cyclosporiasis/biology.html\" target=\"_blank\">http://www.cdc.gov/parasites/cyclosporiasis/biology.html</a> (Accessed on March 25, 2015).</div><div id=\"graphicVersion\">Graphic 100519 Version 3.0</div></div></div>"},"100524":{"type":"graphic_figure","displayName":"Flow cytometry for CD11b in LAD-I","title":"Flow cytometry for CD11b in leukocyte adhesion deficiency I (LAD-I).","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow cytometry for CD11b in leukocyte adhesion deficiency I (LAD-I).</div><div class=\"cntnt\"><img style=\"width:273px; height:557px;\" src=\"images/HEME/100524_CD11b.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometry on stimulated neutrophils from an&nbsp;individual with normal neutrophil function, an LAD-I carrier (heterozygote), and moderate and severe LAD-I, showing&nbsp;CD11b fluorescence&nbsp;(solid line)&nbsp;versus a nonspecific control (dashed line).&nbsp; Percentages refer to the amount of fluorescence intensity relative to the normal control.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Dinauer MC, Coates TD. Disorders of phagocyte function. In: Hematology: Basic Principles and Practice, 6th ed, Hoffman R, Benz EJ Jr, Silberstein LE (Eds), Elsevier, Philadelphia 2012. p.655. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100524 Version 1.0</div></div></div>"},"100525":{"type":"graphic_picture","displayName":"Cyclospora safranin stain","title":"<em>Cyclospora</em> (safranin stain)","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\"><em>Cyclospora</em> (safranin stain)</div><div class=\"cntnt\"><img style=\"width:711px; height:712px;\" src=\"images/ID/100525_Cyclospora_safranin_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a fresh stool sample prepared using a 10%&nbsp;formalin solution and stained with safranin; three uniformly stained <EM>Cyclospora cayetanensis</EM> oocysts may be seen. It is important to distinguish <EM>Cyclospora</EM> oocysts (diameter 8 to 10 microns) from those of <EM>Cryptosporidium</EM>, which are also acid fast but smaller (diameter 5 microns). </div><div class=\"graphic_reference\">Photo courtesy of Melanie Moser. Reproduced from the Centers for Disease Control and Prevention Public Health Image Library. Available at: <a href=\"http://phil.cdc.gov/phil/home.asp\" spellcheck=\"true\" target=\"_blank\">http://phil.cdc.gov/phil/home.asp</a> (Accessed March 25, 2015).</div><div id=\"graphicVersion\">Graphic 100525 Version 3.0</div></div></div>"},"100527":{"type":"graphic_picture","displayName":"Cyclospora acid fast stain","title":"<em>Cyclospora</em> (acid-fast stain)","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\"><em>Cyclospora</em> (acid-fast stain)</div><div class=\"cntnt\"><img style=\"width:711px; height:711px;\" src=\"images/ID/100527_Cyclospora_acid_fast_stain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a fresh stool sample prepared using a 10%&nbsp;formalin solution and stained with modified acid-fast stain; four <EM>Cyclospora cayetanensis</EM> oocysts may be seen. It is important to distinguish <EM>Cyclospora</EM> oocysts (diameter 8 to 10 microns) from those of <EM>Cryptosporidium</EM>, which are also acid fast but smaller (diameter 5 microns).<br />Compared with wet mount preparations, the oocysts are less perfectly round and have a wrinkled appearance due to this method of fixation, and the staining is variable among the four oocysts.</div><div class=\"graphic_reference\">Photo courtesy of Melanie Moser. Reproduced from the Centers for Disease Control and Prevention Public Health Image Library. Available at: <a href=\"http://phil.cdc.gov/phil/home.asp\" target=\"_blank\">http://phil.cdc.gov/phil/home.asp</a> (Accessed March 25, 2015).</div><div id=\"graphicVersion\">Graphic 100527 Version 4.0</div></div></div>"},"100534":{"type":"graphic_figure","displayName":"Wilson frame","title":"Prone position using the Wilson frame on the operating table","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Prone position using the Wilson frame on the operating table</div><div class=\"cntnt\"><img style=\"width:530px; height:266px;\" src=\"images/ANEST/100534_Wilson_frame.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient's face is below the level of the heart, which can result in venous congestion and edema.</div><div id=\"graphicVersion\">Graphic 100534 Version 2.0</div></div></div>"},"100537":{"type":"graphic_algorithm","displayName":"Acute knee injury in the child or skeletally immature adolescent","title":"Acute knee injury in the child or skeletally immature adolescent","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Acute knee injury in the child or skeletally immature adolescent</div><div class=\"cntnt\"><img style=\"width:661px; height:1404px;\" src=\"images/EM/100537_Acutekneeinjurychild.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* In situations where tibiofemoral (knee joint) dislocation is strongly suggested based upon clinical findings and radiography is not rapidly available, the clinician should proceed with reduction. Emergency imaging should include plain radiographs. After reduction, additional imaging consists of Doppler flow study or arteriography of the popliteal artery in patients with signs of vascular compromise. Refer to UpToDate topics on knee (tibiofemoral) dislocation.<br />¶ Refer to UpToDate topics on acute knee pain and injury in children and skeletally immature adolescents and on knee examination.</div><div id=\"graphicVersion\">Graphic 100537 Version 6.0</div></div></div>"},"100539":{"type":"graphic_figure","displayName":"Laboratory testing CGD","title":"Laboratory testing in chronic granulomatous disease (CGD)","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Laboratory testing in chronic granulomatous disease (CGD)</div><div class=\"cntnt\"><img style=\"width:726px; height:628px;\" src=\"images/HEME/100539_Laboratory_testing_CGD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Testing of the ability of neutrophils to generate superoxide is used in the diagnosis of chronic granulomatous disease (CGD). This testing&nbsp;can be done using flow cytometry to detect the ability to reduce dihydrorhodamine (DHR) to its fluorescent form, or&nbsp;the ability to reduce nitroblue tetrazolium (NBT), which is assayed on a slide. Normally functioning neutrophils will generate&nbsp;high fluorescence intensity&nbsp;from DHR (blue bar in flow cytometry panels) and high levels of&nbsp;reduced NBT (blue cytoplasm in cells on the slide).&nbsp;Refer to UpToDate topics on CGD and laboratory testing for disorders of neutrophil function for further details.</div><div class=\"graphic_footnotes\">PMA: phorbol myristate acetate (used to stimulate neutrophils); DHR: dihyrdrorhodamine; NBT: nitroblue tetrazolium.<br /></div><div class=\"graphic_reference\">Courtesy of Thomas Coates, MD</div><div id=\"graphicVersion\">Graphic 100539 Version 1.0</div></div></div>"},"100540":{"type":"graphic_algorithm","displayName":"C. difficile diagnostic approach","title":"Approach to diagnosis of <em>Clostridium difficile</em> via EIA screening followed by reflex NAAT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to diagnosis of <em>Clostridium difficile</em> via EIA screening followed by reflex NAAT</div><div class=\"cntnt\"><img style=\"width:424px; height:399px;\" src=\"images/ID/100540_Cdifficilediagnosticappr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Only liquid stool samples from patients with ≥3 loose stools in 24 hours should be tested. </LI>&#xD;&#xA;<LI>The GDH antigen test uses antibodies to test for the presence of the GDH enzyme, a protein present in all <EM>C. difficile</EM> isolates. It is a useful screening test with good sensitivity, rapid turnaround time, and low cost. However, specificity is poor since this assay does not test for toxin production and cannot distinguish between toxigenic and nontoxigenic strains of <EM>C. difficile</EM>.</LI>&#xD;&#xA;<LI>The toxin test uses antibodies to detect the presence of <EM>C. difficile</EM> toxin A and/or toxin B; testing for both toxins is preferred. The toxin test has high specificity with rapid turnaround time and low cost. However, the sensitivity is low so there is a high rate of false negatives. </LI>&#xD;&#xA;<LI>The NAAT tests for the presence of toxigenic <EM>C. difficile</EM> organisms in stool by amplifying one or more genes specific to toxigenic strains; the critical gene is <EM>tcdB</EM>, which encodes for toxin B. This test is specific for toxigenic strains but does not test for active toxin production and also detects asymptomatic carriers of toxigenic <EM>C. difficile</EM>.</LI>&#xD;&#xA;<LI>If both tests are done and are discordant (an indeterminate result), there are several possible explanations: &#xD;&#xA;<UL>&#xD;&#xA;<LI>The patient has active toxigenic <EM>C. difficile</EM> infection (one or the other of the tests was a false negative).</LI>&#xD;&#xA;<LI>The patient has nontoxigenic <EM>C. difficile</EM> colonization (the GDH test was positive, but the toxin test was a true negative).</LI>&#xD;&#xA;<LI>The patient is an asymptomatic carrier of toxigenic <EM>C. difficile</EM> but does not have active disease (again, one or the other of tests was a false negative, perhaps related to the density of the organism in stool). Patients should only be tested if they are symptomatic to avoid detection of asymptomatic carriage.</LI></UL></LI>&#xD;&#xA;<LI>If there is clinical suspicion that the NAAT reflects asymptomatic carriage, a cell culture cytotoxicity assay may be useful to detect active production of toxin. (Refer to the UpToDate topic on clinical manifestations and diagnosis of <EM>C. difficile</EM> infection in adults.)</LI></UL></div><div class=\"graphic_footnotes\">EIA: enzyme immunoassay; NAAT: nucleic acid amplification test; GDH: glutamate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 100540 Version 5.0</div></div></div>"},"100541":{"type":"graphic_table","displayName":"Therapeutic regimens - tinea versicolor","title":"Therapeutic regimens for tinea versicolor (pityriasis versicolor)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic regimens for tinea versicolor (pityriasis versicolor)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical therapies</td> </tr> <tr> <td class=\"indent1\">Various azole antifungal preparations (including creams, solutions, lotions, foams, and gels)*</td> <td>Once- or twice-daily application</td> <td>One to four weeks (typically two weeks)</td> </tr> <tr> <td class=\"indent1\">Ketoconazole 2% shampoo</td> <td>One five-minute application daily</td> <td>Three consecutive days (a single application may be similarly effective)</td> </tr> <tr> <td class=\"indent1\">Terbinafine 1% cream or gel</td> <td>Twice-daily application</td> <td>One week</td> </tr> <tr> <td class=\"indent1\">Ciclopirox 0.77% cream</td> <td>Twice-daily application</td> <td>Two weeks</td> </tr> <tr> <td class=\"indent1\">Selenium sulfide 2.5% shampoo</td> <td>One ten-minute application daily</td> <td>One week</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zinc pyrithione 1 or 2% shampoo</td> <td>One five-minute application daily</td> <td>Two weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oral therapies<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Fluconazole</td> <td>300 mg orally <strong>once weekly</strong></td> <td>Two weeks</td> </tr> <tr> <td class=\"indent1\">Itraconazole</td> <td>200 mg orally once daily</td> <td>Five days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Topical azole antifungals include: clotrimazole 1%, econazole 1%, efinaconazole 10%, ketoconazole 2%, luliconazole 1%, miconazole 2%, oxiconazole 1%, sertaconazole 2%, and sulconazole 1%. For additional detail on available formulations and frequency of application refer to the Lexicomp drug-specific monographs included with UpToDate.<br />&para; Oral therapy is reserved for patients with disease refractory to topical therapy or widespread disease that makes the application of topical therapy difficult. Oral terbinafine and griseofulvin are <strong>not</strong> effective; oral ketoconazole is not recommended (refer to topic discussion). Doses provided are for adults.</div><div class=\"graphic_reference\">Prepared with data from: Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146:1132.</div><div id=\"graphicVersion\">Graphic 100541 Version 2.0</div></div></div>"},"100548":{"type":"graphic_algorithm","displayName":"Algorithm straddle injury in girls","title":"Algorithm: Initial management of straddle injury in girls","html":"<div class=\"graphic\"><div style=\"width: 882px\" class=\"figure\"><div class=\"ttl\">Algorithm: Initial management of straddle injury in girls</div><div class=\"cntnt\"><img style=\"width:862px; height:940px;\" src=\"images/EM/100548_Algo_straddle_injury_girls.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The clinician should have suspicion for sexual abuse when penetrating injuries have the following characteristics: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Extensive or severe trauma</LI>&#xD;&#xA;<LI>Penetrating injury to the hymen, vagina, or rectum without explanation</LI>&#xD;&#xA;<LI>Injury to the posterior fourchette</LI>&#xD;&#xA;<LI>Presence of suspicious traumatic findings in addition to genital injury</LI>&#xD;&#xA;<LI>Infants younger than 9 months of age</LI>&#xD;&#xA;<LI>Genital lesions or secretions suggesting a sexually transmitted infection</LI></OL>Patients with these characteristics warrant evaluation for sexual abuse and reporting of possible child abuse to proper authorities. Refer to UpToDate topics on physical and sexual abuse in children and adolescents.<br />¶ Provide sedation and/or analgesia prior to examination as needed.<br />Δ Patients with superficial lacerations of the mons, clitoris, or labia may have pooling of blood in the vagina. Gentle irrigation with normal saline can be helpful to determine whether bleeding is coming from the vagina or elsewhere.<br /><FONT class=lozenge>◊</FONT> Girls who are initially reluctant to void and who do not have an overdistended bladder can receive local measures (eg, application of a cold pack) or, in the absence of serious injury, oral analgesia (eg, acetaminophen or ibuprofen) to encourage urination.<br />§ Large lacerations, particularly those that may involve the urethra or extend near the rectum warrant consultation with a surgeon with pediatric gynecologic expertise for repair.</div><div id=\"graphicVersion\">Graphic 100548 Version 1.0</div></div></div>"},"100549":{"type":"graphic_algorithm","displayName":"Algorithm straddle injury in boys","title":"Algorithm: Initial management of straddle injury in boys","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Algorithm: Initial management of straddle injury in boys</div><div class=\"cntnt\"><img style=\"width:580px; height:1292px;\" src=\"images/EM/100549_Algo_straddle_injury_boys.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The clinician should have suspicion for child abuse if the following findings are present:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Extensive or severe trauma</li>&#xD;&#xA;    <li>Penetrating injury to the rectum without explanation</li>&#xD;&#xA;    <li>Presence of suspicious traumatic findings in addition to genital injury</li>&#xD;&#xA;    <li>Infants younger than 9 months of age</li>&#xD;&#xA;    <li>Genital lesions or secretions suggesting a sexually transmitted infection</li>&#xD;&#xA;</ol>&#xD;&#xA;Patients with these findings warrant evaluation for sexual abuse and reporting of possible child abuse to proper authorities. Refer to UpToDate topics on physical and sexual abuse in children and adolescents.<br />&para; Many boys initially refuse to urinate. If physical findings indicate that the bladder is NOT overdistended and that the likelihood of urethral injury is low, the clinician may encourage voiding by administering acetaminophen, local measures to reduce pain (eg, ice packs, if tolerated), and verbal reassurance.<br />&Delta; These injuries require emergent evaluation and operative care by a surgeon with pediatric urologic expertise.</div><div id=\"graphicVersion\">Graphic 100549 Version 1.0</div></div></div>"},"100552":{"type":"graphic_table","displayName":"Immunodeficiency newborn period","title":"Most common causes of immunodeficiency presenting at birth or in early infancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common causes of immunodeficiency presenting at birth or in early infancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Humoral (antibody) deficiencies (IgG &#60;400 mg/dL, severe &#60;200 mg/dL)</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Prematurity</td> <td>Severe infection in infants less than 1500 g</td> </tr> <tr> <td>Physiologic hypogammaglobulinemia of infancy</td> <td>Usually asymptomatic</td> </tr> <tr> <td>Maternal hypogammaglobulinemia</td> <td>Mother has untreated hypogammaglobulinemia or on immunosuppression causing low B cells</td> </tr> <tr> <td>Immunoglobulin loss</td> <td>Surgery, blood drawing, diarrhea, exudative skin lesions</td> </tr> <tr> <td>Congenital agammaglobulinemias</td> <td>Usually asymptomatic, IgG low after several months</td> </tr> <tr> <td>Combined immunodeficiencies</td> <td>Severe infection, IgG low after several months</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Cellular (T cell) immunodeficiencies (CD3 T cells &#60;500 cells/microL, severe &#60;200 cells/microL)</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Severe combined immunodeficiencies</td> <td>Thrush, diarrhea, failure to thrive, <em>Pneumocystis jirovecii</em> pneumonia</td> </tr> <tr> <td>DiGeorge syndrome</td> <td>Outflow cardiac defects, typical facies, hypocalcemia, absent thymic shadow</td> </tr> <tr> <td>Wiskott-Aldrich syndrome</td> <td>Boys with thrombocytopenia, bleeding, eczema, respiratory infections</td> </tr> <tr> <td>Hyperimmunoglobulin M syndromes</td> <td>Respiratory infection (eg, <em>P. jirovecii</em> pneumonia), neutropenia, elevated IgM hemolytic anemia</td> </tr> <tr> <td>Mucocutaneous candidiasis</td> <td>Early onset of thrush, esophagitis, skin infections, endocrinopathies</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Neutropenia (Granulocytes &#60;500 cells/microL, severe &#60;200 cells/L)</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Neutropenia due to maternal hypertension mild</td> <td>Asymptomatic</td> </tr> <tr> <td>Drug-induced neutropenia</td> <td>Various drugs, usually reversible, asymptomatic</td> </tr> <tr> <td>Benign neutropenia</td> <td>Moderate, asymptomatic, normalizes with infection</td> </tr> <tr> <td>Severe congenital neutropenia</td> <td>Early onset of refractory infection</td> </tr> <tr> <td>Cyclic neutropenia</td> <td>Moderate or severe infections, often asymptomatic</td> </tr> <tr> <td>Autoimmune or isoimmune neutropenia</td> <td>Maternal neutropenia, neutrophil antibodies, familial</td> </tr> <tr> <td>Neutropenia of infection</td> <td>Develops during severe infection of the newborn, poor prognostic sign</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Other phagocytic immunodeficiencies (T and B cell function normal, no neutropenia)</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Chronic granulomatous disease</td> <td>Deep-seated infections, abscesses, pneumonia, moderate leukocytosis</td> </tr> <tr> <td>Leukocyte adhesion deficiency</td> <td>Marked leukocytosis, poor wound healing, delayed umbilical cord separation (&#62;30 days)</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Immunoregulatory disorders</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Mendelian susceptibility to mycobacterial diseases</td> <td>Chronic Bacillus Calmette-Gu&#233;rin (BCG) infection, environmental nontuberculous mycobacteria</td> </tr> <tr> <td>Hemophagocytic lymphohistiocytosis (HLH)</td> <td>Fever, vomiting, hepatosplenomegaly, seizures, liver failure</td> </tr> <tr> <td>Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</td> <td>Boys with enteropathy/colitis, diabetes, dermatitis</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Innate immune defects</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>NF-kappa-B essential modulator (NEMO) defects</td> <td>Severe infections, sparse hair</td> </tr> <tr> <td>Toll-like receptor (TLR) defects</td> <td>Severe bacterial infections (especially <em>Staphylococcus </em>and pneumococcus) with little or no fever or elevation of inflammatory markers</td> </tr> <tr> <td>Congenital asplenia</td> <td>Overwhelming sepsis, other abnormalities</td> </tr> <tr> <td>Natural killer cell deficiencies</td> <td>Severe herpes infections</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Complement deficiencies</td> </tr> <tr> <td class=\"subtitle2\">Cause</td> <td class=\"subtitle2\">Features</td> </tr> <tr> <td>Prematurity with opsonic defects</td> <td>Neonatal sepsis in infants &#60;1500 g</td> </tr> <tr> <td>Regulatory protein deficiencies</td> <td>Hemolytic-uremic syndrome, renal failure, thrombocytopenia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M.</div><div id=\"graphicVersion\">Graphic 100552 Version 4.0</div></div></div>"},"100554":{"type":"graphic_picture","displayName":"Volar pole of scaphoid","title":"Volar pole of scaphoid","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Volar pole of scaphoid</div><div class=\"cntnt\"><img style=\"width:711px; height:531px;\" src=\"images/EM/100554_Volar_pole_scaphoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The volar (distal) pole of the scaphoid can be palpated just distal to the wrist crease at the base of the thenar eminence. As the wrist is moved from ulnar to radial deviation, the pole becomes more prominent volarly, as the scaphoid flexes. The volar pole becomes easier to palpate as this motion (ulnar to radial deviation) is repeated.</div><div class=\"graphic_reference\">Courtesy of Kevin DeWeber, MD.</div><div id=\"graphicVersion\">Graphic 100554 Version 2.0</div></div></div>"},"100556":{"type":"graphic_diagnosticimage","displayName":"Radiography of meconium ileus in cystic fibrosis in an infant","title":"Meconium ileus and cystic fibrosis on radiography in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Meconium ileus and cystic fibrosis on radiography in a newborn infant</div><div class=\"cntnt\"><img style=\"width:436px; height:505px;\" src=\"images/RADIOL/100556_Rd_mcnm_ils_cystc_fbrs_infn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frontal radiograph in supine position shows dilated loops of bowel indicating intestinal obstruction. The nine-hour-old male infant had a known prenatal diagnosis of intestinal obstruction.</div><div class=\"graphic_reference\">Courtesy of Michael Callahan, MD.</div><div id=\"graphicVersion\">Graphic 100556 Version 1.0</div></div></div>"},"100557":{"type":"graphic_diagnosticimage","displayName":"Contrast enema in infant with CF and meconium ileus","title":"Cystic fibrosis and meconium ileus on contrast enema in infant","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Cystic fibrosis and meconium ileus on contrast enema in infant</div><div class=\"cntnt\"><img style=\"width:740px; height:483px;\" src=\"images/RADIOL/100557_Cntrs_enm_infnt_CF_mcnm_ils.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A contrast enema on a nine-hour-old infant with prenatal diagnosis of intestinal obstruction (A) shows a microcolon (arrows) and dilated gas-filled loops of small bowel (arrowheads), characteristic of meconium ileus. Image B shows calcifications (arrows) in the right upper quadrant, consistent with meconium peritonitis from in-utero perforation.</div><div class=\"graphic_reference\">Courtesy of Michael Callahan, MD.</div><div id=\"graphicVersion\">Graphic 100557 Version 2.0</div></div></div>"},"100558":{"type":"graphic_diagnosticimage","displayName":"CT of DIOS in cystic fibrosis","title":"Cystic fibrosis and distal intestinal obstruction syndrome (DIOS) on CT","html":"<div class=\"graphic\"><div style=\"width: 787px\" class=\"figure\"><div class=\"ttl\">Cystic fibrosis and distal intestinal obstruction syndrome (DIOS) on CT</div><div class=\"cntnt\"><img style=\"width:767px; height:405px;\" src=\"images/RADIOL/100558_CT_DIOS_cystic_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 20-year-old male with CF and with past history of DIOS presents with abdominal pain for two days and inability to stool. The CT scan shows a dilated distal small bowel (asterisk) filled with inspissated, fecalized content (arrow). The ascending colon (arrowhead) and descending colon (dashed arrow) are decompressed, suggesting small bowel obstruction in the setting of DIOS. Image B is a coronal reconstruction of the CT and shows the dilated distal small bowel (asterisk) filled with inspissated fecal-like intraluminal material (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; CF: cystic fibrosis; DIOS: distal intestinal obstruction syndrome.</div><div class=\"graphic_reference\">Courtesy of Michael Callahan, MD.</div><div id=\"graphicVersion\">Graphic 100558 Version 1.0</div></div></div>"},"100559":{"type":"graphic_diagnosticimage","displayName":"Therapeutic gastrografin enema in CF and DIOS","title":"Cystic fibrosis, distal intestinal obstruction, and therapeutic Gastrografin enema","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Cystic fibrosis, distal intestinal obstruction, and therapeutic Gastrografin enema</div><div class=\"cntnt\"><img style=\"width:526px; height:510px;\" src=\"images/RADIOL/100559_Thrptc_gstrgrfn_enm_CF_DIOS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Therapeutic enema with diatrizoate meglumine and diatrizoate sodium (Gastrografin) in a patient with cystic fibrosis and small bowel obstruction due to distal intestinal obstruction syndrome (DIOS). A spot view of the cecum shows a contrast-filled cecum (asterisk). Two days following the enema, the patient's symptoms improved with normal stooling and ability to tolerate solid foods.</div><div class=\"graphic_reference\">Courtesy of Michael Callahan, MD.</div><div id=\"graphicVersion\">Graphic 100559 Version 1.0</div></div></div>"},"100561":{"type":"graphic_diagnosticimage","displayName":"Imaging scaphoid fracture","title":"Scaphoid fracture on radiography and CT scan","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Scaphoid fracture on radiography and CT scan</div><div class=\"cntnt\"><img style=\"width:481px; height:495px;\" src=\"images/RADIOL/100561_Imag_scaphoid_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P view of the wrist (A) shows a transverse fracture through the distal third of the right scaphoid (arrow). Image B is a magnified view and shows a simple appearing transverse fracture (arrow). Image C is a coronal reconstruction of the wrist and shows a comminuted fracture (arrow). Image D is a magnified view and confirms the comminuted fracture (arrow), with anatomically aligned components.</div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100561 Version 1.0</div></div></div>"},"100562":{"type":"graphic_diagnosticimage","displayName":"MRI scaphoid fracture","title":"Scaphoid fracture on MRI","html":"<div class=\"graphic\"><div style=\"width: 845px\" class=\"figure\"><div class=\"ttl\">Scaphoid fracture on MRI</div><div class=\"cntnt\"><img style=\"width:825px; height:428px;\" src=\"images/CARD/100562_MRI_scaphoid_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T1 weighted MRI of a coronal view of the wrist (A) shows a fracture through the mid to distal portion of the scaphoid. The distal fragment (asterisk) is dark on this sequence. Image B is a T2 weighted sequence and shows a simple transverse fracture (arrow) with a contusion of the distal fragment (asterisk) and edema of the surrounding tissues (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 100562 Version 1.0</div></div></div>"},"100563":{"type":"graphic_diagnosticimage","displayName":"Imaging non-union scaphoid fracture","title":"Scaphoid fracture with non-union, avascular necrosis, and scapholunate ligament injury on radiography and CT","html":"<div class=\"graphic\"><div style=\"width: 883px\" class=\"figure\"><div class=\"ttl\">Scaphoid fracture with non-union, avascular necrosis, and scapholunate ligament injury on radiography and CT</div><div class=\"cntnt\"><img style=\"width:863px; height:437px;\" src=\"images/RADIOL/100563_Imag_non_unn_scphd_frctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A scaphoid view (A) shows non-union of a proximal scaphoid fracture (arrow) with avascular necrosis of the dense proximal fragment (asterisk) and scapholunate ligament injury aka \"Terry Thomas\" sign (arrowhead). Image B is a coronal reconstruction of a CT scan and shows non-union of the fracture (arrow), a dense proximal fragment (asterisk) indicating avascular necrosis, and a widened scapholunate joint (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100563 Version 1.0</div></div></div>"},"100564":{"type":"graphic_figure","displayName":"Tibial tubercle apophyseal fracture","title":"Tibial tubercle apophyseal fracture","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Tibial tubercle apophyseal fracture</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/EM/100564_Tibia_tubercle_apophyseal_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forced flexion against actively contracting quadriceps in skeletally immature male adolescent athletes can cause a tibial tubercle apophyseal fracture. These injuries&nbsp;are associated with&nbsp;an acute compartment syndrome. </div><div id=\"graphicVersion\">Graphic 100564 Version 1.0</div></div></div>"},"100565":{"type":"graphic_figure","displayName":"Proximal tibial physeal fracture with popliteal artery tear","title":"Proximal tibial physeal fracture with popliteal artery tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal tibial physeal fracture with popliteal artery tear</div><div class=\"cntnt\"><img style=\"width:263px; height:604px;\" src=\"images/EM/100565_Prxmtblphysfrcppltart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A proximal tibial physeal fracture can be associated with posterior displacement of the metaphyseal fragment&nbsp;and laceration of the popliteal artery&nbsp;that is tethered by the more distal tibial artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100565 Version 3.0</div></div></div>"},"100567":{"type":"graphic_picture","displayName":"Postinflammatory hyperpigmentation shape","title":"Postinflammatory hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100567_Pstnflmmtry_hyperpigmnt_shp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postinflammatory hyperpigmentation mimicking the shape of a preceding inflammatory dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100567 Version 1.0</div></div></div>"},"100568":{"type":"graphic_picture","displayName":"Exogenous ochronosis pathology","title":"Exogenous ochronosis","html":"<div class=\"graphic\"><div style=\"width: 889px\" class=\"figure\"><div class=\"ttl\">Exogenous ochronosis</div><div class=\"cntnt\"><img style=\"width:869px; height:441px;\" src=\"images/DERM/100568_Exogenousochronosispthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple yellow-orange to yellow-brown fibers in the superficial dermis.</div><div class=\"graphic_reference\">Reproduced with permission from: Maize JC, Ralston JS. Metabolic diseases of the skin. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100568 Version 3.0</div></div></div>"},"100569":{"type":"graphic_picture","displayName":"Postinflammatory hyperpigmentation pathology","title":"Postinflammatory hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:712px; height:467px;\" src=\"images/DERM/100569_Pstnflmmtryhyprpgpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are numerous melanophages in the papillary dermis along with a mild perivascular lymphocytic infiltrate. The epidermis is normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Fedeles F, Robinson-Bostom L. Pigmentary disorders of the skin. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 100569 Version 3.0</div></div></div>"},"100572":{"type":"graphic_table","displayName":"Principles of pain management in CKD","title":"Principles of pain management in chronic kidney disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principles of pain management in chronic kidney disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">General principle</td> <td class=\"subtitle1\">Specific consideration in CKD</td> </tr> <tr> <td>\"By mouth\"</td> <td> <p>Hemodialysis patients have easy IV access. However, this is to be avoided as the route of administration for analgesics for chronic pain management.</p> Oral or transdermal routes are preferred.</td> </tr> <tr> <td>\"By the clock\"</td> <td>Some patients with mild pain may achieve adequate pain relief with analgesic dosing post-hemodialysis only. An example would be mild neuropathic pain dosed with gabapentin postdialysis.</td> </tr> <tr> <td>\"By the ladder\"</td> <td> <p>Careful selection of analgesics for each step of the ladder, taking into account degree of kidney failure, is critical.</p> Sustained-release preparations are generally not recommended in patients with advanced CKD.</td> </tr> <tr> <td>\"For the individual\"</td> <td>Chronic pain is often experienced in the context of numerous other physical, psychosocial, and spiritual concerns, including end-of-life issues. Close attention to these other issues must not be forgotten as part of the pain management strategy.</td> </tr> <tr> <td>\"Attention to detail\"</td> <td>Regular reassessment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 100572 Version 1.0</div></div></div>"},"100573":{"type":"graphic_table","displayName":"Analgesic medications chronic pain management CKD stages 4 and 5","title":"Preferred analgesic medications for chronic pain management in CKD stages 4 and 5","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred analgesic medications for chronic pain management in CKD stages 4 and 5</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">WHO step</td> <td class=\"subtitle1\">Recommended</td> <td class=\"subtitle1\">Use with caution</td> <td class=\"subtitle1\">Do not use</td> </tr> <tr> <td>1</td> <td>Acetaminophen</td> <td>&nbsp;</td> <td>NSAIDs</td> </tr> <tr> <td>2</td> <td>&nbsp;</td> <td>Tramadol</td> <td>Codeine</td> </tr> <tr> <td>3</td> <td> <p>Hydromorphone</p> <p>Fentanyl, alfentanil</p> <p>Methadone</p> Buprenorphine</td> <td>Oxycodone</td> <td> <p>Morphine</p> <p>Meperidine </p> Propoxyphene</td> </tr> <tr> <td>Adjuvant</td> <td> <p>Gabapentin</p> Pregabalin</td> <td>TCAs</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Heath Organization; NSAID: nonsteroidal anti-inflammatory drug; TCA: tricyclic antidepressant.</div><div id=\"graphicVersion\">Graphic 100573 Version 1.0</div></div></div>"},"100574":{"type":"graphic_picture","displayName":"Intralesional pentavalent antimony","title":"Intralesional treatment with pentavalent antimony","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Intralesional treatment with pentavalent antimony</div><div class=\"cntnt\"><img style=\"width:715px; height:485px;\" src=\"images/ID/100574_Intrlsnl_pntvl_antm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient receiving intralesional injection for the treatment of cutaneous leishmaniasis.</div><div class=\"graphic_reference\">Copyright &copy; World Health Organization/C. Black, 2016.</div><div id=\"graphicVersion\">Graphic 100574 Version 1.0</div></div></div>"},"100576":{"type":"graphic_table","displayName":"Symptom assessment tools","title":"Symptom assessment tools","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptom assessment tools</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Clinical utility</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Edmonton Symptom Assessment System Revised:Renal (ESAS-r:Renal)<sup>[1-3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Thirteen&nbsp;visual analog scales with a superimposed 0 to 10 scale for pain, tiredness, drowsiness, nausea, lack of appetite, shortness of breath, depression, anxiety, well-being, itching, sleep, restless legs, and other. The scale for each symptom is anchored by the words \"no\" and \"severe\" at 0 and 10, respectively. The sum of all scores makes up the overall symptom distress score, ranging from 0 to 130.</td> <td><strong>Comprehensive symptom screening</strong> &ndash; A short, practical tool for screening symptoms, which can be rapidly and repeatedly completed by patients and therefore incorporated easily into routine clinical care, even for patients who are preterminal. It has been translated into several languages. It was originally used in cancer and has been adapted for use in many disease states, allowing for comparisons to be made across disease states.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Palliative Care Outcome Scale-Renal (POS-renal)<sup>[4,5]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Assesses 17 symptoms, which are rated in terms of how the patient has been affected by the symptom over the last three days from 0 (not at all) to 4 (overwhelmingly). Symptoms assessed are pain, shortness of breath, weakness or lack of energy, nausea, vomiting, poor appetite, constipation, mouth problems, drowsiness, poor mobility, itching, difficulty sleeping, restless legs or difficulty keeping legs still, anxiety, depression, changes in skin, and diarrhea.</td> <td><strong>Comprehensive symptom screening</strong> &ndash; This tool is simple to use and can be incorporated easily into routine clinical care, even for patients who are preterminal. It has been translated into several languages. It was originally used in cancer and has been adapted for use in many disease states, allowing for comparisons to be made across disease states.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Physical Symptom Distress Scale (PSDS)<sup>[6]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Assesses 16 symptoms: swelling in feet, muscle cramps, fatigue, itching, nausea or vomiting, stiffness of joints, difficulty sleeping, poor appetite, pain, constipation or diarrhea, decrease in concentration, shortness of breath, numbness/tingling, dizziness, impaired visual ability, and headache. Symptoms are rated by patients on a four-point Likert scale (0 = not bothered at all, 4 = extremely bothered).</td> <td><strong>Comprehensive symptom screening</strong> &ndash; This tool was specifically designed for CKD patients, but there is not much experience with its use. There is some redundancy with respect to items pertaining to pain. It appears practical and simple enough to incorporate into routine clinical care.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dialysis Symptom Index (DSI)<sup>[7]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Assesses 30 symptoms, rating them from 1 (not at all bothered) to 5 (very much bothered). Symptoms related to pain include bone/joint pain, muscle soreness, muscle cramps, headaches, and chest pain. Other symptoms include constipation, diarrhea, nausea, vomiting, decreased appetite, swelling in legs, shortness of breath, light-headedness, restless legs, numbness, feeling tired, cough, dry mouth, difficulty concentrating, dry skin, itching, worrying, nervousness, trouble falling asleep, trouble staying asleep, feeling irritable, feeling sad, feeling anxious, decreased interest in sex, and difficulty becoming sexually aroused.</td> <td><strong>Comprehensive symptom screening</strong> &ndash; The tool is easy to use and can be self-completed by patients. Respondent burden is greater than for the ESAS-r:Renal or POS-renal, but less than the HRQL tools. There is limited experience with it being incorporated into routine clinical care for symptom screening. It was originally used in cancer patients prior to being adapted for use in CKD, allowing for comparisons to be made.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">The Brief Pain Inventory (BPI)<sup>[8]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Assesses the location, type (nociceptive versus neuropathic), and intensity of pain. It also evaluates the impact of pain on general activity, mood, walking ability, work, relationships, sleep, and enjoyment of life. The standard 32-question instrument has been condensed to a nine-question short form.</td> <td><strong>Pain assessment</strong> &ndash; This tool has been used successfully in clinical and research settings internationally to assess pain once identified as a problem. Seriously ill patients have been successful in completing this questionnaire. The short form is simple to use, with minimal respondent burden.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Short-form McGill Pain Questionnaire (SF-MPQ)<sup>[9]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Describes the quality and intensity of pain. The scale is rated from 0 to 78 with higher scores reflecting worse pain.</td> <td><strong>Pain screening and assessment</strong> &ndash; This is not a simple screening tool for pain and does not assess other symptoms, decreasing its clinical utility for routine comprehensive symptom screening in CKD. It is incomplete as a pain assessment tool as it does not explore adequately the impact of the pain on function and quality of life.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Kidney Dialysis Quality of Life Short Form/ SF-36 (KDQOL-SF)<sup>[10]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>This is a self-reported HRQL measure developed for CKD patients as a less burdensome version of the longer KDQOL questionnaire. There are 37 questions, some with multiple stems, over 19 pages. The tool focuses on physical and emotional symptoms, effects on kidney disease on daily life, burden of disease, cognitive function, work status, sexual function, and quality of social interaction. There are also three quality-of-life scales focusing on social support, staff encouragement, and patient satisfaction.</td> <td><strong>HRQL:</strong> Takes approximately 30 minutes to complete in healthier individuals, but typically requires interviewer assistance and substantially more time in older, frail patients. It provides comprehensive HRQL information, but is more suited to a research environment where dedicated staff can help with the administration and complex scoring.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">CHOICE Health Experience Questionnaire (CHEQ) + SF-36<sup>[11]</sup></td> </tr> <tr> <td>This is a self-reported HRQL tool that incorporates an assessment of symptoms and was designed to complement the generic SF-36 (in a fashion similar to the KDQOL).</td> <td><strong>HRQL:</strong> Requires at least 30 minutes to complete in healthier individuals, but typically requires interviewer assistance and takes longer in older, frail patients. It provides comprehensive HRQL information, but is more suited to a research environment where dedicated staff can help with the administration and complex scoring.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESAS-r: Edmonton Symptom Assessment System Revised; POS: Palliative Care Outcome Scale; PSDS: Physical Symptom Distress Scale; CKD: chronic kidney disease; DSI: Dialysis Symptom Index; HRLQ: health-related quality of life; BPI: Brief Pain Inventory; SF-MPQ: Short Form-McGill Pain Questionnaire; KDQOL-SF: Kidney Dialysis Quality of Life Short Form ; CHEQ: CHOICE Health Experience Questionnaire.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 2006; 69:1621.</li>&#xD;&#xA;    <li>Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 2006; 21:3189.</li>&#xD;&#xA;    <li>Walke LM, Byers AL, McCorkle R, Fried TR. Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manag 2006; 31:31.</li>&#xD;&#xA;    <li>Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clinical Practice 2009; 111:c74.</li>&#xD;&#xA;    <li>Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Car 1999; 8:219.</li>&#xD;&#xA;    <li>Chiou CP. Development and psychometric assessment of the physical symptom distress scale. J Pain Symptom Manag 1998; 16:87.</li>&#xD;&#xA;    <li>Weisbord SD, Fried LF, Arnold RM, et al. Development of a symptom assessment instrument for chronic hemodialysis patients: The Dialysis Symptom Index. J Pain Symptom Manag 2004; 27:226.</li>&#xD;&#xA;    <li>Davison SN. Pain in hemodialysis patients: Prevalence, cause, severity, and management. Am J Kidney Dis 2003; 42:1239.</li>&#xD;&#xA;    <li>Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1:277.</li>&#xD;&#xA;    <li>Joshi VD, Mooppil N, Lim JF. Validation of the kidney disease quality of life-short form: a cross-sectional study of a dialysis-targeted health measure in Singapore. BMC Nephrol 2010; 11:36.</li>&#xD;&#xA;    <li>Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-satge renal disease: the CHOICE Health Experience Questionnaire. Am J Kidney Dis 2001; 37:11.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: A scoping review. Semin Dial 2014; 27:188. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/sdi.12196/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/sdi.12196/abstract</a>. Copyright &copy; 2014 Wiley Periodicals, Inc. Modified and reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 100576 Version 2.0</div></div></div>"},"100577":{"type":"graphic_algorithm","displayName":"Surgical management of pancreatic neuroendocrine tumors","title":"Surgical management of pancreatic neuroendocrine tumors","html":"<div class=\"graphic\"><div style=\"width: 936px\" class=\"figure\"><div class=\"ttl\">Surgical management of pancreatic neuroendocrine tumors</div><div class=\"cntnt\"><img style=\"width:916px; height:554px;\" src=\"images/SURG/100577_Srgcl_mng_pncrt_nrndc_tmr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PNET: pancreatic neuroendocrine tumor.<br />* PNETs associated with multiple endocrine neoplasia or Zollinger-Ellison syndrome are managed differently.<br />&para; Rarely, localized primary tumor will be unresectable (eg, directly invading the celiac plexus).<br />&Delta; Based on evidence of local invasion, regional lymphadenopathy, metastases.<br /><span class=\"lozenge\">&loz;</span> Includes: long-acting somatostatin analogs, proton pump inhibitors (gastrinoma), diazoxide (insulinoma).<br />&sect; Observation rather than initial resection is an option for small (&lt;2 cm) localized nonprogressing tumors that are well-differentiated, and low grade (Ki67 &lt;2%)​.</div><div id=\"graphicVersion\">Graphic 100577 Version 2.0</div></div></div>"},"100580":{"type":"graphic_figure","displayName":"Sites of large bowel obstruction","title":"Sites of large bowel obstruction","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Sites of large bowel obstruction</div><div class=\"cntnt\"><img style=\"width:534px; height:513px;\" src=\"images/SURG/100580_Sites_of_large_bowel_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Buechter KJ, Boustany C, Caillouette R, Cohn I Jr. Surgical management of the acutely obstructed colon. A review of 127 cases. Am J Surg 1988; 156:163.</div><div id=\"graphicVersion\">Graphic 100580 Version 1.0</div></div></div>"},"100581":{"type":"graphic_picture","displayName":"SICK scapula syndrome","title":"SICK scapula syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">SICK scapula syndrome</div><div class=\"cntnt\"><img style=\"width:359px; height:607px;\" src=\"images/EM/100581_SICK_scapula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A professional right-handed baseball pitcher with a SICK right scapula viewed from posterior (A). Viewed from the anterior (B), the apparent inferior position of the lateral clavicle caused by scapular protraction can be seen.</div><div class=\"graphic_reference\">Reproduced from: Burkhart SS, Morgan CD, Kibler WB. The disabled throwing shoulder: Spectrum of pathology part III: The SICK scapula, scapular dyskinesis, the kinetic chain, and rehabilitation. Arthroscopy 2003; 19:641. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100581 Version 1.0</div></div></div>"},"100582":{"type":"graphic_picture","displayName":"Scapula malposition with SICK syndrome","title":"Scapula malposition with SICK syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapula malposition with SICK syndrome</div><div class=\"cntnt\"><img style=\"width:359px; height:543px;\" src=\"images/EM/100582_Static_scapular_malposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three categories of static scapular malposition may be seen with the SICK scapula syndrome. All three malpositions&mdash;inferior medial border prominence, lateral protraction, and abduction&mdash;are illustrated in panel A, which shows a high school quarterback's right shoulder. One or any combination of the three malpositions may occur, as seen in the right shoulder of a college baseball pitcher (panel B) with an isolated abduction component of the SICK scapula syndrome.</div><div class=\"graphic_reference\">Reproduced from: Burkhart SS, Morgan CD, Kibler WB. The disabled throwing shoulder: Spectrum of pathology part III: The SICK scapula, scapular dyskinesis, the kinetic chain, and rehabilitation. Arthroscopy 2003; 19:641. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100582 Version 2.0</div></div></div>"},"100583":{"type":"graphic_picture","displayName":"Tennis player with SICK scapula syndrome","title":"Tennis player with SICK scapula syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tennis player with SICK scapula syndrome</div><div class=\"cntnt\"><img style=\"width:359px; height:629px;\" src=\"images/EM/100583_Tennis_playr_SICK_rght_scpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above is of a&nbsp;high-level woman tennis player with SICK scapula syndrome on the right side (A). Note that the severity of the problem is more evident when the scapular margins are outlined (B).</div><div class=\"graphic_reference\">Reproduced from: Burkhart SS, Morgan CD, Kibler WB. The disabled throwing shoulder: Spectrum of pathology part III: The SICK scapula, scapular dyskinesis, the kinetic chain, and rehabilitation. Arthroscopy 2003; 19:641. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100583 Version 1.0</div></div></div>"},"100585":{"type":"graphic_figure","displayName":"Technique of intraoperative colonic lavage","title":"Technique of intraoperative colonic lavage","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Technique of intraoperative colonic lavage</div><div class=\"cntnt\"><img style=\"width:524px; height:530px;\" src=\"images/SURG/100585_Technique_of_intraoperative_colonic_lavage.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Dudley HA, Racliffe AG, McGeehan D. Intraoperative irrigation of the colon to permit primary anastomosis. Br J Surg 1980; 67:80.</div><div id=\"graphicVersion\">Graphic 100585 Version 2.0</div></div></div>"},"100586":{"type":"graphic_algorithm","displayName":"BCM neonatal platelet transfusion guidelines","title":"Dept of Pediatrics: BCM guidelines for neonatal platelet transfusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dept of Pediatrics: BCM guidelines for neonatal platelet transfusion</div><div class=\"cntnt\"><img style=\"width:442px; height:406px;\" src=\"images/PEDS/100586_BCM_neonatal_pltlt_trnsfsn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BCM: Baylor College of Medicine; PLC: platelet count; IVH: intraventricular hemorrhage.<br />* Use human-platelet-antigen-compatible platelets for infants with suspected or proven neonatal alloimmune thrombocytopenia.</div><div class=\"graphic_reference\">Reproduced with permission from: Guidelines for Acute Care of the Neonate, 22nd edition (2014-2015), Abrams SA, Adams JM, Anderson DM, et al (Eds), Baylor College of Medicine, Houston, 2014. Copyright &copy; 2014 Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 100586 Version 1.0</div></div></div>"},"100611":{"type":"graphic_picture","displayName":"Histiocytic sarcoma path","title":"Pathologic features of histiocytic sarcoma","html":"<div class=\"graphic\"><div style=\"width: 823px\" class=\"figure\"><div class=\"ttl\">Pathologic features of histiocytic sarcoma</div><div class=\"cntnt\"><img style=\"width:803px; height:177px;\" src=\"images/HEME/100611_Hstcytc_sarcoma_pth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histiocytic sarcoma. A) Note the multinucleated tumor cell. B) The cytoplasm is relatively abundant, but the neoplasm is difficult to distinguish from a large B cell lymphoma without a battery of immunohistochemical studies. C) Diffuse staining for the lysosomal marker CD68.&nbsp; </div><div class=\"graphic_reference\">Reprinted from WHO Classification of Tumours of Haematopoietic and Lymphiod Tissues, 4th ed, Grogan TM, Pileri SA, Chan JKC, et al, Histiocytic sarcoma, p. 356, 2008.</div><div id=\"graphicVersion\">Graphic 100611 Version 1.0</div></div></div>"},"100612":{"type":"graphic_picture","displayName":"Histiocytic sarcoma bowel path","title":"Histiocytic sarcoma involving the bowel","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Histiocytic sarcoma involving the bowel</div><div class=\"cntnt\"><img style=\"width:798px; height:532px;\" src=\"images/HEME/100612_Hstcytc_srcm_bwl_pth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histiocytic sarcoma. A) Histiocytic sarcoma involving the bowel. B) Note the abundant cytoplasm, which stains strongly for CD68 (C) and lysozyme (D). </div><div class=\"graphic_reference\">Reprinted from WHO Classification of Tumours of Haematopoietic and Lymphiod Tissues, 4th ed, Grogan TM, Pileri SA, Chan JKC, et al, Histiocytic sarcoma, p. 357, 2008.</div><div id=\"graphicVersion\">Graphic 100612 Version 1.0</div></div></div>"},"100618":{"type":"graphic_figure","displayName":"Neural crest development and neuroblastoma tumorigenesis","title":"Neural crest development and neuroblastoma tumorigenesis","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Neural crest development and neuroblastoma tumorigenesis</div><div class=\"cntnt\"><img style=\"width:555px; height:293px;\" src=\"images/ONC/100618_Nrl_crst_dvlp_nrblstm_tmrgn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neuroblastoma arises during the course of embryonal neural crest specification and differentiation. This process involves a programmed epithelial-to-mesenchymal transition (EMT) of multipotent early neural crest cells and generates a plethora of distinct tissues, including the sympathoadrenal lineages. Disruptoin of this moral developmental process with distinct oncogenic drivers (eg, <em>MYCN </em>of <em>ALK </em>oncogenes), at different times, can lead to multiple subtypes of neuroblastoma tumors. Interaction between different epigenetic and genetic drivers complicates the task of defining a primary oncogenic pathway for neuroblastoma. This results in a wide range of pathology, biology, and response to therapy.</div><div class=\"graphic_reference\">Modified with permission from:&nbsp;Louis CU, Shohet, JM. Neuroblastoma: Molecular pathogenesis and therapy. Annu Rev Med 2015; 66:49. Volume 66 © 2015 by Annual Reviews, <A spellcheck=true href=\"http://www.annualreviews.org/\" target=_blank>http://www.annualreviews.org</A>.</div><div id=\"graphicVersion\">Graphic 100618 Version 4.0</div></div></div>"},"100620":{"type":"graphic_algorithm","displayName":"Fair process for considering futility cases","title":"Fair process for considering medical cases in which futile or potentially inappropriate therapies are being considered, American Medical Association (AMA)","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Fair process for considering medical cases in which futile or potentially inappropriate therapies are being considered, American Medical Association (AMA)</div><div class=\"cntnt\"><img style=\"width:629px; height:602px;\" src=\"images/PALC/100620_Fairprcsscnsdrftltycase.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Council on Ethical and Judicial Affairs, American Medical Association. Medical Futility in End-of-Life Care: Report on the Council of Ethical and Judicial Affairs. JAMA 1999; 281:937. Copyright &copy; 1999 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100620 Version 4.0</div></div></div>"},"100621":{"type":"graphic_picture","displayName":"Dimple sign of knee dislocation","title":"Dimple sign of knee dislocation","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Dimple sign of knee dislocation</div><div class=\"cntnt\"><img style=\"width:666px; height:726px;\" src=\"images/EM/100621_Dimplesign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"dimple sign\" is a transverse groove in the skin at the medial joint line caused by invagination of a portion of the medial capsule. Presence of this sign suggests a posterolateral knee dislocation that cannot be manually reduced. </div><div class=\"graphic_reference\">From: Saini R, Mootha AK, Goni VG, Dhillon MS. Neglected irreducible posterolateral knee dislocation. Indian J of Ortho 2010; 44:468. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2010 Indian Orthopaedic Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 100621 Version 2.0</div></div></div>"},"100626":{"type":"graphic_table","displayName":"Response criteria for MDS MPN ","title":"Proposed criteria for measurement of treatment response in adults with chronic myelomonocytic leukemia or other myelodysplastic/myeloproliferative neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed criteria for measurement of treatment response in adults with chronic myelomonocytic leukemia or other myelodysplastic/myeloproliferative neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Complete&nbsp;response (presence of all of the following improvements)*</td> </tr> <tr> <td class=\"indent1\">Bone marrow: &#8804;5% myeloblasts (including monocytic blast equivalent in case of CMML) with normal maturation of all cell lines and return to normal cellularity*</td> </tr> <tr> <td class=\"indent1\">Osteomyelofibrosis absent or equal to \"mild reticulin fibrosis\" (&#8804;grade 1 fibrosis)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Peripheral blood<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">WBC &#8804;10 x 10<sup>9</sup> cells/L</td> </tr> <tr> <td class=\"indent2\">Hgb &#8805;11 g/dL</td> </tr> <tr> <td class=\"indent2\">Platelets &#8805;100 x 10<sup>9</sup>/L; &#8804;450 x 10<sup>9</sup>/L</td> </tr> <tr> <td class=\"indent2\">Neutrophils &#8805;1.0 x 10<sup>9</sup>/L</td> </tr> <tr> <td class=\"indent2\">Blasts 0%</td> </tr> <tr> <td class=\"indent2\">Neutrophil precursors reduced to &#8804;2%</td> </tr> <tr> <td class=\"indent2\">Monocytes &#8804;1 x 10<sup>9</sup>/L</td> </tr> <tr> <td class=\"indent1\">Extramedullary disease: Complete resolution of extramedullary disease present before therapy (eg, cutaneous disease, disease-related serous effusions), including palpable hepatosplenomegaly</td> </tr> <tr> <td class=\"indent1\">Provisional category of CR with resolution of symptoms:<sup>&#916;</sup> CR as described above, and complete resolution of disease-related symptoms as noted by the MPN-SAF TSS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Persistent low-level dysplasia is permitted given subjectivity of assignment of dysplasia*</td> </tr> <tr> <td class=\"subtitle1_single\">Complete cytogenetic remission</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Resolution of previously present chromosomal abnormality (known to be associated with myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN), as seen on classic karyotyping with minimal of 20 metaphases or FISH<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Partial remission</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normalization of peripheral counts and hepatosplenomegaly with bone marrow blasts (and blast equivalents) reduced by 50%, but remaining &#62;5% of cellularity <em>except</em> in cases of MDS/MPN with &#8804;5% bone marrow blasts at baseline</td> </tr> <tr> <td class=\"subtitle1_single\">Marrow response</td> </tr> <tr> <td class=\"indent1\">Optimal marrow response: Presence of all marrow criteria necessary for CR without normalization of peripheral blood indices as presented above</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Partial marrow response: Bone marrow blasts (and blast equivalents) reduced by 50%, but remaining &#62;5% of cellularity, <em>or</em> reduction in grading of reticulin fibrosis from baseline on at least two bone marrow evaluations spaced at least two months apart</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical benefit</td> </tr> <tr> <td class=\"indent1\">Requires one of the following in the absence of progression or CR/partial response and independent of marrow response (cord blood response must be verified at &#8805;8 weeks) to be considered a clinical benefit</td> </tr> <tr> <td class=\"indent1\">Erythroid response</td> </tr> <tr> <td class=\"indent2\">Hgb increase by &#8805;2.0 g/dL</td> </tr> <tr> <td class=\"indent2\">TI for &#8805;8 weeks for patients requiring at least four packed red blood cell transfusions in the previous eight weeks</td> </tr> <tr> <td class=\"indent2\">Only red blood cell transfusions given based on physician's judgment for a pretreatment Hgb of &#8804;8.5 g/dL will count in the red blood cell TI response evaluation<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Platelet response</td> </tr> <tr> <td class=\"indent2\">Transfusion independence when previously requiring platelet transfusions of at least a rate of four platelet transfusions in the previous eight weeks</td> </tr> <tr> <td class=\"indent2\">Pretreatment &#8804;20 x 10<sup>9</sup>/L: Increase from &#60;20 x 10<sup>9</sup>/L to &#62;20 x 10<sup>9</sup>/L and by at least 100%</td> </tr> <tr> <td class=\"indent2\">Pretreatment &#62;20 x 10<sup>9</sup>/L but &#8804;100 x 10<sup>9</sup>/L: Absolute increase of &#8805;30 x 10<sup>9</sup>/L<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Neutrophil response</td> </tr> <tr> <td class=\"indent2\">Pretreatment &#8804;0.5 x 10<sup>9</sup>/L at least 100% increase and an absolute increase &#8805;0.5 x 10<sup>9</sup>/L</td> </tr> <tr> <td class=\"indent2\">Pretreatment &#62;0.5 x 10<sup>9</sup>/L and &#8804;1.0 x 10<sup>9</sup>/L at least 50% increase and an absolute increase &#8805;0.5 x 10<sup>9</sup>/L<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Spleen response</td> </tr> <tr> <td class=\"indent2\">Either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable</td> </tr> <tr> <td class=\"indent1\">Symptom response</td> </tr> <tr> <td class=\"indent2\">Improvement in symptoms as noted by decrease of &#8805;50% as per the MPN-SAF TSS scoring &#60;20 were not considered eligible for measuring clinical benefit<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMML: chronic myelomonocytic leukemia; CR: complete response; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; WBC: white blood cell; Hgb: hemoglobin; FISH: fluorescence in situ hybridization; TI:&nbsp;transfusion independence; MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form&nbsp;total symptom score; MDS IWG: Myelodysplastic Syndrome International Working Group. &nbsp;&nbsp;&nbsp;<br />* Presence of dysplastic changes, which may be interpreted within the scope of normal range of dysplastic changes, may still exist in the presence of CR as allowed in MDS IWG. Marrow should exhibit age-adjusted normocellularity in CR.<br />¶ If there is no significant fibrosis present on the initial bone marrow biopsy, a second biopsy is not required to prove resolution of fibrosis. Grading of fibrosis in measurement of treatment response should be according to the European Consensus System.<br />Δ Given the current lack of a validated tool to assess complete resolution of symptoms in MDS/MPN, \"CR with resolution of symptoms\" (a complete resolution of disease related symptoms as noted by the MPN-SAF TSS in presence of CR) will be a provisional category of disease response.<br /><FONT class=lozenge>◊</FONT> Loss of cytogenetic burden of disease by (via FISH or classic karyotyping) known to adversely affect prognosis is required to reach complete cytogenetic remission. Decrease in the cytogenetic burden of disease must be by ≥50% (via FISH or classic karyotyping) to be indicative of a partial cytogenetic response. Given variability of fluorescent probes used in FISH, cytogenetic normalization via FISH will depend on the performance characteristics of the specific probes used.<br />§ Resolution of abnormal peripheral blood counts must persist for at least two separate analyses over at least eight weeks. In the case of proliferative MDS/MPN, CR will include resolution of thrombocytosis to a normal platelet count (150 to 450 x 10<SUP>9</SUP>/L) and resolution of leukocytosis to WBC ≤10 x 10<SUP>9</SUP> cells/L but ≥1.5 x 10<SUP>9</SUP>/L. Hgb should be maintained &gt;11 g/dL and platelets ≥100 x 10<SUP>9</SUP>/L without the support of transfusions. Clinical benefit may occur when these changes occur in absence of other changes required for CR or marrow response. Platelet and packed red blood cell TI would be considered for clinical benefit, and duration of TI should be monitored. Reduction in myeloid precursors (promyelocytes, myelocytes, metamyelocytes, nucleated red blood cells) to less than appreciable levels (≤2 to 3%) and/or 1 x 10<SUP>9</SUP>/L monocytosis in the absence of infection, cytokine treatment, or other reactive causes.<br />¥ MPN-SAF TSS validation among patients with MDS/MPN is currently under way (RA Mesa, personal communication, 2014).</div><div class=\"graphic_reference\">This research was originally published in Blood. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 2015; 125:1857. Copyright &copy; 2015 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 100626 Version 1.0</div></div></div>"},"100627":{"type":"graphic_table","displayName":"Criteria for disease progression in MDS/MPN","title":"Proposed criteria for measurement of disease progression in adults with chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed criteria for measurement of disease progression in adults with chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative&nbsp;neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Combination of two major criteria, one major and two minor criteria, or three minor criteria from list</strong></td> </tr> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\">Increase in blast count*</td> </tr> <tr> <td class=\"indent2\">&#60;5% blasts: &#8805;50% increase and to &#62;5% blasts</td> </tr> <tr> <td class=\"indent2\">5 to 10% blasts: &#8805;50% increase and to &#62;10% blasts</td> </tr> <tr> <td class=\"indent2\">10 to 20% blasts: &#8805;50% increase and to &#62;20% blasts</td> </tr> <tr> <td class=\"indent2\">20 to 30% blasts: &#8805;50% increase and to &#62;30% blasts<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Evidence of cytogenetic evolution<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Appearance of a previously present or new cytogenetic abnormality in complete cytogenetic remission via FISH or classic karyotyping</td> </tr> <tr> <td class=\"indent2\">Increase in cytogenetic burden of disease by &#8805;50% in partial cytogenetic remission via FISH or classic karyotyping</td> </tr> <tr> <td class=\"indent1\">New extramedullary disease</td> </tr> <tr> <td class=\"indent2\">Worsening splenomegaly</td> </tr> <tr> <td class=\"indent3\">Progressive splenomegaly that is defined by IWG-MRT: The appearance of a previously absent splenomegaly that is palpable at &#62;5 cm below the left costal margin or a minimum 100% increase in palpable distance for baseline splenomegaly of 5 to 10 cm or a minimum 50% increase in palpable distance for baseline splenomegaly of &#62;10 cm</td> </tr> <tr> <td class=\"indent2\">Extramedullary disease outside of the spleen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">To include new/worsening hepatomegaly, granulocytic sarcoma, skin lesions, etc</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Transfusion dependence<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Significant loss of maximal response on cytopenias &#8805;50% decrement from maximum remission/response in granulocytes or platelets</td> </tr> <tr> <td class=\"indent1\">Reduction in Hgb by &#8805;1.5 g/dL from best response or from baseline as noted on complete blood count</td> </tr> <tr> <td class=\"indent1\">Increasing symptoms as noted by increase in &#8805;50% as per the MPN-SAF TSS<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Evidence of clonal evolution (molecular)<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table describes uniform criteria proposed by an international consortium to be used in clinical trials for the measurement of disease progression in adults with&nbsp;chronic myelomonocytic leukemia&nbsp;and other myelodysplastic/myeloproliferative disorders. </div><div class=\"graphic_footnotes\">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; IWG-MRT: International Working&nbsp;Group for Myelofibrosis Research and Treatment; FISH: fluorescence in situ hybridization; Hgb: hemoglobin; MPN-SAF TSS:&nbsp;Myeloproliferative Neoplasm Symptom Assessment Form&nbsp;total symptom score.<br />* Blasts as measured from the bone marrow.<br />¶ Patients with development of acute myeloid leukemia from MDS/MPN; 20 to 30% blasts may be allowed on some clinical trials for patients with MDS/MPN.<br />Δ Increase in cytogenetic burden of disease by ≥50% (via FISH or classic karyotyping). Given variability of fluorescent probes used in FISH, cytogenetic normalization via FISH will depend on specific probes used.<br /><FONT class=lozenge>◊</FONT> Transfusion dependency is defined by a history of at least 2 units of red blood cell transfusions in the past month for a hemoglobin level &lt;8.5 g/dL that was not associated with clinically overt bleeding. Cytopenias resulting from therapy should not be considered in assessment of progression.<br />§ MPN-SAF TSS validation among patients with MDS/MPN is currently under way (RA Mesa, personal communication, 2014).<br />¥ The identification of new abnormalities using single nucleotide polymorphism arrays or sequencing or a clearly significant increase in mutational burden of a previously detected abnormality. Precise criteria for defining new abnormalities and what exactly constitutes a significant increase in mutational burden are open to interpretation; we suggest that this criterion should be used conservatively based on current evidence.</div><div class=\"graphic_reference\">This research was originally published in Blood. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 2015; 125:1857. Copyright &copy; 2015 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 100627 Version 1.0</div></div></div>"},"100630":{"type":"graphic_table","displayName":"Exacerbating factors for RLS","title":"Exacerbating factors for restless legs syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exacerbating factors for restless legs syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Known</td> </tr> <tr> <td class=\"indent1\">Iron deficiency</td> </tr> <tr> <td class=\"indent1\">Prolonged immobility (airplane, car, etc)</td> </tr> <tr> <td class=\"indent1\">Serotonergic antidepressants</td> </tr> <tr> <td class=\"indent1\">Renal failure</td> </tr> <tr> <td class=\"subtitle1_single\">Suspected</td> </tr> <tr> <td class=\"indent1\">Sedating antihistamines</td> </tr> <tr> <td class=\"indent1\">Dopamine antagonists (antiemetics, antipsychotics)</td> </tr> <tr> <td class=\"indent1\">Sleep deprivation</td> </tr> <tr> <td class=\"indent1\">Sleep apnea</td> </tr> <tr> <td class=\"indent1\">Hypoxia</td> </tr> <tr> <td class=\"indent1\">Caffeine</td> </tr> <tr> <td class=\"indent1\">Tobacco</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Pain</td> </tr> <tr> <td class=\"indent1\">Peripheral neuropathy</td> </tr> <tr> <td class=\"indent1\">Radiculopathy</td> </tr> <tr> <td class=\"indent1\">Venous insufficiency</td> </tr> <tr> <td class=\"indent1\">Inflammatory/immunological conditions</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev 2015; 22:64. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100630 Version 3.0</div></div></div>"},"100632":{"type":"graphic_figure","displayName":"Congenital anomalies in Hirschsprung disease","title":"Frequency of congenital anomalies in Hirschsprung disease","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Frequency of congenital anomalies in Hirschsprung disease</div><div class=\"cntnt\"><img style=\"width:511px; height:492px;\" src=\"images/PEDS/100632_Cngntl_anml_Hrschsprng_dss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from a study of 106 patients with Hirschsprung disease who underwent systematic screening for congenital anomalies. Syndromic HD represented 9.4 percent&nbsp;of patients, and included Down Syndrome (6.6 percent&nbsp;of all patients), Turner, cat-eye, and congenital central hypoventilation syndromes.</div><div class=\"graphic_footnotes\">HD: Hirschsprung disease; CAKUT: congenital anomalies of the kidney and urinary tract; CNS: central nervous system.<br />* Ophthalmologic abnormalities were mostly refractive errors (hyperopia, astigmatism, or myopia), strabismus, or amblyopia. No major ocular anomalies were detected. Visual impairment was present in 9.4 percent.<br />¶ CNS anomalies included agenesis of the corpus callosum; no other major brain abnormalities were detected. <br />Δ Other anomalies included metabolic issues (growth hormone deficiency, hypothyroidism, or precocious puberty), gastrointestinal anomalies (atresia, pancreas anularis or malrotation), familial medullary thyroid carcinoma, cryptorchidism, epilepsy, and cleft palate.</div><div class=\"graphic_reference\">Data from Pini Prato A, Rossi V, Mosconi M, et al. A prospective observational study of associated anomalies in Hirschsprung's disease. Orphanet Journal of Rare Diseases. 2013; 8:184.</div><div id=\"graphicVersion\">Graphic 100632 Version 1.0</div></div></div>"},"100633":{"type":"graphic_algorithm","displayName":"Prenatal screening for hemoglobinopathies","title":"Prenatal screening for hemoglobinopathies","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Prenatal screening for hemoglobinopathies</div><div class=\"cntnt\"><img style=\"width:707px; height:464px;\" src=\"images/OBGYN/100633_Prntl_scrn_hmglbnpth.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HPLC: high performance liquid chromatography; CBC: complete blood count; Hb: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin.<br />* Whether screening for hemoglobinopathy should be performed routinely or targeted to populations at increased risk is controversial. Given the increasingly diverse ethnic and geographic distribution of hemoglobinopathy genotypes in the United States and elsewhere, risk assessment based on race and ethnic origin alone may not be reliable.<br />¶ If MCV &lt;80 fL and/or MCH &lt;27 pg, iron deficiency must be excluded (eg, ferritin level) because it can mask beta-thalassemia trait. The diagnosis heterozygous beta-thalassemia is based on an increased HbA2 level; individuals with beta-thalassemia and concomitant iron deficiency can have a normal rather than increased HbA2 level.<br />Δ If other hemoglobin variants are detected, consult a hematologist.<br /><FONT class=lozenge>◊</FONT> CBC and hemoglobin analysis will not identify alpha thalassemia minima (ie, silent carrier with loss of one of the four alpha globin genes), which can only be identified by DNA analysis. If the mother is a silent carrier and the father has cis alpha thalassemia trait (loss of two alpha globin genes on the same chromosome), or vice versa, their child has a one in four chance of HbH disease (ie, loss of three of the four alpha globin genes). Fetuses with HbH disease have hemolytic anemia and are symptomatic at birth, often presenting with neonatal jaundice and anemia, and occasionally with hydrops fetalis. Most affected individuals do not require chronic transfusion support during the first decade of life, but splenectomy or transfusion support during the second or third decade of life is often necessary. Iron overload due to increased iron absorption is also a significant issue.</div><div id=\"graphicVersion\">Graphic 100633 Version 2.0</div></div></div>"},"100634":{"type":"graphic_picture","displayName":"Mycosis fungoides in axilla","title":"Mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100634_Mycosis_fungoides_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patch with fine scale in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100634 Version 1.0</div></div></div>"},"100635":{"type":"graphic_diagnosticimage","displayName":"PET CT scan of GCA patient with aortic involvement","title":"PET CT scan of GCA patient with aortic involvement","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">PET CT scan of GCA patient with aortic involvement</div><div class=\"cntnt\"><img style=\"width:472px; height:351px;\" src=\"images/RHEUM/100635_PET_CT_scn_GCA_artc_invlv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PET CT scan of a patient with biopsy-proven GCA, showing increased FDG uptake in the walls of the ascending and descending aorta.</div><div class=\"graphic_footnotes\">PET: positron emission tomography; CT: computed tomography; GCA: giant cell arteritis; FDG: fluorodeoxyglucose.</div><div class=\"graphic_reference\">From: Docken WP. Two inflammatory conditions—polymyalgia rheumatica and giant cell arteritis-share clinical connection. The Rheumatologist 2013. <A spellcheck=true href=\"http://www.the-rheumatologist.org/article/two-inflammatory-conditionspolymyalgia-rheumatica-and-giant-cell-arteritisshare-clinical-connection/\" target=_blank>http://www.the-rheumatologist.org/article/two-inflammatory-conditionspolymyalgia-rheumatica-and-giant-cell-arteritisshare-clinical-connection/</A>. Copyright © 2013 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 100635 Version 1.0</div></div></div>"},"100637":{"type":"graphic_table","displayName":"PHQ-4 for anxiety and depression","title":"Four-item Patient Health Questionnaire (PHQ-4) for anxiety and depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Four-item Patient Health Questionnaire (PHQ-4) for anxiety and depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Over the <em>last&nbsp;two weeks</em>, how often have you been bothered by the following problems?</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">Several days</td> <td class=\"subtitle1\">More than half the days</td> <td class=\"subtitle1\">Nearly every day</td> </tr> <tr> <td>Feeling nervous, anxious or on edge</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td>Not being able to stop or control worrying</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td>Feeling down, depressed or hopeless</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td>Little interest or pleasure in doing things</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total score &ge; 3 for first two questions suggests anxiety.<br />Total score &ge; 3 for last two questions suggests depression.</div><div class=\"graphic_reference\">Reproduced from: Kroenke K, Spitzer RL, Williams JB, L&ouml;we B. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics 2009; 50:613. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100637 Version 2.0</div></div></div>"},"100638":{"type":"graphic_figure","displayName":"Methods for detecting RBC agglutination","title":"Methods for detecting RBC agglutination","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Methods for detecting RBC agglutination</div><div class=\"cntnt\"><img style=\"width:522px; height:681px;\" src=\"images/HEME/100638_Agglutination_methods.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Agglutination can be scored by various methods; the degree of agglutination generally correlates with the concentration of the anti-RBC antibody. (A) In the tube method, agglutination is assessed following resuspension of RBCs and is graded according to a visual scale, with complete resuspension of cells (no agglutination) scored as \"0\" and complete lack of resuspension (greatest agglutination) scored as \"4\". (B) In the solid phase method, patient plasma and indicator RBCs are added to a microwell plate that is pre-coated with RBC membranes containing antigen. Greater adhesion along the entire well correlates with greater agglutination. (C) In the column method, agglutinated cells are retained in the column, whereas unagglutinated cells pellet at the bottom of the tube. Results can be read by an automated system. Refer to UpToDate topics on pretransfusion testing for further information.</div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div id=\"graphicVersion\">Graphic 100638 Version 2.0</div></div></div>"},"100639":{"type":"graphic_figure","displayName":"Direct and indirect antiglobulin (Coombs) testing","title":"Direct and indirect antiglobulin (Coombs) testing","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Direct and indirect antiglobulin (Coombs) testing</div><div class=\"cntnt\"><img style=\"width:510px; height:514px;\" src=\"images/HEME/100639_Coombs_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The direct antiglobulin (Coombs) test (DAT)&nbsp;is performed&nbsp;by adding&nbsp;anti-human globulin (green)&nbsp;to patient RBCs. The indirect Coombs test is performed by adding patient plasma to test RBCs followed by the addition of anti-human globulin. Agglutination occurs when an antibody&nbsp;on patient&nbsp;RBCs or in patient plasma&nbsp;(blue)&nbsp;binds to a RBC antigen and&nbsp;is crosslinked by the anti-human globulin. Refer&nbsp;to UpToDate topics on pretransfusion testing and immune hemolytic anemia&nbsp;regarding uses of these tests.</div><div class=\"graphic_footnotes\">RBCs: red blood cells.</div><div id=\"graphicVersion\">Graphic 100639 Version 2.0</div></div></div>"},"100666":{"type":"graphic_table","displayName":"Stool tests C. difficile","title":"Summary of stool tests for <em>Clostridium difficile</em>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of stool tests for <em>Clostridium difficile</em></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Sensitivity and specificity</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rapid tests for organism* (results available in one to four hours)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">NAAT (PCR&nbsp;or loop-mediated isothermal amplification)&nbsp;</td> <td> <p><span style=\"color: black;\">Sensitivity: 95%</span></p> <p><span style=\"color: black;\">Specificity: &#62;97%</span></p> </td> <td> <ul> <li>Expensive </li> <li>Requires trained personnel </li> <li>May be used as standalone test </li> <li>Cannot distinguish between asymptomatic carriage, active infection, or previous infection </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">EIA for GDH antigen&nbsp;</td> <td> <p><span style=\"color: black;\">Sensitivity: 90%</span></p> <p><span style=\"color: black;\">Specificity: 94%</span></p> </td> <td> <ul> <li>Inexpensive </li> <li>Cannot distinguish toxigenic from non-toxigenic strains </li> <li>Must be used in multi-step algorithms </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rapid test for toxins* (results available in one to four hours)</td> </tr> <tr> <td class=\"indent1\">EIA for toxins A and/or B</td> <td> <p><span style=\"color: black;\">Sensitivity: 70%</span></p> <span style=\"color: black;\">Specificity: 98%</span></td> <td> <ul> <li>Inexpensive </li> <li>Not recommended for standalone test but used in multistep algorithms </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sample multi-step algorithms<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">EIA for GDH followed by NAAT</td> <td> <p>Sensitivity: 91 to 98%</p> Specificity: 96 to 98%</td> <td> <ul> <li>NAAT is performed only if GDH is positive </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">EIA for GDH followed by EIA for toxins A and B</td> <td> <p>Sensitivity: 58 to 84%</p> Specificity: &#62;99%</td> <td> <ul> <li>Toxin EIA is performed only if GDH is positive </li> <li>If GDH is positive and toxin EIA is negative, specimens should be further tested by NAAT </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Traditional reference standards (results available in&nbsp;two to&nbsp;five&nbsp;days)</td> </tr> <tr> <td class=\"indent1\">Toxigenic culture</td> <td>Reference standard for detecting toxigenic <em>C. difficile</em></td> <td> <ul> <li>Selective anaerobic culture with toxin testing of <em>C. difficile</em> organisms isolated </li> <li>Labor intensive </li> <li>Permits molecular typing and susceptibility testing </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Cell culture cytotoxicity assay</td> <td>Reference standard for detecting <em>C. difficile</em> toxins</td> <td> <ul> <li>Labor intensive </li> <li>Requires trained personnel </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EIA: enzyme immunoassay; GDH: glutamate dehydrogenase; NAAT: nucleic acid amplification test; PCR: polymerase chain reaction.<br />* Sensitivity and specificity data from Butler M, et al.<br />¶ Sensitivity and specificity data from Planche TD, et al.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Society for Microbiology. A practical guidance document for the laboratory detection of toxigenic <EM>Clostridium difficile</EM>. September 21, 2010. Available at: <A spellcheck=true href=\"http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf\" target=_blank>www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf</A> (Accessed on April 7, 2015).</LI>&#xD;&#xA;<LI>Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015; 313:398. </LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Butler M, Olson A, Drekonja D, et al. Early diagnosis, prevention, and treatment of Clostridium difficile: Update. Comparative Effectiveness Review No. 172. Agency for Healthcare Research and Quality, Rockville, MD. March 2016.&nbsp;<A spellcheck=true href=\"https://effectivehealthcare.ahrq.gov/topics/c-difficile-update/research\" target=_blank>https://effectivehealthcare.ahrq.gov/topics/c-difficile-update/research</A> (Accessed on February 16, 2018).</SPAN>&nbsp;</LI>&#xD;&#xA;<LI>Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013; 13:936. </LI>&#xD;&#xA;<LI>Tamma PD, Sandora TJ. Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc 2012; 1:230. </LI></OL></div><div id=\"graphicVersion\">Graphic 100666 Version 2.0</div></div></div>"},"100667":{"type":"graphic_figure","displayName":"CMT facial asymmetry","title":"Craniofacial asymmetry associated with torticollis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Craniofacial asymmetry associated with torticollis</div><div class=\"cntnt\"><img style=\"width:526px; height:330px;\" src=\"images/PEDS/100667_CMT_facial_asymmetry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Schematic diagram of potential skeletal changes with persistent torticollis, including decreased ramal height, recession of the zygoma, and changes in the orbit on the affected side (right). <br />(B) Schematic diagram of potential facial changes with persistent torticollis, including recession of the ear and narrowing of the palpebral fissure on the affected (right) side, with associated asymmetry of the nose and commissures.</div><div class=\"graphic_reference\">Adapted from: Hollier L, Kim J, Grayson BH, McCarthy JG. Congenital muscular torticollis and the associated craniofacial changes. Plast Reconstr Surg 2000; 105:827.</div><div id=\"graphicVersion\">Graphic 100667 Version 1.0</div></div></div>"},"100668":{"type":"graphic_figure","displayName":"Cervical rotation range of motion","title":"Assessment of passive cervical rotation in congenital muscular torticollis","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Assessment of passive cervical rotation in congenital muscular torticollis</div><div class=\"cntnt\"><img style=\"width:489px; height:350px;\" src=\"images/PEDS/100668_Cervical_rotation_range_of_motion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Passive cervical range of motion is measured from the midline. In infants, the normal range of passive cervical rotation is past the shoulder (ie, &gt;90 to 120°). </div><div id=\"graphicVersion\">Graphic 100668 Version 1.0</div></div></div>"},"100669":{"type":"graphic_figure","displayName":"Plagiocephaly variations","title":"Types of plagiocephaly","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Types of plagiocephaly</div><div class=\"cntnt\"><img style=\"width:466px; height:350px;\" src=\"images/PEDS/100669_Plagiocephaly_variations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plagiocephaly is best viewed from the top of the child's head. Anterior plagiocephaly is caused by unilateral craniosynostosis (premature fusion) of the coronal suture. Posterior plagiocephaly is caused by unilateral craniosynostosis of the lambdoid suture. Deformational plagiocephaly is caused by positional deformation, which is associated with congenital torticollis.</div><div id=\"graphicVersion\">Graphic 100669 Version 1.0</div></div></div>"},"100700":{"type":"graphic_table","displayName":"Meds seasonal allergies PI","title":"Medications commonly used for seasonal allergies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications commonly used for seasonal allergies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Medications and sample US brand name(s)</td> <td class=\"subtitle1\">Prescription required or available over-the-counter (OTC) in the US?</td> </tr> <tr> <td>Nasal steroid sprays</td> <td>Over-the-counter: <ul class=\"decimal_heading\"> <li>Budesonide (Rhinocort Allergy)&nbsp; </li> <li>Fluticasone furoate (Flonase Sensimist) </li> <li>Fluticasone propionate (Flonase Allergy Relief, GoodSense Nasoflow) </li> <li>Triamcinolone (GoodSense Nasal Allergy, Nasacort Allergy 24 hour, Nasal Allergy 24 Hour) </li> </ul> Prescription: <ul class=\"decimal_heading\"> <li>Beclomethasone (Beconase AQ, Qnasl) </li> <li>Ciclesonide (Omnaris, Zetonna) </li> <li>Flunisolide (generic) </li> <li>Fluticasone propionate (Ticaspray and generic versions) </li> <li>Mometasone (Nasonex and generic versions) </li> <li>Triamcinolone (generic) </li> </ul> </td> <td>Some prescription, some OTC</td> </tr> <tr> <td>Less-sedating oral antihistamine pills</td> <td>Over-the-counter: <ul class=\"decimal_heading\"> <li>Cetirizine (ZyrTEC, others) </li> <li>Fexofenadine (Allegra, others) </li> <li>Loratadine (Claritin, Alavert, others) </li> </ul> Prescription: <ul class=\"decimal_heading\"> <li>Desloratadine (Clarinex) </li> <li>Levocetirizine (Xyzal) </li> </ul> </td> <td>Some prescription, some OTC</td> </tr> <tr> <td>Sedating oral antihistamine pills*</td> <td> <ul> <li>Brompheniramine </li> <li>Chlorpheniramine (Chlor-Trimeton, others) </li> <li>Clemastine (Tavist, others) </li> <li>Diphenhydramine (Benadryl, others) </li> </ul> </td> <td>OTC</td> </tr> <tr> <td>Nasal antihistamine sprays</td> <td> <ul> <li>Azelastine (Astelin, Astepro) </li> <li>Olopatadine (Patanase) </li> </ul> </td> <td>Prescription</td> </tr> <tr> <td>Nasal steroid/antihistamine combination spray</td> <td> <ul> <li>Fluticasone and azelastine (Dymista, Ticalast) </li> </ul> </td> <td>Prescription</td> </tr> <tr> <td>Oral decongestant/antihistamine combination pills&#182;</td> <td> <ul> <li>Brompheniramine-pseudoephedrine (Brotapp, Rynex PSE, others) </li> <li>Cetirizine-pseudoephedrine (ZyrTEC-D Allergy &#38; Congestion, others) </li> <li>Chlorpheniramine-pseudoephedrine (SudoGest, others) </li> <li>Fexofenadine-pseudoephedrine (Allegra-D,&nbsp;others) </li> <li>Loratadine-pseudoephedrine (Claritin-D, Alavert Allergy and Sinus, others) </li> </ul> </td> <td>OTC</td> </tr> <tr> <td>Nasal cromolyn spray</td> <td> <ul> <li>Cromolyn (Nasalcrom and generic versions) </li> </ul> </td> <td>OTC</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">OTC: Over-the-counter means that you do not need a doctor's prescription to buy these.&nbsp;OTC medicines can be sold under many different brand names and store brands. Always read the generic names on the label of your OTC medicines to be sure you are not taking more than one product that has the same medicine in it. Taking too much of the same medicine can be harmful. If you are also taking other medicines or have health problems, check with your doctor to be sure OTC medicines are safe for you to use. Many medicines that used to be available by prescription only are becoming available over-the-counter.</div><div class=\"graphic_footnotes\">* These medications often cause sedation and should not be used before driving or operating machinery. The less-sedating oral antihistamines are often a better choice since they don't cause impairment.<br />&para; Pseudoephedrine should <strong>not </strong>be used in children, older adults, or people with certain medical problems (such as high blood pressure, heart disease, stroke, or trouble urinating due to an enlarged prostate). Talk to your doctor before using pseudoephedrine. Many OTC decongestants contain phenylephrine rather than pseudoephedrine. We do not recommend phenylephrine for seasonal allergies because it does not work well.</div><div id=\"graphicVersion\">Graphic 100700 Version 10.0</div></div></div>"},"100701":{"type":"graphic_algorithm","displayName":"The ATS approach to managing conscientious objections in the ICU","title":"The American Thoracic Society (ATS) approach to managing conscientious objections in the ICU, based on a clinician's belief that a requested medical service is medically inappropriate or futile","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">The American Thoracic Society (ATS) approach to managing conscientious objections in the ICU, based on a clinician's belief that a requested medical service is medically inappropriate or futile</div><div class=\"cntnt\"><img style=\"width:536px; height:558px;\" src=\"images/PALC/100701_ATS_manag_conscient_obj_ICU.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An approach to managing conscientious objections based on a clinician's belief that a requested medical service is medically inappropriate or futile.</div><div class=\"graphic_footnotes\">CO: conscientious objections; ICU: intensive care unit.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Medical futility in end-of-life care: report of the Council on Ethical and Judicial Affairs. JAMA 1999; 281:937.</li>&#xD;&#xA;    <li>Consensus statement of the Society of Critical Care Medicine's Ethics Committee regarding futile and other possibly inadvisable treatments. Crit Care Med 1997; 25:887.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. Lewis-Newby M, Wicclair M, Pope T, et al. An Official American Thoracic Society Policy Statement: Managing Conscientious Objections in Intensive Care Medicine. Am J Respir Crit Care Med 2015; 191:219. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 100701 Version 1.0</div></div></div>"},"100702":{"type":"graphic_figure","displayName":"Iron deficiency and IDA in the US population","title":"Prevalence of iron deficiency and iron deficiency anemia in the US population, 2000","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Prevalence of iron deficiency and iron deficiency anemia in the US population, 2000</div><div class=\"cntnt\"><img style=\"width:652px; height:494px;\" src=\"images/PEDS/100702_Iron_deficiency_IDA_US_pop.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The prevalence of iron deficiency anemia is less than 1 percent in children 3 to 11 years of age.<sup>[1]</sup></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Recommendations to Prevent and Control Iron Deficiency in the United States. MMWR 1998; 47 (No. RR-3).</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from: Centers for Disease Control and Prevention (CDC). Iron deficiency--United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2002; 51:897.</div><div id=\"graphicVersion\">Graphic 100702 Version 2.0</div></div></div>"},"100704":{"type":"graphic_figure","displayName":"Anemia in preschool aged children by country","title":"Anemia as a public health problem in preschool aged children, by country","html":"<div class=\"graphic\"><div style=\"width: 825px\" class=\"figure\"><div class=\"ttl\">Anemia as a public health problem in preschool aged children, by country</div><div class=\"cntnt\"><img style=\"width:805px; height:505px;\" src=\"images/PEDS/100704_Anm_prschl_age_chld_cntry.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted from the World Health Organization, DeBenoist, B, McLean, E, Egli, I, et al, Worldwide prevalence of anemia 1993-2005: WHO global database on anemia, Copyright &copy; 2008 World Health Organization.</div><div id=\"graphicVersion\">Graphic 100704 Version 1.0</div></div></div>"},"100705":{"type":"graphic_table","displayName":"Severity C. difficile children","title":"Suggested classification of <EM>Clostridium difficile</EM> infection in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested classification of <EM>Clostridium difficile</EM> infection in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> <td class=\"subtitle1\">Fulminant</td> </tr> <tr> <td> <ul> <li>Afebrile </li> <li>Diarrhea (without systemic findings) </li> </ul> </td> <td> <ul> <li>Fever </li> <li>Profuse diarrhea </li> <li>Abdominal pain </li> </ul> </td> <td> <ul> <li>Fever </li> <li>Profuse diarrhea </li> <li>Abdominal pain and &nbsp;tenderness </li> <li>Abdominal distention </li> <li>Leukocytosis (white blood cells &#62;15,000 cells/microL) </li> <li>Elevated age-adjusted creatinine level </li> <li>Serum albumin &#60;2.5 g/dL </li> <li>Pseudomembranous colitis </li> </ul> </td> <td> <ul> <li>Hypotension </li> <li>Shock </li> <li>Ileus </li> <li>Toxic megacolon </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There is no consensus definition of severe <em>C. difficile</em> infection in children. Determination of disease severity should be guided by clinician judgment.</div><div id=\"graphicVersion\">Graphic 100705 Version 3.0</div></div></div>"},"100706":{"type":"graphic_picture","displayName":"Capnocytophaga blood smear Giemsa stain","title":"<em>Capnocytophaga</em>: Giemsa stain of peripheral blood smear","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\"><em>Capnocytophaga</em>: Giemsa stain of peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:784px; height:579px;\" src=\"images/ID/100706_Cpncytphg_bld_smr_gms_stn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Giemsa stain of peripheral blood smear showing rod-shaped bacteria within polymorphonuclear leukocytes.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Eefting M, Paardenkooper T. Capnocytophaga canimorsus sepsis. Blood 2010; 116:1396; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 100706 Version 5.0</div></div></div>"},"100710":{"type":"graphic_diagnosticimage","displayName":"CTA of renal artery stenosis","title":"Renal artery stenosis on CTA","html":"<div class=\"graphic\"><div style=\"width: 831px\" class=\"figure\"><div class=\"ttl\">Renal artery stenosis on CTA</div><div class=\"cntnt\"><img style=\"width:811px; height:474px;\" src=\"images/RADIOL/100710_CTA_renal_artery_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CTA projected in the coronal plain (A) shows a moderately high grade stenosis of the left renal artery (arrow). Image B is an axial CT scan through the kidneys of a second patient and shows a moderate stenosis of the left renal artery (arrow), a small left kidney with a thin cortex (arrowhead), and a small left accessory renal artery (dashed arrow).</div><div class=\"graphic_footnotes\">CTA: computed tomography angiography.</div><div id=\"graphicVersion\">Graphic 100710 Version 1.0</div></div></div>"},"100711":{"type":"graphic_diagnosticimage","displayName":"MRA of high grade renal artery stenosis","title":"Renal artery stenosis on MRA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal artery stenosis on MRA</div><div class=\"cntnt\"><img style=\"width:346px; height:504px;\" src=\"images/RADIOL/100711_MRA_hgh_grd_rnl_artry_stns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An MRA shows severe left RAS (arrow) and atherosclerotic infrarenal aneurysm and diffuse atherosclerosis of the aorto-iliac system. An accessory right renal artery is of incidental note (dashed arrow).</div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiography.</div><div id=\"graphicVersion\">Graphic 100711 Version 1.0</div></div></div>"},"100713":{"type":"graphic_diagnosticimage","displayName":"MRI of optic pathway glioma","title":"Optic pathway glioma on MRI","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Optic pathway glioma on MRI</div><div class=\"cntnt\"><img style=\"width:797px; height:279px;\" src=\"images/RADIOL/100713_MRI_optic_pthwy_glioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial T2 weighted MRI (A) and coronal T2 weighted image (B) show diffuse high signal intensity of a large left intra-orbital optic nerve glioma (arrow). An Axial T1 weighted image following gadolinium (C) shows diffuse, intense enhancement of the tumor (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Caroline Robson, MBChB.</div><div id=\"graphicVersion\">Graphic 100713 Version 1.0</div></div></div>"},"100714":{"type":"graphic_diagnosticimage","displayName":"Diffuse intrinsic pontine glioma","title":"CT and MRI appearance of diffuse intrinsic pontine glioma","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">CT and MRI appearance of diffuse intrinsic pontine glioma</div><div class=\"cntnt\"><img style=\"width:787px; height:279px;\" src=\"images/RADIOL/100714_CT_dffs_infiltrat_pntn_glm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial unenhanced CT of the brain (A) shows diffuse, symmetric low attenuation expansion of the pons (arrows). There is mass effect on the ventral aspect of the fourth ventricle (arrowhead). An axial T2-weighted image (B) reveals a large pontine mass associated with diffuse high signal intensity (arrows). An area of signal heterogeneity within the tumor likely reflects necrosis (dashed arrow). A sagittal Gd-enhanced T1-weighted image (C) shows non-enhancement of the central necrotic region (asterisk), enhancement of the region surrounding the necrosis (arrow), and non-enhancement of the rest of the tumor (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computerized tomography; MRI: magnetic resonance imaging; Gd: gadolinium.</div><div class=\"graphic_reference\">Courtesy of Caroline Robson, MBChB.</div><div id=\"graphicVersion\">Graphic 100714 Version 2.0</div></div></div>"},"100715":{"type":"graphic_picture","displayName":"External lag test for rotator cuff tear","title":"External lag test for rotator cuff tear","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">External lag test for rotator cuff tear</div><div class=\"cntnt\"><img style=\"width:566px; height:716px;\" src=\"images/EM/100715_Extrnl_lag_tst_rttr_cff_tr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the external lag test, the clinician places the patient's shoulder - using passive motion - in a position of full external rotation (pictured above), and then asks the patient to maintain this position actively. The difference between the two is the lag.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 100715 Version 1.0</div></div></div>"},"100716":{"type":"graphic_picture","displayName":"Internal lag test for rotator cuff tear","title":"Internal lag test for rotator cuff tear","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Internal lag test for rotator cuff tear</div><div class=\"cntnt\"><img style=\"width:481px; height:721px;\" src=\"images/EM/100716_Intrnl_lag_tst_rttr_cff_tr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform the internal lag test, the clinician places the patient's shoulder - using passive motion - in a position of full internal rotation (pictured above), and then asks the patient to maintain this position actively. The difference between the two is the lag.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD.</div><div id=\"graphicVersion\">Graphic 100716 Version 1.0</div></div></div>"},"100717":{"type":"graphic_picture","displayName":"Windup phase of throwing","title":"Windup phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Windup phase of throwing</div><div class=\"cntnt\"><img style=\"width:712px; height:598px;\" src=\"images/EM/100717_Windup_phase_throwing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph shows a baseball pitcher in the windup phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 100717 Version 1.0</div></div></div>"},"100718":{"type":"graphic_picture","displayName":"Stride phase of throwing","title":"Stride phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Stride phase of throwing</div><div class=\"cntnt\"><img style=\"width:712px; height:559px;\" src=\"images/EM/100718_Stride_phase_throwing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a baseball pitcher in the stride (or early cocking) phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 100718 Version 1.0</div></div></div>"},"100719":{"type":"graphic_picture","displayName":"Cocking phase of throwing","title":"Cocking phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Cocking phase of throwing</div><div class=\"cntnt\"><img style=\"width:712px; height:489px;\" src=\"images/EM/100719_Cock_phase_throwing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a baseball pitcher in the cocking (or late cocking) phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 100719 Version 1.0</div></div></div>"},"100720":{"type":"graphic_picture","displayName":"Acceleration phase of throwing","title":"Acceleration phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Acceleration phase of throwing</div><div class=\"cntnt\"><img style=\"width:712px; height:484px;\" src=\"images/EM/100720_Acceleration_phase_throw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a baseball pitcher in the acceleration phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 100720 Version 1.0</div></div></div>"},"100721":{"type":"graphic_picture","displayName":"Follow-through phase of throwing","title":"Follow-through phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Follow-through phase of throwing</div><div class=\"cntnt\"><img style=\"width:648px; height:438px;\" src=\"images/EM/100721_Follow_through_phase_throw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a baseball pitcher in the follow-through phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 100721 Version 1.0</div></div></div>"},"100722":{"type":"graphic_table","displayName":"TMA syndromes and other systemic disorders","title":"TMA syndromes and other systemic disorders associated with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TMA syndromes and other systemic disorders associated with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Primary thrombotic microangiopathy (TMA) syndromes</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura (TTP)</td> <td> <p>May have severe neurologic abnormalities.&nbsp;</p> <p>Inherited; may present in a newborn infant, a child with thrombocytopenia, or, less commonly, an adult. Among adults, a common presentation is during a first pregnancy.</p> Acquired autoimmune: Uncommon in children.</td> <td> <p>Severe MAHA and&nbsp;thrombocytopenia; acute kidney injury is rare.</p> <p>Severe deficiency of ADAMTS13 (activity &#60;10%). Acquired cases often have a detectable ADAMTS13 inhibitor (autoantibody).</p> <p>Inherited TTP has <em>ADAMTS13</em> gene mutation.</p> </td> </tr> <tr> <td class=\"indent1\">Complement-mediated TMA</td> <td> <p>Inherited and acquired disorders may present in children or adults. </p> </td> <td> <p>Renal failure is prominent. </p> <p>Inherited disorders usually have a heterozygous mutation in a gene encoding a regulatory protein in the alternate complement pathway (eg, <em>CFH</em>, <em>CFI</em>, <em>CD46/MCP</em>, <em>C3</em>, <em>CFB, CFHRs</em>). </p> <p>Acquired disorder has antibodies to complement factor H or I.</p> </td> </tr> <tr> <td class=\"indent1\">Shiga toxin-mediated hemolytic uremic syndrome (ST-HUS)</td> <td>Abdominal pain; diarrhea (often bloody); possible history of outbreak or exposure to livestock or&nbsp;contaminated food, although most cases are sporadic.</td> <td>Renal failure is prominent. Stool may be positive for the organism (<em>Escherichia coli</em> or <em>Shigella dysenteriae</em>) or Shiga toxin.</td> </tr> <tr> <td class=\"indent1\">Drug-induced TMA</td> <td>History of exposure to quinine or other&nbsp;implicated medication. Immune-mediated forms have an abrupt onset with fever, chills, abdominal pain, nausea, anuric acute kidney injury. Toxic, dose-related etiologies may arise gradually, or onset may be sudden with an intravenous toxic agent (eg, Opana-ER).</td> <td> <p>Immune mediated: Severe acute kidney injury; drug-dependent antibodies to platelets and/or neutrophils can be demonstrated.</p> <p>Toxic, dose related: May have gradual or sudden onset of renal failure and hypertension.</p> </td> </tr> <tr> <td class=\"indent1\">Coagulation-mediated TMA</td> <td>Inherited, typically presents in children &#60;1 year old.</td> <td><em>DGKE</em>, thrombomodulin, or plasminogen gene mutation.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Metabolism-mediated TMA</td> <td>Inherited, typically presents in children &#60;1 year old, but may also present in adults.</td> <td>Elevated serum&nbsp;homocysteine and methylmalonic acid, and&nbsp;low methionine levels; increased urinary methyl-malonic acid. <em>MMACHC</em> gene mutation.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Systemic disorders that may present with MAHA and thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation (DIC)</td> <td>May be caused by infection, malignancy, postpartum hemorrhage with hypotension, or a vascular abnormality such as a giant hemangioma (eg, Kasabach-Merritt syndrome).</td> <td>Thrombocytopenia, decreased fibrinogen, and elevated D-dimer are typical with acute or chronic DIC. MAHA may occur. Prolongation of the PT and aPTT are seen in acute DIC.</td> </tr> <tr> <td class=\"indent1\">Systemic infection</td> <td>May include bacterial, viral, rickettsial, or fungal organisms. High fever and shaking chills are common.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Systemic malignancy</td> <td>May occur with occult systemic malignancy. Breast, prostate, lung, pancreatic, or gastrointestinal tumors are often responsible.</td> <td>Depends on specific tumor.</td> </tr> <tr> <td class=\"indent1\">Pregnancy-related syndromes (eg, severe preeclampsia, HELLP)</td> <td>Typically present in third trimester or postpartum. Severe hypertension and liver involvement are often present. Abnormalities resolve with delivery.</td> <td>Elevated hepatic transaminases. Acute kidney injury is uncommon.</td> </tr> <tr> <td class=\"indent1\">Severe hypertension</td> <td>Typically, systolic BP &#62;200 mm Hg&nbsp;and diastolic BP &#62;100 mm Hg. Neurologic features including PRES may be present. Hypertension may also occur in primary TMAs with severe renal involvement, so the temporal relationship is important. Abnormalities resolve with control of the BP.</td> <td>Often associated with severe renal failure. Renal biopsy demonstrates TMA identical to the primary TMA syndromes.</td> </tr> <tr> <td class=\"indent1\">Systemic rheumatic diseases (eg, SLE, SSc, APS)</td> <td>SLE may be associated with hypertension, renal insufficiency, and autoimmune cytopenias. APS typically presents with arterial and/or venous thromboembolism but can also produce a TMA.</td> <td>Serologic testing may show autoantibodies characteristic of the underlying condition; APS may have prolonged aPTT. Renal biopsy may demonstrate TMA identical to the primary TMA syndromes.</td> </tr> <tr> <td class=\"indent1\">Hematopoietic cell transplant</td> <td>May occur&nbsp;with autologous or allogeneic transplant. May be associated with exposure to cytotoxic chemotherapy, radiation, systemic infection, or a calcineurin inhibitor.</td> <td>No specific findings.</td> </tr> <tr> <td class=\"indent1\">Solid organ transplant</td> <td>May be associated with calcineurin inhibitor administration. May be associated with infection such as CMV in the setting of immunosuppression. In patients receiving a kidney transplant for a primary TMA syndrome, the syndrome may recur in the transplanted kidney.</td> <td>Renal biopsy may have features of rejection.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Therapy for primary TMAs is directed at the underlying pathophysiology; therapy for other systemic disorders associated with MAHA and thrombocytopenia is focused on the underlying disorder. Refer to UpToDate topics on evaluating patients with suspected TMA and on specific syndromes for additional information on presentation/diagnosis and management.</div><div class=\"graphic_footnotes\">TMA: thrombotic microangiopathy; ADAMTS13: A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif, member 13; DGKE: diacylglycerol kinase epsilon; HELLP: hemolysis, elevated liver function tests, and low platelets; BP: blood pressure; PRES: posterior reversible encephalopathy; SLE: systemic lupus erythematosus; SSc: systemic sclerosis (scleroderma); APS: antiphospholipid syndrome; CMV: cytomegalovirus; PT: prothrombin time; aPTT: activated partial thromboplastin time.</div><div class=\"graphic_reference\">Modified from: George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Eng J Med 2014; 371:654.</div><div id=\"graphicVersion\">Graphic 100722 Version 5.0</div></div></div>"},"100723":{"type":"graphic_algorithm","displayName":"Likely causes of MAHA and thrombocytopenia","title":"Likely causes of microangiopathic hemolytic anemia and thrombocytopenia according to presenting findings","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Likely causes of microangiopathic hemolytic anemia and thrombocytopenia according to presenting findings</div><div class=\"cntnt\"><img style=\"width:716px; height:496px;\" src=\"images/HEME/100723_Causes_MAHA_thrmbcytpn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">No clinical finding is completely sensitive or specific for a specific primary TMA diagnosis. Refer to UpToDate content on the approach to the patient with a suspected thrombotic microangiopathy for further information and an approach to the diagnostic evaluation.</div><div class=\"graphic_footnotes\">TMA: thrombotic microangiopathy; MAHA: microangiopathic hemolytic anemia; DIC: disseminated intravascular coagulation; HELLP: hemolysis, elevated liver function tests, low platelets; HUS: hemolytic-uremic syndrome; TTP: thrombotic thrombocytopenic purpura.</div><div class=\"graphic_reference\">Modified from: George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Eng J Med 2014; 371:654.</div><div id=\"graphicVersion\">Graphic 100723 Version 3.0</div></div></div>"},"100724":{"type":"graphic_table","displayName":"Patient-centered clinically important outcomes","title":"Patient-centered clinically important outcomes with pharmacologic interventions for urgency urinary incontinence compared with placebo*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient-centered clinically important outcomes with pharmacologic interventions for urgency urinary incontinence compared with placebo*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Outcome and drug</td> <td class=\"subtitle1\">RCTs</td> <td class=\"subtitle1\">Patients in analyses (n)</td> <td class=\"subtitle1\">Rate in active treatment group (%)</td> <td class=\"subtitle1\">Rate in control group (%)</td> <td class=\"subtitle1\">Relative risk (95% CI)</td> <td class=\"subtitle1\">Absolute risk difference (95% CI)</td> <td class=\"subtitle1\">Strength of evidence</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Continence</td> </tr> <tr> <td class=\"indent1\">Fesoterodine</td> <td>2</td> <td>2465</td> <td>61</td> <td>48.5</td> <td>1.3 (1.1 to 1.5)</td> <td>0.13 (0.06 to 0.2)</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Oxybutynin</td> <td>4</td> <td>992</td> <td>27</td> <td>16</td> <td>1.7 (1.3 to 2.1)</td> <td>0.11 (0.06 to 0.16)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Solifenacin</td> <td>5</td> <td>6304</td> <td>39.2</td> <td>28.1</td> <td>1.5 (1.4 to 1.6)</td> <td>0.11 (0.06 to 0.16)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Tolterodine</td> <td>4</td> <td>3404</td> <td>53.2</td> <td>43.7</td> <td>1.2 (1.1 to 1.4)</td> <td>0.09 (0.04 to 0.13)</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trospium</td> <td>4</td> <td>2677</td> <td>28.3</td> <td>16.6</td> <td>1.7 (1.5 to 2)</td> <td>0.11 (0.08 to 0.14)</td> <td>High</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Clinically important improvement in incontinence</td> </tr> <tr> <td class=\"indent1\">Darifenacin</td> <td>3</td> <td>1011</td> <td>48.4</td> <td>33</td> <td>1.3 (1 to 1.5)</td> <td>0.12 (0.06 to 0.17)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Fesoterodine</td> <td>2</td> <td>1896</td> <td>42</td> <td>32</td> <td>1.3 (1.2 to 1.5)</td> <td>0.1 (0.06 to 0.15)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Oxybutynin</td> <td>9</td> <td>1244</td> <td>53</td> <td>32</td> <td>1.5 (1.2 to 1.9)</td> <td>0.17 (0.1 to 0.24)</td> <td>Moderate</td> </tr> <tr> <td class=\"indent1\">Solifenacin</td> <td>2</td> <td>1507</td> <td>60.2</td> <td>42</td> <td>1.5 (1 to 2.1)</td> <td>0.18 (0.1 to 0.26)</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">Tolterodine</td> <td>7</td> <td>6119</td> <td>45</td> <td>37</td> <td>1.3 (1.1 to 1.4)</td> <td>0.1 (0.04 to 0.15)</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Trospium</td> <td>2</td> <td>1176</td> <td>32.4</td> <td>25.4</td> <td>1.1 (0.6 to 2)</td> <td>0.08 (&ndash;0.1 to 0.25)</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RCT: randomized, controlled trial. <br />* Pooled with random effects estimates from randomized, controlled clinical trials.</div><div class=\"graphic_reference\">From<em> Annals of Internal Medicine</em>, Shamliyan T, Wyman JF, Ramakrishnan R, et al, Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review, 156, 861. Copyright &copy;2012 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 100724 Version 4.0</div></div></div>"},"100726":{"type":"graphic_figure","displayName":"Common postural malalignments","title":"Common postural malalignments","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Common postural malalignments</div><div class=\"cntnt\"><img style=\"width:501px; height:694px;\" src=\"images/EM/100726_Postural_alignments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior pelvic tilt&nbsp;is associated with a number of conditions&nbsp;including the pelvic cross syndrome,&nbsp;an abnormal condition associated with tight hip flexors, weak hip extensors and hamstrings, and sacroiliac dysfunction.&nbsp;An exaggerated posterior pelvic tilt with the buttocks appearing “tucked in” (ie, loss of normal gluteal contour) is associated with a number of conditions, including high grade spondylolisthesis.</div><div id=\"graphicVersion\">Graphic 100726 Version 2.0</div></div></div>"},"100727":{"type":"graphic_figure","displayName":"Adductor sports injuries","title":"Adductor sports injuries","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Adductor sports injuries</div><div class=\"cntnt\"><img style=\"width:504px; height:675px;\" src=\"images/EM/100727_Adductor_sports_injuries.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forced abduction of the hip that places an extreme stretch on the adductor muscles and tendons is one mechanism for acute adductor injury. This might occur while stretching for a return during tennis or performing a slide tackle in soccer.</div><div id=\"graphicVersion\">Graphic 100727 Version 1.0</div></div></div>"},"100729":{"type":"graphic_figure","displayName":"Rotator cuff tear classification","title":"Rotator cuff tear classification","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Rotator cuff tear classification</div><div class=\"cntnt\"><img style=\"width:531px; height:708px;\" src=\"images/EM/100729_Rotator_cuff_tears.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Classification from: Ellman H. Diagnosis and treatment of incomplete rotator cuff tears. Clin Orthop Relat Res 1990; 254:64.<br />Illustration modified from: Funk L. Partial thickness rotator cuff tears: Arthroscopic classification. Rotator cuff classifications. ShoulderDoc, 2015.</div><div id=\"graphicVersion\">Graphic 100729 Version 3.0</div></div></div>"},"100732":{"type":"graphic_table","displayName":"Immediate allergic reactions to drugs","title":"Immediate allergic reactions to drugs (IgE-mediated or non-IgE-mediated): Possible signs and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immediate allergic&nbsp;reactions to drugs&nbsp;(IgE-mediated or non-IgE-mediated): Possible signs and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Skin</strong></td> <td> <p>Warmth</p> <p>Flushing</p> <p>Itching*</p> <p>Urticaria*</p> <p>Angioedema*</p> Other exanthema</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Eyes, ears, nose</strong></td> <td> <p>Ocular itching</p> <p>Tearing</p> <p>Conjunctival injection and/or edema</p> <p>Periorbital edema*</p> <p>Rhinorrhea*</p> <p>Nasal itching*</p> <p>Nasal congestion*</p> Sneezing</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mouth</strong></td> <td> <p>Itching or tingling of lips, tongue, oral mucosa*</p> <p>Metallic taste</p> Angioedema of lips, tongue, or uvula*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Throat</strong></td> <td> <p>Itching*</p> <p>Sense of constriction or swelling in throat*</p> <p>Change in voice quality*</p> <p>Hoarseness</p> <p>Difficulty swallowing*</p> <p>Drooling</p> Stridor*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lungs</strong></td> <td> <p>Shortness of breath*</p> <p>Chest tightness*</p> <p>Repetitive cough*</p> <p>Wheezing*</p> Drop in oxygen saturation, cyanosis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cardiovascular</strong></td> <td> <p>Lightheadedness/faintness/dizziness*</p> <p>Tachycardia or occasionally, bradycardia*</p> <p>Syncope/loss of consciousness</p> <p>Palpitations</p> <p>Tunnel vision</p> <p>Difficulty hearing</p> <p>Hypotension*</p> <p>Urinary or fecal incontinence</p> Cardiac arrest</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gastrointestinal</strong></td> <td> <p>Nausea</p> <p>Vomiting</p> <p>Abdominal cramping or pain</p> Diarrhea</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gynecologic</strong></td> <td> <p>Vaginal itching</p> Uterine cramping or bleeding</td> </tr> <tr> <td><strong>Neurologic</strong></td> <td> <p>Anxiety</p> <p>Sense of impending doom</p> <p>Altered mental status/confusion</p> Seizures</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Immediate reactions to drugs often present with combinations of the signs and symptoms listed in the table.&nbsp;Those marked with an asterisk (*) are more consistent and representative&nbsp;than the others,&nbsp;and one or more of these should be present&nbsp;to consider the reaction immediate. &nbsp;</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 100732 Version 4.0</div></div></div>"},"100735":{"type":"graphic_diagnosticimage","displayName":"CT chest – thoracic endometriosis","title":"Chest computed tomography of a patient with thoracic endometriosis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Chest computed tomography of a patient with thoracic endometriosis</div><div class=\"cntnt\"><img style=\"width:567px; height:707px;\" src=\"images/PULM/100735_CTchstthrccendmtrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomogram (CT) of the chest showing opacities in the right lower lobe (arrow) in a young woman with chest pain during menstruation (panel A). The opacities have completely resolved two weeks later after menstruation (panel B), illustrating the importance of obtaining imaging when patients with suspected thoracic endometriosis are symptomatic peri-menstruation.</div><div class=\"graphic_reference\">Reproduced with permission from: Chung SY, Kim SJ, Kim TH, et al. Computed tomography findings of pathologically confirmed pulmonary parenchymal endometriosis. J Comput Assist Tomogr 2005; 29:815. Copyright © 2005 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 100735 Version 3.0</div></div></div>"},"100736":{"type":"graphic_picture","displayName":"Diaphragmatic defects","title":"Diaphragmatic defects in thoracic endometriosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragmatic defects in thoracic endometriosis</div><div class=\"cntnt\"><img style=\"width:426px; height:670px;\" src=\"images/PULM/100736_Diaphragmatic_defects.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross pathology of diaphragmatic defects (pores) seen in some patients with thoracic endometriosis. Panel A shows the dome of the diaphragm punctuated by multiple areas of \"thinning\" (arrows). When the diaphragm is lifted off the surface of the liver (panel B), these areas can be more clearly seen as perforations or pores. These lesions are seen in &lt;50% of patients with thoracic endometriosis and when present may vary in number from 1 to 30 or more.</div><div class=\"graphic_reference\">Reproduced from: Korom S, Canyurt H, Missbach A, et al. Catamenial pneumothorax revisited: clinical approach and systematic review of the literature. J Thorac Cardiovasc Surg 2004; 128:502. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 100736 Version 1.0</div></div></div>"},"100737":{"type":"graphic_figure","displayName":"Delayed presentation of thoracic endometriosis","title":"Delayed presentation of thoracic endometriosis","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Delayed presentation of thoracic endometriosis</div><div class=\"cntnt\"><img style=\"width:607px; height:373px;\" src=\"images/PULM/100737_Dlydprsntthrcendmtrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bar graph representing the number of episodes of pneumothorax, hemothorax, and hemoptysis that occurred in patients prior to definitive diagnosis. The majority of patients (&gt;70 percent) presented with two episodes or more of any one of these symptoms before a diagnosis was made.</div><div class=\"graphic_reference\">Reproduced with permission from: Channabasavaiah AD, Joseph JV. Thoracic endometriosis: revisiting the association between clinical presentation and thoracic pathology based on thoracoscopic findings in 110 patients. Medicine (Baltimore) 2010; 89:183. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 100737 Version 2.0</div></div></div>"},"100740":{"type":"graphic_figure","displayName":"Right-sided predominance of thoracic endometriosis","title":"Right-sided distribution of thoracic endometriosis","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Right-sided distribution of thoracic endometriosis</div><div class=\"cntnt\"><img style=\"width:579px; height:396px;\" src=\"images/PULM/100740_Rghtsddprdmnncthrcendmt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bar graph displays the predilection of thoracic endometriosis to the right side with the majority of patients presenting with right-sided pneumothorax, hemothorax, or hemoptysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Channabasavaiah AD, Joseph JV. Thoracic endometriosis: revisiting the association between clinical presentation and thoracic pathology based on thoracoscopic findings in 110 patients. Medicine (Baltimore) 2010; 89:183. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 100740 Version 2.0</div></div></div>"},"100742":{"type":"graphic_table","displayName":"Potential underlying meaning of \"I want everything done\"","title":"Potential underlying meaning of \"everything\" in patients with an advanced serious illness who request that \"everything be done\"","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential underlying meaning of \"everything\" in patients with an advanced serious illness who request that \"everything be done\"</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Domain</td> <td class=\"subtitle1\">Concept</td> <td class=\"subtitle1\">What \"everything\" might mean</td> <td class=\"subtitle1\">Questions to ask</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Affective</td> <td>Abandonment</td> <td>\"Don't give up on me.\"</td> <td>\"What worries you the most?\"</td> </tr> <tr> <td>Fear</td> <td>\"Keep trying for me.\"</td> <td>\"What are you most afraid of?\"</td> </tr> <tr> <td>Anxiety</td> <td>\"I don't want to leave my family.\"</td> <td>\"What does your doctor say about your prospects?\"</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Depression</td> <td>\"I'm scared of dying.\"</td> <td>\"What is the hardest part for you?\"</td> </tr> <tr class=\"divider_bottom\"> <td>\"I would feel like I'm giving up.\"</td> <td>\"What are you hoping for?\"</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Cognitive</td> <td>Incomplete understanding</td> <td>\"I do not really understand how sick I am.\"</td> <td>\"What are your most important goals?\"</td> </tr> <tr> <td>Wanting reassurance that best medical care has been given</td> <td>\"Do everything you think as a doctor is worthwhile.\"</td> <td>\"What is your understanding of your condition/prognosis?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Wanting reassurance that all possible life-prolonging treatment is given</td> <td> <p>\"Don't leave any stone unturned.\"</p> <p>\"I really want every possible treatment that has a chance of helping me live longer.\"</p> \"I will go through anything, regardless of how hard it is.\"</td> <td> <p>\"What have others told you about what is going on with your illness?\"</p> <p>\"What have they said the impact of these treatments would be?</p> \"Tell me more about what you mean by 'everything'.\"</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Spiritual</td> <td>Vitalism</td> <td>\"I value every moment of life, regardless of the pain and suffering (which has important meaning for me).\"</td> <td>\"Does your religion (faith) provide any guidance in these matters?\"</td> </tr> <tr class=\"divider_bottom\"> <td>Faith in God's will</td> <td>\"I will leave my fate in God's hands; I am hoping for a miracle; only He can decide when it is time to stop.\"</td> <td>\"How might we know when God thinks it is your time?\"</td> </tr> <tr> <td rowspan=\"3\">Family</td> <td>Differing perceptions</td> <td>\"I cannot bear the thought of leaving my children (wife/husband).\"</td> <td>\"How is your family handling this?\"</td> </tr> <tr> <td>Family conflict</td> <td>\"My husband will never let me go.\"</td> <td>\"What do your children know?\"</td> </tr> <tr> <td>Children or dependents</td> <td> <p>\"My family is only after my money.\"</p> \"I don't want to bother my children with all this.\"</td> <td> <p>\"Have you made plans for your children (other dependents)?\"</p> <p>\"Have you discussed who will make decisions for you if you cannot?\"</p> \"Have you completed a will?\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Quill TE, Arnold R, Back AL, Discussing treatment preferences with patients who want \"everything,\" 151, 345. Copyright © 2009 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 100742 Version 4.0</div></div></div>"},"100743":{"type":"graphic_table","displayName":"Treatment philosophies underlying requests for \"everything\"","title":"Different treatment philosophies underlying requests for \"everything\" to be done in patients with advanced serious illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Different treatment philosophies underlying requests for \"everything\" to be done in patients with advanced serious illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Everything that might provide maximum relief of suffering, even if it might unintentionally shorten life.</td> </tr> <tr> <td>Everything that has a reasonable chance of prolonging life, but not if it would increase the patient's suffering.</td> </tr> <tr> <td>Everything that has a reasonable chance of prolonging life, even if it may cause a modest increase in suffering.</td> </tr> <tr> <td>Everything that has a reasonable chance of prolonging life even a small amount, regardless of its effect on the patient&rsquo;s suffering.</td> </tr> <tr> <td>Everything that has any possible potential to prolong life even a small amount, regardless of its effect on the patient&rsquo;s suffering.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From <EM>Annals of Internal Medicine</EM>, Quill TE, Arnold R, Back AL, Discussing treatment preferences with patients who want \"everything,\" 151, 345. Copyright © 2009 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 100743 Version 4.0</div></div></div>"},"100744":{"type":"graphic_table","displayName":"Croup severity score","title":"Westley croup severity score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Westley croup severity score</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Assigned score</td> </tr> <tr> <td>Level of consciousness</td> <td> <p>Normal, including sleep = 0</p> Disoriented = 5</td> </tr> <tr> <td>Cyanosis</td> <td> <p>None = 0</p> <p>With agitation = 4</p> At rest = 5</td> </tr> <tr> <td>Stridor</td> <td> <p>None = 0</p> <p>With agitation = 1</p> At rest = 2</td> </tr> <tr> <td>Air entry</td> <td> <p>Normal = 0</p> <p>Decreased = 1</p> Markedly decreased = 2</td> </tr> <tr> <td>Retractions</td> <td> <p>None = 0</p> <p>Mild = 1</p> <p>Moderate = 2</p> Severe = 3</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Severity</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td>&#8804;2</td> <td>Mild</td> <td>Occasional barky cough, no stridor at rest, mild or no retractions</td> <td> <p>Home treatment: Symptomatic care including antipyretics, mist, and oral fluids</p> Outpatient treatment: Single dose of oral dexamethasone 0.15 to 0.6 mg/kg (maximum 16 mg)*</td> </tr> <tr> <td>3 to 7</td> <td>Moderate</td> <td>Frequent barky cough, stridor at rest, and mild to moderate retractions, but no or little distress or agitation</td> <td> <p>Single dose of oral dexamethasone 0.6 mg/kg (maximum 16 mg)*</p> <p>Nebulized epinephrine<sup>&#182;</sup></p> Hospitalization is generally not needed, but may be warranted for persistent or worsening symptoms after treatment with glucocorticoid and nebulized epinephrine</td> </tr> <tr> <td>8 to 11</td> <td>Severe</td> <td>Frequent barky cough, stridor at rest, marked retractions, significant distress and agitation</td> <td> <p>Single dose of oral/IM/IV dexamethasone 0.6 mg/kg (maximum 16 mg)*</p> <p>Repeated doses of nebulized epinephrine<sup>&#182;</sup> may be needed</p> Inpatient admission is generally required unless marked improvement occurs after treatment with glucocorticoid and nebulized epinephrine</td> </tr> <tr> <td>&#8805;12</td> <td>Impending respiratory failure</td> <td>Depressed level of consciousness, stridor at rest, severe retractions, poor air entry, cyanosis or pallor</td> <td> <p>Single dose of IM/IV dexamethasone 0.6 mg/kg (maximum 16 mg)</p> <p>Repeated doses of nebulized epinephrine<sup>&#182;</sup> may be needed</p> <p>Intensive care unit admission is generally required </p> Consultation with anesthesiologist or ENT surgeon may be warranted to arrange for intubation in a controlled setting</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: Intravenous; IM: intramuscular; ENT: ear, nose, throat.<br />* The intravenous preparation of dexamethasone (4 mg per mL) can be given orally; mix with flavored syrup.<br />&para; Nebulized epinephrine has an onset of effect within 10 minutes. Nebulized racemic epinephrine is administered as 0.05 mL/kg per dose (maximum of 0.5 mL) of a 2.25% solution diluted to 3 mL total volume with normal saline. Racemic epinephrine is commercially available in the United States and some other countries as a nebulizer preparation (ie, single-use preservative free bullets [ampules]). Nebulized L-epinephrine is administered as 0.5 mL/kg per dose (maximum of 5 mL) of a 1 mg/mL (1:1000) preservative-free solution. L-epinephrine is the same type of epinephrine used in other medical indications (eg, IM injection for anaphylaxis) and is widely available as a parenteral preparation. Use of either product by nebulization is acceptable and may be determined by availability and institutional protocol. Refer to topic for detail.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978; 132:484.</LI>&#xD;&#xA;<LI>Toward Optimized Practice (TOP) Working Group for Croup. Guidelines for the diagnosis and management of croup (revised 2008). Available at www.topalbertadoctors.org/download/252/croup_guideline.pdf (Accessed on March 13, 2015).</LI>&#xD;&#xA;<LI>Clarke M, Allaire J. An evidence-based approach to the evaluation and treatment of croup in children. Pediatric Emergency Medicine Practice 2012; 9:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 100744 Version 5.0</div></div></div>"},"100745":{"type":"graphic_algorithm","displayName":"Approach to penicillin allergy","title":"Approach to penicillin allergy","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Approach to penicillin allergy</div><div class=\"cntnt\"><img style=\"width:573px; height:300px;\" src=\"images/ALLRG/100745_Approach_penicillin_allergy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* A penicillin allergy history includes the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Each agent reportedly associated with a reaction and the indication for its use (to make sure that the agent matches the indication).</LI>&#xD;&#xA;<LI>The exact signs and symptoms that occurred, in as much detail as the patient and/or medical record can provide.</LI>&#xD;&#xA;<LI>When the reaction occurred (ie, how long ago) and at what point in therapy (immediately after starting or later in course).</LI>&#xD;&#xA;<LI>The dose and route of medication taken (if known).</LI>&#xD;&#xA;<LI>Other concurrent medications, especially if they were new or temporary.</LI>&#xD;&#xA;<LI>Any treatment given and response to that treatment (including the duration of reaction).</LI></UL>¶ Allergy can be excluded based upon history if: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Reaction was not allergic (eg, isolated nausea or diarrhea, yeast vaginitis, other predictable adverse effect of drug)<STRONG>&nbsp;or</STRONG>&nbsp;</LI>&#xD;&#xA;<LI>Patient never took a penicillin but has family members with penicillin allergy.</LI></UL>Δ Immediate reactions usually begin within one hour of the last administered dose and may begin within minutes. Some guidelines include reactions beginning up to six hours after the last administered dose. Common symptoms and signs include pruritus, flushing, urticaria, angioedema, bronchospasm (wheezing, repetitive cough, difficulty breathing), laryngeal edema (throat tightness, change in voice quality), abdominal cramping, nausea, vomiting, diarrhea, and hypotension. <br /><FONT class=lozenge>◊</FONT> Delayed reactions begin later than six hours and more typically days into a course of treatment. A maculopapular or morbilliform eruption is the most common form of delayed reaction, but more serious forms exist. The evaluation and management of delayed reactions are discussed in the UpToDate topic on delayed hypersensitivity reactions to penicillins. <br />§ Alternative agents include antibiotics that are unrelated to penicillin, such as sulfonamides, tetracyclines, macrolides, or fluoroquinolones. See the discussion of the use of related antibiotics (ie, cephalosporins, carbapenems, and monobactams) in the UpToDate topic on choice of antibiotics in penicillin-allergic patients.</div><div id=\"graphicVersion\">Graphic 100745 Version 2.0</div></div></div>"},"100746":{"type":"graphic_algorithm","displayName":"Discuss treatment preferences with patients wanting \"Everything\"","title":"Discussing treatment preferences with patients who want \"Everything\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discussing treatment preferences with patients who want \"Everything\"</div><div class=\"cntnt\"><img style=\"width:396px; height:475px;\" src=\"images/PALC/100746_Dscs_trt_prfr_ptnt_wnt_evry.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Source: Quill TE, Arnold R, Back AL. Discussing treatment preferences with patients who want \"everything\". Ann Intern Med 2009; 151:345.</div><div id=\"graphicVersion\">Graphic 100746 Version 1.0</div></div></div>"},"100747":{"type":"graphic_algorithm","displayName":"Croup management approach","title":"Management of croup in the outpatient and emergency department settings","html":"<div class=\"graphic\"><div style=\"width: 1022px\" class=\"figure\"><div class=\"ttl\">Management of croup in the outpatient and emergency department settings</div><div class=\"cntnt\"><img style=\"width:1002px; height:1139px;\" src=\"images/PEDS/100747_Croupmgmtapproached1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular; ICU: intensive care unit; ENT: ear, nose, throat.<br />* Signs of impending respiratory failure include: Fatigue and listlessness, profound retractions, decreased or absent breath sounds, depressed level of consciousness, tachycardia out of proportion to fever (note that tachycardia may also be caused by epinephrine), and/or poor color (cyanosis or pallor).<br />¶ The intravenous preparation of dexamethasone (4 mg per mL) can be given orally; mix with flavored syrup.<br />Δ A single dose of nebulized budesonide (2 mg [2 mL solution] via nebulizer) may provide an alternative to IM or IV dexamethasone for children with vomiting and no IV access.<br /><FONT class=lozenge>◊</FONT> Nebulized epinephrine has an onset of effect within 10 minutes. Nebulized racemic epinephrine is administered as 0.05 mL/kg per dose (maximum of 0.5 mL) of a 2.25% solution diluted to 3 mL total volume with normal saline. Racemic epinephrine is commercially available in the United States and some other countries as a nebulizer preparation (ie, single-use preservative free bullets [ampules]). Nebulized L-epinephrine is administered as 0.5 mL/kg per dose (maximum of 5 mL) of a 1 mg/mL (1:1000) preservative-free solution. L-epinephrine is the same type of epinephrine used in other medical indications (eg, IM injection for anaphylaxis) and is widely available as a parenteral preparation. Use of either product by nebulization is acceptable and may be determined by availability and institutional protocol. Refer to UpToDate content on the management of croup for details.<br />§ Poor response to nebulized epinephrine in conjunction with high fever and toxic appearance should prompt consideration of bacterial tracheitis. Refer to UpToDate topic on evaluation and diagnosis of croup for a guide to the differential diagnosis.<br />¥ Discharge criteria include <STRONG>all</STRONG> of the following: No stridor at rest, normal pulse oximetry, good air exchange, normal color, tolerating fluids by mouth, and caregivers understand instructions and are able to return for care if needed.</div><div class=\"graphic_reference\">Courtesy of Charles Woods, MD with additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Toward Optimized Practice (TOP) Working Group for Croup. Guideline for the diagnosis and management of croup (revised 2008). Available at: http://www.topalbertadoctors.org/download/252/croup_guideline.pdf (Accessed on March 13, 2015).</LI>&#xD;&#xA;<LI>Clarke M, Allaire J. An evidence-based approach to the evaluation and treatment of croup in children. Pediatr Emerg Med Pract 2012; 9:1.</LI>&#xD;&#xA;<LI>Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med 1998; 339:498.</LI></OL></div><div id=\"graphicVersion\">Graphic 100747 Version 4.0</div></div></div>"},"100748":{"type":"graphic_algorithm","displayName":"Treatment algorithm for congenital CMV infection","title":"Treatment approach for infants with congenital CMV infection","html":"<div class=\"graphic\"><div style=\"width: 884px\" class=\"figure\"><div class=\"ttl\">Treatment approach for infants with congenital CMV infection</div><div class=\"cntnt\"><img style=\"width:864px; height:428px;\" src=\"images/PEDS/100748_Tx_infants_congenital_CMV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; SCID: severe combined immunodeficiency.<br />* Evidence is lacking and expert opinion varies as to whether the benefits of antiviral therapy outweigh the risks in infants with isolated hearing loss.</div><div id=\"graphicVersion\">Graphic 100748 Version 1.0</div></div></div>"},"100749":{"type":"graphic_algorithm","displayName":"Treatment algorithm for non-life-threatening congenital CMV","title":"Approach to the treatment of non-life-threatening congenital CMV infection","html":"<div class=\"graphic\"><div style=\"width: 934px\" class=\"figure\"><div class=\"ttl\">Approach to the treatment of non-life-threatening congenital CMV infection</div><div class=\"cntnt\"><img style=\"width:914px; height:754px;\" src=\"images/PEDS/100749_Tx_nonsevere_congenital_CMV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; IV: intravenous; CBC: complete blood count; LFTs: liver function tests; CMV DNAemia: measurement of CMV viremia by quantitative polymerase chain reaction (PCR); ANC: absolute neutrophil count; PLT: platelets.<br />* Dose must be adjusted in infants with renal impairment. Dosing recommendations for valganciclovir are for commercially available oral suspension only.<br />&para; IV ganciclovir therapy should not exceed six weeks due to risks of toxicity.<br />&Delta; Significant toxicity includes any of the following:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Persistent neutropenia (ANC &lt;500/microL).</li>&#xD;&#xA;    <li>Persistent thrombocytopenia (PLT &lt;50,000 cells/microL) requiring transfusion. Worsening thrombocytopenia during antiviral therapy while CMV DNAemia levels are declining suggests possible drug-induced thrombocytopenia.</li>&#xD;&#xA;    <li>Persistent hepatitis (transaminases &gt;250 int. units/L) without other identified causes.</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span> Alternatively, patients with ganciclovir-induced neutropenia may be treated with granulocyte colony stimulating factor (G-CSF).</div><div id=\"graphicVersion\">Graphic 100749 Version 4.0</div></div></div>"},"100750":{"type":"graphic_algorithm","displayName":"Treatment algorithm for life-threatening congenital CMV","title":"Approach to the treatment of life-threatening congenital CMV infection","html":"<div class=\"graphic\"><div style=\"width: 1132px\" class=\"figure\"><div class=\"ttl\">Approach to the treatment of life-threatening congenital CMV infection</div><div class=\"cntnt\"><img style=\"width:1112px; height:1112px;\" src=\"images/PEDS/100750_Tx_severe_congenital_CMV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; SCID: severe combined immunodeficiency; IV: intravenous; CBC: complete blood count; LFTs: liver function tests; CMV DNAemia: measurement of CMV viremia by quantitative polymerase chain reaction (PCR); ANC: absolute neutrophil count; PLT: platelets.<br />* Dose must be adjusted in infants with renal impairment. Dosing recommendations for valganciclovir are for commercially available oral suspension only.<br />&para; Significant toxicity includes any of the following:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Persistent neutropenia (ANC &lt;500/microL).</li>&#xD;&#xA;    <li>Persistent thrombocytopenia (PLT &lt;50,000 cells/microL) requiring transfusion. Worsening thrombocytopenia during antiviral therapy while CMV DNAemia levels are declining suggests possible drug-induced thrombocytopenia.</li>&#xD;&#xA;    <li>Persistent hepatitis (transaminases &gt;250 int. units/L) without other identified causes.</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; Alternatively, patients with ganciclovir-induced neutropenia may be treated with granulocyte colony stimulating factor (G-CSF).<br /><span class=\"lozenge\">&loz;</span> IV ganciclovir therapy should not exceed six weeks due to risks of toxicity.</div><div id=\"graphicVersion\">Graphic 100750 Version 2.0</div></div></div>"},"100755":{"type":"graphic_diagnosticimage","displayName":"Fetal pleural effusion transverse view","title":"Fetal pleural effusion transverse view","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Fetal pleural effusion transverse view</div><div class=\"cntnt\"><img style=\"width:584px; height:393px;\" src=\"images/OBGYN/100755_Fetal_plrl_effsn_trnsvrs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleural effusion: transverse image of the fetal chest and heart. Arrows show the echolucent fluid within the lungs at the level of the fetal heart.</div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD.</div><div id=\"graphicVersion\">Graphic 100755 Version 1.0</div></div></div>"},"100761":{"type":"graphic_figure","displayName":"Giardia life cycle","title":"<em>Giardia</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\"><em>Giardia</em> life cycle</div><div class=\"cntnt\"><img style=\"width:452px; height:544px;\" src=\"images/ID/100761_Giardia_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cysts are resistant forms and are responsible for transmission of giardiasis. Both cysts and trophozoites can be found in the feces (diagnostic stages) <strong>(1)</strong>. The cysts are hardy and can survive several months in cold water. Infection occurs by the ingestion of cysts in contaminated water, food, or by the fecal-oral route (hands or fomites) <strong>(2)</strong>. In the small intestine, excystation releases trophozoites (each cyst produces two trophozoites) <strong>(3)</strong>. Trophozoites multiply by longitudinal binary fission, remaining in the lumen of the proximal small bowel where they can be free or attached to the mucosa by a ventral sucking disk <strong>(4)</strong>. Encystation occurs as the parasites transit toward the colon. The cyst is the stage found most commonly in nondiarrheal feces <strong>(5)</strong>. Because the cysts are infectious when passed in the stool or shortly afterward, person-to-person transmission is possible. While animals are infected with <em>Giardia</em>, their importance as a reservoir is unclear.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Giardia. Available at: <A href=\"http://www.cdc.gov/parasites/giardia/biology.html\" target=_blank>http://www.cdc.gov/parasites/giardia/biology.html</A> (Accessed on April 13, 2015).</div><div id=\"graphicVersion\">Graphic 100761 Version 1.0</div></div></div>"},"100762":{"type":"graphic_picture","displayName":"Chemotherapy-related mucositis","title":"Chemotherapy-related mucositis","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Chemotherapy-related mucositis</div><div class=\"cntnt\"><img style=\"width:798px; height:599px;\" src=\"images/ONC/100762_Chemotherap_relat_mucositis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Sook-Bin Woo, MS, DMD, MMSc. Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100762 Version 1.0</div></div></div>"},"100988":{"type":"graphic_diagnosticimage","displayName":"Imaging aspiration with atelectasis","title":"Aspiration and atelectasis on CT scan and radiography","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Aspiration and atelectasis on CT scan and radiography</div><div class=\"cntnt\"><img style=\"width:726px; height:349px;\" src=\"images/RADIOL/100988_Imag_aspirat_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper chest (A) shows atelectasis of the left lower lobe (asterisk) with aspirated contents in the left mainstem bronchus (arrowhead). The mediastinum is shifted to the left and a small pleural effusion is present (arrow). Image B is a magnified view and shows the aspirated material (arrowhead) and atelectasis (asterisk). Image C is a frontal radiograph at the time of aspiration showing the atelectasis of the left lower lobe (asterisk). The radiograph performed one week later shows clearing of the left base (D).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100988 Version 2.0</div></div></div>"},"100989":{"type":"graphic_diagnosticimage","displayName":"Imaging aspiration, atelectasis, and pneumonitis","title":"Aspiration, atelectasis, and pneumonitis on CT scan and radiography","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Aspiration, atelectasis, and pneumonitis on CT scan and radiography</div><div class=\"cntnt\"><img style=\"width:726px; height:368px;\" src=\"images/RADIOL/100989_Img_asprtn_atlcts_pnmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal radiograph (A) shows an almost complete white-out of the right chest (asterisk) with mediastinal shift (arrow). Image B is a CT scan showing aspirated material in the right mainstem bronchus (arrowhead), an interstitial process in remaining aerated lung (arrow), and infiltrates in the middle and lower lobes (asterisks). Image C is a magnified view showing aspirated material in the mainstem and middle lobe bronchi (arrowheads) and an interstitial process in the aerated lung (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100989 Version 2.0</div></div></div>"},"100990":{"type":"graphic_diagnosticimage","displayName":"Imaging aspiration following a seizure","title":"Seizure-induced aspiration on CT scan and chest radiography","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Seizure-induced aspiration on CT scan and chest radiography</div><div class=\"cntnt\"><img style=\"width:725px; height:207px;\" src=\"images/RADIOL/100990_Imag_aspiration_fllw_szr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan following a seizure shows bibasilar infiltrates (asterisks). Image B is a frontal radiograph showing bilateral infiltrates (asterisks) and air bronchograms (arrows) indicating alveolar infiltrates. Image C is a normal frontal radiograph one month later.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100990 Version 2.0</div></div></div>"},"100991":{"type":"graphic_diagnosticimage","displayName":"CT imaging of lipoid pneumonia","title":"Lipoid pneumonia on CT scan","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">Lipoid pneumonia on CT scan</div><div class=\"cntnt\"><img style=\"width:731px; height:477px;\" src=\"images/RADIOL/100991_CT_imag_lipoid_pnmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the mid chest shows a focal accumulation of fat in the parenchyma. The density measured -124 HU confirming the fatty nature of the parenchymal abnormality. Image B shows a similar abnormality in the parenchyma in the posteromedial aspect of the left lung (arrow). Image C is a magnification of the abnormality in the right lung (arrow) and image D is a magnification of the abnormality in the left lung (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; HU: Hounsfield units.</div><div id=\"graphicVersion\">Graphic 100991 Version 2.0</div></div></div>"},"100992":{"type":"graphic_diagnosticimage","displayName":"CT scan of barium aspiration","title":"Aspiration of barium on CT scan","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Aspiration of barium on CT scan</div><div class=\"cntnt\"><img style=\"width:726px; height:259px;\" src=\"images/RADIOL/100992_CT_scn_barium_aspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT image through the mid chest shows a left lower lobe consolidation (asterisk) with barium in the airways (arrows). Image B is a reconstruction of the CT scan in the coronal plane and shows the consolidated left lower lobe (asterisk with barium [arrow]) within the airways.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100992 Version 1.0</div></div></div>"},"100993":{"type":"graphic_diagnosticimage","displayName":"Imaging chronic aspiration ILD and bronchiectasis","title":"Chronic aspiration ILD bronchiectasis radiography CT and barium swallow","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Chronic aspiration ILD bronchiectasis radiography CT and barium swallow</div><div class=\"cntnt\"><img style=\"width:725px; height:394px;\" src=\"images/RADIOL/100993_Img_chrnc_asprtn_ILD_brnchc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the chest (A) is normal with clear lung bases. Image B is a corresponding normal frontal chest radiograph. Image C is a barium swallow showing free aspiration into left mainstem bronchus (arrow). Image D is a CT scan performed two years later. A coarse reticular pattern and bronchiectasis are present in the lung bases (arrows), most likely due to fibrosis from chronic aspiration. Bilateral pleural effusions are also present (arrowheads), corresponding to bibasilar pleuro-parenchymal disease (arrows). Image E is a corresponding chest radiograph and shows bilateral pleural effusions (arrows).</div><div class=\"graphic_footnotes\">ILD: interstitial lung disease; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 100993 Version 3.0</div></div></div>"},"100995":{"type":"graphic_picture","displayName":"Linear IgA dermatosis palmar","title":"Linear IgA dermatosis​","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Linear IgA dermatosis​</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/100995_Linear_IgA_dermatosis_palmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic blisters on the palm of a patient with linear IgA dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 100995 Version 1.0</div></div></div>"}};